<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antidepressants and benzodiazepines for panic disorder in adults - Bighelli, I - 2016 | Cochrane Library</title> <meta content="Antidepressants and benzodiazepines for panic disorder in adults - Bighelli, I - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011567.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antidepressants and benzodiazepines for panic disorder in adults - Bighelli, I - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011567.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011567.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antidepressants and benzodiazepines for panic disorder in adults" name="citation_title"/> <meta content="Irene Bighelli" name="citation_author"/> <meta content="University of Verona" name="citation_author_institution"/> <meta content="irene.bighelli@univr.it" name="citation_author_email"/> <meta content="Carlotta Trespidi" name="citation_author"/> <meta content="University of Verona" name="citation_author_institution"/> <meta content="Mariasole Castellazzi" name="citation_author"/> <meta content="University of Verona" name="citation_author_institution"/> <meta content="Andrea Cipriani" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Toshi A Furukawa" name="citation_author"/> <meta content="Kyoto University Graduate School of Medicine/School of Public Health" name="citation_author_institution"/> <meta content="Francesca Girlanda" name="citation_author"/> <meta content="University of Verona" name="citation_author_institution"/> <meta content="Giuseppe Guaiana" name="citation_author"/> <meta content="Western University" name="citation_author_institution"/> <meta content="Markus Koesters" name="citation_author"/> <meta content="Ulm University" name="citation_author_institution"/> <meta content="Corrado Barbui" name="citation_author"/> <meta content="University of Verona" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD011567.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/09/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011567.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011567.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011567.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011567.pub2&amp;doi=10.1002/14651858.CD011567.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="tkZQC4GK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011567\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011567\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011567\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011567\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011567.pub2",title:"Antidepressants and benzodiazepines for panic disorder in adults",firstPublishedDate:"Sep 12, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Common Mental Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011567.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011567.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011567.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011567.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011567.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011567.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011567.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011567.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011567.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011567.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6333 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011567.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-sec-0432"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-sec-0079"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-sec-0426"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/appendices#CD011567-sec-0439"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/table_n/CD011567StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/table_n/CD011567StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antidepressants and benzodiazepines for panic disorder in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/information#CD011567-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Irene Bighelli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/information#CD011567-cr-0003">Carlotta Trespidi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/information#CD011567-cr-0004">Mariasole Castellazzi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/information#CD011567-cr-0005">Andrea Cipriani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/information#CD011567-cr-0006">Toshi A Furukawa</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/information#CD011567-cr-0007">Francesca Girlanda</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/information#CD011567-cr-0008">Giuseppe Guaiana</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/information#CD011567-cr-0009">Markus Koesters</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011567.pub2/information#CD011567-cr-0010">Corrado Barbui</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/information/en#CD011567-sec-0443">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 September 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011567.pub2">https://doi.org/10.1002/14651858.CD011567.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011567-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011567-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011567-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011567-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011567-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011567-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011567-abs-0001" lang="en"> <section id="CD011567-sec-0001"> <h3 class="title" id="CD011567-sec-0001">Background</h3> <p>A panic attack is a discrete period of fear or anxiety that has a rapid onset, reaches a peak within 10 minutes and in which at least four of 13 characteristic symptoms are experienced, including racing heart, chest pain, sweating, shaking, dizziness, flushing, stomach churning, faintness and breathlessness. Panic disorder is common in the general population with a lifetime prevalence of 1% to 4%. The treatment of panic disorder includes psychological and pharmacological interventions. Amongst pharmacological agents, antidepressants and benzodiazepines are the mainstay of treatment for panic disorder. Different classes of antidepressants have been compared; and the British Association for Psychopharmacology, and National Institute for Health and Care Excellence (NICE) consider antidepressants (mainly selective serotonin reuptake inhibitors (SSRIs)) as the first‐line treatment for panic disorder, due to their more favourable adverse effect profile over monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs). In addition to antidepressants, benzodiazepines are widely prescribed for the treatment of panic disorder. </p> </section> <section id="CD011567-sec-0002"> <h3 class="title" id="CD011567-sec-0002">Objectives</h3> <p>To assess the evidence for the effects of antidepressants and benzodiazepines for panic disorder in adults. </p> </section> <section id="CD011567-sec-0003"> <h3 class="title" id="CD011567-sec-0003">Search methods</h3> <p>The Specialised Register of the Cochrane Common Mental Disorders Group (CCMDCTR) to 11 September 2015. This register includes relevant randomised controlled trials from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1950‐), Embase (1974‐) and PsycINFO (1967‐). Reference lists of relevant papers and previous systematic reviews were handsearched. We contacted experts in this field for supplemental data. </p> </section> <section id="CD011567-sec-0004"> <h3 class="title" id="CD011567-sec-0004">Selection criteria</h3> <p>All double‐blind randomised controlled trials allocating adult patients with panic disorder to antidepressants or benzodiazepines versus any other active treatment with antidepressants or benzodiazepines. </p> </section> <section id="CD011567-sec-0005"> <h3 class="title" id="CD011567-sec-0005">Data collection and analysis</h3> <p>Two review authors independently checked eligibility and extracted data using a standard form. Data were entered in RevMan 5.3 using a double‐check procedure. Information extracted included study characteristics, participant characteristics, intervention details, settings and outcome measures in terms of efficacy, acceptability and tolerability. </p> </section> <section id="CD011567-sec-0006"> <h3 class="title" id="CD011567-sec-0006">Main results</h3> <p>Thirty‐five studies, including 6785 participants overall (of which 5365 in the arms of interest (antidepressant and benzodiazepines as monotherapy)) were included in this review; however, since studies addressed many different comparisons, only a few trials provided data for primary outcomes. We found low‐quality evidence suggesting no difference between antidepressants and benzodiazepines in terms of response rate (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.67 to 1.47; participants = 215; studies = 2). Very low‐quality evidence suggested a benefit for benzodiazepines compared to antidepressants in terms of dropouts due to any cause, even if confidence interval (CI) ranges from almost no difference to benefit with benzodiazepines (RR 1.64, 95% CI 1.03 to 2.63; participants = 1449; studies = 7). We found some evidence suggesting that serotonin reuptake inhibitors (SSRIs) are better tolerated than TCAs (when looking at the number of patients experiencing adverse effects). We failed to find clinically significant differences between individual benzodiazepines. The majority of studies did not report details on random sequence generation and allocation concealment; similarly, no details were provided about strategies to ensure blinding. The study protocol was not available for almost all studies so it is difficult to make a judgment on the possibility of outcome reporting bias. Information on adverse effects was very limited. </p> </section> <section id="CD011567-sec-0007"> <h3 class="title" id="CD011567-sec-0007">Authors' conclusions</h3> <p>The identified studies are not sufficient to comprehensively address the objectives of the present review. The majority of studies enrolled a small number of participants and did not provide data for all the outcomes specified in the protocol. For these reasons most of the analyses were underpowered and this limits the overall completeness of evidence. In general, based on the results of the current review, the possible role of antidepressants and benzodiazepines should be assessed by the clinician on an individual basis. The choice of which antidepressant and/or benzodiazepine is prescribed can not be made on the basis of this review only, and should be based on evidence of antidepressants and benzodiazepines efficacy and tolerability, including data from placebo‐controlled studies, as a whole. Data on long‐term tolerability issues associated with antidepressants and benzodiazepines exposure should also be carefully considered. </p> <p>The present review highlights the need for further higher‐quality studies comparing antidepressants with benzodiazepines, which should be conducted with high‐methodological standards and including pragmatic outcome measures to provide clinicians with useful and practical data. Data from the present review will be included in a network meta‐analysis of psychopharmacological treatment in panic disorder, which will hopefully provide further useful information on this issue. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011567-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011567-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011567-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011567-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011567-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011567-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011567-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011567-abs-0004" lang="en"> <h3>Antidepressants and benzodiazepines for panic disorder in adults</h3> <p><b>Why is this review important?</b> </p> <p>Panic disorder is common in the general population. It is characterised by panic attacks, periods of fear or anxiety with a rapid onset in which other symptoms are experienced (involving bodily feelings and fearful thoughts). The treatment of panic disorder includes talking therapy and medicines, often used in combination. The most commonly prescribed medicines are antidepressants and benzodiazepines. Evidence for their efficacy in comparison is unclear. It is important to find out if antidepressants and benzodiazepines are effective and acceptable in the treatment of panic disorder. </p> <p><b>Who will be interested in this review?</b> </p> <p>Patients and practitioners.</p> <p><b>What questions does this review aim to answer?</b> </p> <p>This review aims to answer the following questions.</p> <p>What is the efficacy of antidepressants and benzodiazepines compared to other antidepressants and other benzodiazepines? </p> <p>What is the acceptability of antidepressants and benzodiazepines compared to other antidepressants and other benzodiazepines? </p> <p>How many adverse effects do antidepressants and benzodiazepines have compared to other antidepressants and other benzodiazepines? </p> <p><b>Which studies were included in the review?</b> </p> <p>We searched electronic databases to find all relevant studies conducted up to September 2015. To be included in the review, studies had to be randomised controlled trials that compared treatments with antidepressants and benzodiazepines in adults with a diagnosis of panic disorder. We included 35 studies involving a total of 5365 participants in the review. </p> <p><b>What does the evidence from the review tell us?</b> </p> <p>We did not find substantial differences between antidepressants and benzodiazepines in terms of efficacy and tolerability. There was not enough information to compare any differences in adverse effects. However, our findings are limited in the following ways: few studies contributed to each analysis, some studies were funded by pharmaceutical companies, and only short‐term outcomes were assessed. The quality of the available evidence was mainly low, meaning that further research would be very likely to have an important impact on these results. </p> <p><b>What should happen next?</b> </p> <p>Studies with larger sample sizes and fewer risks of bias should be carried out, with head‐to‐head comparisons. Longer‐term outcomes need to be addressed to establish whether the effect is transient or durable. Trials should better report any harms experienced by participants during the trial. In addition, a network meta‐analysis of psychopharmacological treatment in panic disorder will likely shed further light on this compelling issue, also being able to provide more information with regard to comparative efficacy. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011567-sec-0432" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011567-sec-0432"></div> <h3 class="title" id="CD011567-sec-0433">Implications for practice</h3> <section id="CD011567-sec-0433"> <p>The identified studies are not sufficient to comprehensively address the objectives of the present review; the majority of studies enrolled a small number of participants and did not provide data for all the outcomes specified in the protocol. For these reasons most of the analyses were underpowered and this limits the overall completeness of evidence. </p> <p>The findings of this review have few implications for people with panic disorder. Choice of treatment should be guided by patient's preference, if clinically appropriate; patients and their families should continue to reflect with clinicians about the basis of their care and the reasoning behind using a specific antidepressant or benzodiazepine, also taking into account possible psychiatric or medical co‐morbidities. </p> <p>In general, based on the results of the current review, the possible role of antidepressants and benzodiazepines should be assessed each time by the clinician on an individual basis. The choice of which antidepressant and/or benzodiazepine should be prescribed can hardly be made on the basis of this review only, and rather it may be based on whole amount of evidence on antidepressant and benzodiazepine efficacy and tolerability, including data from placebo‐controlled studies. Data on long‐term tolerability issues associated with antidepressant and benzodiazepine exposure should also be carefully considered. </p> </section> <h3 class="title" id="CD011567-sec-0434">Implications for research</h3> <section id="CD011567-sec-0434"> <p>The results described in this systematic review come from evidence of low to very low quality according to the GRADE methodology. Moreover, in many cases, studies were financially supported by pharmaceutical industries. Consequently, there is a high risk that these studies do not provide sufficient and adequate information for clinicians in real‐world settings.The present review highlights the strong need for further higher‐quality studies comparing benzodiazepines with antidepressants, which should be conducted with high‐methodological standards and with the primary intent of providing clinicians with useful practical data on the effectiveness of antidepressant drugs and benzodiazepines, in head‐to‐head comparisons with sufficient statistical power to detect clinically meaningful differences. Alongside rating scales, pragmatic outcome measures, such as quality of life and social functioning, should also be considered. </p> <p>In the meantime, it seems reasonable to make the best use of available evidence. The results of this systematic review will contribute to a Cochrane network meta‐analysis of drug treatments for patients with panic disorder which is in progress, aiming to rank available drug treatments for efficacy and tolerability. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011567-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011567-sec-0029"></div> <div class="table" id="CD011567-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antidepressants compared to benzodiazepines for adults with panic disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antidepressants compared to benzodiazepines for adults with panic disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with panic disorder<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> Antidepressants<br/> <b>Comparison:</b> benzodiazepines </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Benzodiazepines</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Antidepressants</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to respond</b> <br/> Follow‐up: 8‐10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>314 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>310 per 1000</b> <br/> (210 to 461) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> <br/> (0.67 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>total number of dropouts</b> <br/> Follow‐up: 8‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>213 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>350 per 1000</b> <br/> (220 to 561) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.64</b> <br/> (1.03 to 2.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1449<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to remit</b> <br/> Follow‐up: 8‐10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>360 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>425 per 1000</b> <br/> (364 to 493) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> <br/> (1.01 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1002<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms ‐ endpoint score</b> <br/> Follow‐up: 8‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms ‐ endpoint score in the intervention groups was<br/> <b>0.13 lower</b> <br/> (0.72 to 0.47 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1144<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms ‐mean change</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms ‐ mean change in the intervention groups was<br/> <b>0.40 higher</b> <br/> (0.83 lower to 1.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>number of dropouts due to adverse effects</b> <br/> Follow‐up: 8‐10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> <br/> (54 to 149) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.72</b> <br/> (1.03 to 2.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1002<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one point due to high dropout rates (30%) </p> <p><sup>2</sup> Downgraded one point due to imprecision: 95% CI interval ranges from possible benefit with antidepressants to possible benefit with benzodiazepines </p> <p><sup>3</sup> Downgraded one point due to substantial heterogeneity (I<sup>2</sup> = 75%) </p> <p><sup>4</sup> Downgraded one point due to imprecision: 95% CI interval ranges from no difference to possible benefit associated with benzodiazepines </p> <p><sup>5</sup> Downgraded two points due to substantial heterogeneity (I<sup>2</sup> = 95%)<br/> <sup>6</sup> Downgraded two points due to imprecision: number of individuals included in the trial is low (44) and 95% CI ranges from appreciable benefit with TCAs to appreciable benefit with benzodiazepines </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011567-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">TCAs compared to benzodiazepines for adults with panic disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TCAs compared to benzodiazepines for adults with panic disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with panic disorder<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> TCAs<br/> <b>Comparison:</b> benzodiazepines </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Benzodiazepines</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TCAs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to respond</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>537 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>547 per 1000</b> <br/> (338 to 896) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> <br/> (0.63 to 1.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>total number of dropouts</b> <br/> Follow‐up: 8‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>212 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>355 per 1000</b> <br/> (197 to 635) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.67</b> <br/> (0.93 to 2.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1295<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to remit</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>414 per 1000</b> <br/> (348 to 490) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> <br/> (1 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>848<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms ‐ endpoint score</b> <br/> Follow‐up: 8‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms ‐ endpoint score in the intervention groups was<br/> <b>0.25 lower</b> <br/> (1.72 lower to 1.22 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>998<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms ‐ mean change</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms ‐ mean change in the intervention groups was<br/> <b>0.40 higher</b> <br/> (0.83 lower to 1.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>number of dropouts due to adverse effects</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>79 per 1000</b> <br/> (43 to 149) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.10</b> <br/> (1.13 to 3.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>848<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one point due to high dropout rates (around 30%)<br/> <sup>2</sup> Downgraded two points due to imprecision: number of individuals included in the trial is low (61) and 95% CI ranges from appreciable benefit with TCAs to appreciable benefit with benzodiazepines </p> <p><sup>3</sup> Downgraded two points due to substantial heterogeneity (I<sup>2</sup> = 79%) </p> <p><sup>4</sup> Downgraded one point due to imprecision: 95% CI ranges from no difference to appreciable superiority of benzodiazepines in lowering the number of dropouts </p> <p><sup>5</sup> Downgraded two points due to substantial heterogeneity (I<sup>2</sup> = 97%)<br/> <sup>6</sup> Downgraded one point due to imprecision: 95% CI is very wide and ranges from benefit with TCAs and benefit with benzodiazepines<br/> <sup>7</sup> Downgraded two points due to imprecision: number of individuals included in the trial is low (44) and 95% CI ranges from appreciable benefit with TCAs to appreciable benefit with benzodiazepines </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011567-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">SSRIs compared to benzodiazepines for adults with panic disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>SSRIs compared to benzodiazepines for adults with panic disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with panic disorder<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> SSRI<br/> <b>Comparison:</b> benzodiazepines </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Benzodiazepines</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SSRI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to respond</b> <br/> Follow‐up: 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>195 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>181 per 1000</b> <br/> (94 to 351) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b> <br/> (0.48 to 1.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>total number of dropouts</b> <br/> Follow‐up: 10 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>221 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>378 per 1000</b> <br/> (227 to 627) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.71</b> <br/> (1.03 to 2.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to remit</b> <br/> Follow‐up: 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>429 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>480 per 1000</b> <br/> (339 to 681) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/> (0.79 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms in the intervention groups was<br/> <b>0.10 higher</b> <br/> (0.34 lower to 0.54 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>number of dropouts due to adverse effects</b> <br/> Follow‐up: 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>156 per 1000</b> <br/> (71 to 339) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> <br/> (0.55 to 2.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one point due to high dropout rates (30%)<br/> <sup>2</sup> Downgraded two points due to imprecision: number of individuals included in the trial is low (= 154) and 95% CI is wide, including benefit with SSRIs and benefit with benzodiazepines; only one study provides data<br/> <sup>3</sup> Downgraded two points due to imprecision: number of individuals included in the trial is low (= 154) and 95% CI ranges from no difference to appreciable superiority of with benzodiazepines in lowering the number of dropouts; only one study provides data<br/> <sup>4</sup> Downgraded one point due to imprecision: number of individuals included in the trial is low </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011567-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">TCAs compared to SSRI for adults with panic disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TCAs compared to SSRI for adults with panic disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with panic disorder<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> TCA<br/> <b>Comparison:</b> SSRI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SSRI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TCA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to respond</b> <br/> Follow‐up: 8‐12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>378 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>409 per 1000</b> <br/> (269 to 628) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/> (0.71 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>438<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>total number of dropouts</b> <br/> Follow‐up: 8‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>243 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>238 per 1000</b> <br/> (158 to 359) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> <br/> (0.65 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>928<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to remit</b> <br/> Follow‐up: 8‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>502 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>447 per 1000</b> <br/> (316 to 633) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> <br/> (0.63 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>475<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms</b> <br/> Follow‐up: 8‐10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms in the intervention groups was<br/> <b>0.20 lower</b> <br/> (0.88 lower to 0.48 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>number of dropouts due to adverse effects</b> <br/> Follow‐up: 8‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>104 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> <br/> (85 to 257) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.43</b> <br/> (0.82 to 2.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>476<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one point due to moderate heterogeneity (I squared = 61%)<br/> <sup>2</sup> Downgraded one point due to imprecision: 95% CI ranges from appreciable benefit with TCAs to appreciable benefit with SSRIs<br/> <sup>3</sup> Downgraded one point due to moderate heterogeneity (I squared = 47%)<br/> <sup>4</sup> Downgraded one point due to moderate heterogeneity (I squared = 58%)<br/> <sup>5</sup> Downgraded one point due to imprecision: dropout rate in one of the included studies (Nair 1996) is 48% <br/> <sup>6</sup> Downgraded one point due to moderate heterogeneity (I squared = 46%)<br/> <sup>7</sup> Downgraded one point due to imprecision: 95% CI ranges from appreciable benefit with TCAs to no difference<br/> <sup>8</sup> Downgraded one point due to imprecision: 95% CI ranges from no difference to appreciable superiority of SSRIs in lowering the number of dropouts </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011567-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">TCA compared to MAOI for adults with panic disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TCA compared to MAOI for adults with panic disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with panic disorder<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> TCA<br/> <b>Comparison:</b> MAOI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> MAOI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TCA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to respond</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>224 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b> <br/> (63 to 282) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b> <br/> (0.28 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>total number of dropouts</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>386 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>324 per 1000</b> <br/> (235 to 452) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b> <br/> (0.61 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to remit</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies provided data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms in the intervention groups was<br/> <b>0.20 lower</b> <br/> (0.75 lower to 0.35 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>number of dropouts due to adverse events</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>104 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> <br/> (52 to 335) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.27</b> <br/> (0.5 to 3.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two points due to imprecision: number of individuals included in the study is low (= 135) and 95% CI ranges from appreciable benefit with TCAs to no difference; only one study provides data<br/> <sup>2</sup> Downgraded one point due high dropout rates<br/> <sup>3</sup> Downgraded two points due to imprecision: number of individuals included in the study is low (= 135) and 95% CI ranges from appreciable benefit with TCAs to no difference; only one study provides data.<br/> <sup>4</sup> Downgrded two points due to imprecision: number of individuals included in the study is low (= 135) and 95% CI ranges from appreciable benefit with TCAs to appreciable benefit with MAOIs; only one study provides data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011567-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">SSRIs compared to MAOIs for adults with panic disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>SSRIs compared to MAOIs for adults with panic disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with panic disorder<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> SSRI<br/> <b>Comparison:</b> MAOI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> MAOI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SSRI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to respond</b> <br/> Follow‐up: 8‐12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>264 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b> <br/> (219 to 401) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/> (0.83 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>396<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>total number of dropouts</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> <br/> (5 to 970) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> <br/> (0.07 to 14.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to remit</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>467 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>434 per 1000</b> <br/> (346 to 546) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b> <br/> (0.74 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>366<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies provided data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>number of dropouts due to adverse events</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>76 per 1000</b> <br/> (36 to 163) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> <br/> (0.59 to 2.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>366<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one point due to imprecision: 95% CI ranges from no difference to appreciable benefit with MAOIs<br/> <sup>2</sup> Downgraded two points due to imprecision: number of individuals included in the trial is very low (= 30) and 95% CI is very wide, ranging from appreciable benefit with SSRIs to appreciable benefit with MAOIs; only one study provides data<br/> <sup>3</sup> Downgraded one point due to imprecision: even though the number of individuals included in the analysis is not low, only one study provides data<br/> <sup>4</sup> Downgrded two points due to imprecision: 95% CI ranges from appreciable benefit with SSRIs to appreciable benefit with MAOIs; only one study provides data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011567-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">SSRIs compared to SNRIs for adults with panic disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>SSRIs compared to SNRIs for adults with panic disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with panic disorder<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> SSRI<br/> <b>Comparison:</b> SNRI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SNRI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SSRI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to respond</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>232 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>223 per 1000</b> <br/> (174 to 285) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> <br/> (0.75 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>991<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>total number of dropouts</b> <br/> Follow‐up: 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>181 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b> <br/> (134 to 298) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.11</b> <br/> (0.74 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>991<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to remit</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>577 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>606 per 1000</b> <br/> (525 to 698) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> <br/> (0.91 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>991<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms in the intervention groups was<br/> <b>0.12 lower</b> <br/> (0.33 lower to 0.10 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>945<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>number of dropouts due to adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>104 per 1000</b> <br/> (27 to 393) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.86</b> <br/> (0.49 to 7.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>991<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one point due to moderate heterogeneity (I<sup>2</sup> = 53%)<br/> <sup>2</sup> Downgraded one point due to imprecision: 95% CI ranges from appreciable benefit with SSRIs to appreciable benefit with SNRIs<br/> <sup>3</sup> Downgraded one point due to substantial heterogeneity (I<sup>2</sup> = 76%)<br/> <sup>4</sup> Downgraded one point due to serious imprecision: 95% CI ranges from no difference to benefit with SNRIs </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011567-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">SSRIs compared to NaSSAs for adults with panic disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>SSRIs compared to NaSSAs for adults with panic disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with panic disorder<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> SSRI<br/> <b>Comparison:</b> NaSSA </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> NaSSA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SSRI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to respond</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>total number of dropouts</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> <br/> (39 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.50</b> <br/> (0.29 to 7.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to remit</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies provided data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms</b> <br/> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms in the intervention groups was<br/> <b>0.30 higher</b> <br/> (0.49 lower to 1.09 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>number of dropouts due to adverse events</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> <br/> (39 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.50</b> <br/> (0.29 to 7.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two points due to imprecision: number of individuals included in the trial is very low (= 30) and 95% CI is very wide, ranging from appreciable benefit with SSRIs to appreciable benefit with NaSSAs; only one study provides data<br/> <sup>2</sup> Downgraded two points due to imprecision: number of individuals included in the trial is very low (= 22) and 95% CI is very wide, ranging from appreciable benefit with SSRIs to appreciable benefit with NaSSAs; only one study provides data </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011567-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011567-sec-0030"></div> <section id="CD011567-sec-0031"> <h3 class="title" id="CD011567-sec-0031">Description of the condition</h3> <p>A panic attack is a discrete period of fear or anxiety that has a rapid onset, reaches a peak within 10 minutes and in which at least four of 13 characteristic symptoms are experienced. Many of these symptoms involve bodily systems, such as racing heart, chest pain, sweating, shaking, dizziness, flushing, stomach churning, faintness and breathlessness. Further recognised panic attack symptoms involve fearful cognitions, such as the fear of collapse, going mad or dying, and derealisation (<a href="./references#CD011567-bbs2-0083" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV). Fourth. Washington, DC: American Psychiatric Association, 1994. ">APA 1994</a>). </p> <p>Panic disorder first entered diagnostic classification systems in 1980 with the publication of the Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM‐III) (<a href="./references#CD011567-bbs2-0082" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐III). Third Edition. Washington, DC: American Psychiatric Association, 1980. ">APA 1980</a>), following observations that patients with panic attacks responded to treatment with the tricyclic antidepressant (TCA), imipramine (<a href="./references#CD011567-bbs2-0116" title="KleinDF . Delineation of two drug‐responsive anxiety syndromes. Psychopharmacologia1964;5:397‐408. ">Klein 1964</a>). To diagnose panic disorder, further conditions must be met relating to the frequency of attacks, the need for some panic attacks to come on ‘out of the blue’ rather than in a predictable, externally‐triggered situation, and exclusions where attacks are attributable solely to medical causes or panic‐inducing substances, notably caffeine. The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM‐IV) also requires that at least one panic attack has been followed by one of the following: </p> <p> <ol id="CD011567-list-0001"> <li> <p>persistent concern about having additional attacks;</p> </li> <li> <p>worry about the implications of the attack or its consequences;</p> </li> <li> <p>a significant change in behaviour related to the attacks (<a href="./references#CD011567-bbs2-0083" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV). Fourth. Washington, DC: American Psychiatric Association, 1994. ">APA 1994</a>). </p> </li> </ol> </p> <p>The core features of panic attacks remained unchanged in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‐5) (<a href="./references#CD011567-bbs2-0085" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐5). Fifth. Washington, DC: American Psychiatric Association, 2013. ">APA 2013a</a>), but in DSM‐5 panic disorder and agoraphobia are no longer linked and are now coded in two diagnoses (<a href="./references#CD011567-bbs2-0086" title="American Psychiatric Association. Highlights of Changes from DSM‐IV‐TR to DSM‐5. 2013. Available from http://www.dsm5.org/Documents/changes%20from%20dsm‐iv‐tr%20to%20dsm‐5.pdf. ">APA 2013b</a>). </p> <p>Panic disorder is common in the general population with a lifetime prevalence of 1% to 4% (<a href="./references#CD011567-bbs2-0093" title="BijlRV , RavelliA , vanZessenG . Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Social Psychiatry and Psychiatric Epidemiology1998;33:587‐95. ">Bijl 1998</a>; <a href="./references#CD011567-bbs2-0101" title="EatonWW , KesslerRC , WittchenH‐U , MageeWJ . Panic and panic disorder in the United States. American Journal of Psychiatry1994;151:413‐20. ">Eaton 1994</a>). In primary care settings, panic syndromes have been reported to have a prevalence of around 10% (<a href="./references#CD011567-bbs2-0115" title="KingM , NazarethI , LevyG , WalkerC , MorrisR , WeichS , et al. Prevalence of common mental disorders in general practice attendees across Europe. British Journal of Psychiatry2008;192:362‐7. ">King 2008</a>). Its aetiology is not fully understood and is probably heterogeneous. Biological theories incorporate the faulty triggering of an inbuilt anxiety response. Evidence for this comes from biological challenge tests (lactate and carbon dioxide trigger panic in those with the disorder) and from animal experiments and neuroimaging studies in humans that show activation of fear circuits, such as those involving the periaqueductal grey matter (<a href="./references#CD011567-bbs2-0108" title="GormanJM , KentJM , SullivanGM , CoplanJD . Neuroanatomical hypothesis of panic disorder, revised. American Journal of Psychiatry2000;157:493‐505. ">Gorman 2000</a>). </p> <p>Agoraphobia is anxiety about being in places or situations from which escape might be difficult or embarrassing, or in which help may not be available in the event of having a panic attack (<a href="./references#CD011567-bbs2-0083" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV). Fourth. Washington, DC: American Psychiatric Association, 1994. ">APA 1994</a>) . About one‐fourth of people suffering from panic disorder also have agoraphobia (<a href="./references#CD011567-bbs2-0114" title="KesslerRC , ChiuWT , JinR , RuscioAM , ShearK , WaltersEE . The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Archives of General Psychiatry2006;63:415‐24. ">Kessler 2006</a>). The presence of agoraphobia is associated with increased severity and worse outcome (<a href="./references#CD011567-bbs2-0114" title="KesslerRC , ChiuWT , JinR , RuscioAM , ShearK , WaltersEE . The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Archives of General Psychiatry2006;63:415‐24. ">Kessler 2006</a>). There are several risk factors that predict the development of agoraphobia in people suffering from panic disorder: female gender, more severe dizziness during panic attacks, cognitive factors, dependent personality traits and social anxiety disorder (<a href="./references#CD011567-bbs2-0126" title="StarcevicV . Anxiety Disorders in Adults: A Clinical Guide. New York: Oxford University Press, 2009. ">Starcevic 2009</a>). </p> <p>Panic disorder, with or without agoraphobia, is highly co‐morbid with other psychiatric disorders, such as drug dependence, major depression, bipolar I disorder, social phobia, specific phobia, and generalised anxiety disorder (<a href="./references#CD011567-bbs2-0109" title="GrantBF , HasinDS , StinsonFS , DawsonDA , GoldsteinRB , SmithS , et al. The epidemiology of DSM‐IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry2006;67:363‐74. ">Grant 2006</a>). It is estimated that generalised anxiety disorder co‐occurs in 68% of people with panic disorder, whilst major depression has a prevalence of 24% to 88% among people with panic disorder (<a href="./references#CD011567-bbs2-0126" title="StarcevicV . Anxiety Disorders in Adults: A Clinical Guide. New York: Oxford University Press, 2009. ">Starcevic 2009</a>). </p> </section> <section id="CD011567-sec-0032"> <h3 class="title" id="CD011567-sec-0032">Description of the intervention</h3> <p>The treatment of panic disorder includes psychological and pharmacological interventions, often used in combination (<a href="./references#CD011567-bbs2-0106" title="FurukawaTA , WatanabeN , ChurchillR . Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD004364.pub2] ">Furukawa 2007</a>). Historically, pharmacological interventions for panic disorder have been based on the use of monoamine oxidase inhibitors (MAOIs) and TCAs (<a href="./references#CD011567-bbs2-0096" title="BruceSE , VasileRG , GoismanRM , SalzmanC , SpencerM , MachanJT , et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?. American Journal of Psychiatry2003;160:1432‐8. ">Bruce 2003</a>). However, MAOIs and TCAs are associated with severe adverse effects, such as the risk of hypertensive crisis for MAOIs, and anticholinergic, arrhythmogenic and overall poor tolerability for TCAs (<a href="./references#CD011567-bbs2-0129" title="WadeAG . Antidepressants in panic disorder. International Clinical Psychopharmacology1999;14(Suppl 2):13‐7. ">Wade 1999</a>). Recent guidelines by the American Psychiatric Association (<a href="./references#CD011567-bbs2-0084" title="American Psychiatric Association. Practice Guideline for the Treatment of Patients With Panic Disorder. Second Edition. 2009. Available from http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf. ">APA 2009</a>), British Association for Psychopharmacology (<a href="./references#CD011567-bbs2-0090" title="BaldwinDS , AndersonIM , NuttDJ , BandelowB , BondA , DavidsonJR , et al. Evidence‐based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology2005;19:567‐96. ">BAP 2005</a>), and National Institute for Health and Care Excellence (NICE) (<a href="./references#CD011567-bbs2-0121" title="National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: Management in primary, secondary and community care. NICE guidelines [CG113]. Published date: January 2011. Available from http://www.nice.org.uk/guidance/cg113/chapter/guidance. ">NICE 2011</a>) recommend antidepressants, mainly selective serotonin reuptake inhibitors (SSRIs), as the first‐line treatment for panic disorder, due to their more favourable adverse effect profile over MAOIs and TCAs. A meta‐analysis of 43 studies (randomised and non randomised) comparing SSRIs and TCAs in panic disorder showed that SSRIs were as effective as TCAs, and were better tolerated (<a href="./references#CD011567-bbs2-0087" title="BakkerA , vanBalkomAJ , SpinhovenP . SSRIs vs. TCAs in the treatment of panic disorder: a meta‐analysis. Acta Psychiatrica Scandinavica2002;106:163‐7. ">Bakker 2002</a>), although other studies showed a possible overestimation of the efficacy of SSRIs over older antidepressants in panic disorder, finding no difference in their efficacy (<a href="./references#CD011567-bbs2-0123" title="OttoMW , TubyKS , GouldRA , McLeanRY , PollackMH . An effect‐size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. American Journal of Psychiatry2000;158:1989‐92. ">Otto 2001</a>, effect‐size analysis of 12 placebo‐controlled, efficacy trials of SSRIs for panic disorder). It appears that TCAs can still have a role in the treatment of panic disorder. </p> <p>Benzodiazepines, particularly high‐potency ones, have also been used in panic disorder (<a href="./references#CD011567-bbs2-0128" title="SteinM , StecklerT , LightfootJD , HayE , GoddardAW . Pharmacologic treatment of panic disorder. Current Topics in Behavioral Neurosciences2010;2:469‐85. ">Stein 2010</a>). Benzodiazepines have a higher incidence of dependence and withdrawal reaction when compared to antidepressants (<a href="./references#CD011567-bbs2-0129" title="WadeAG . Antidepressants in panic disorder. International Clinical Psychopharmacology1999;14(Suppl 2):13‐7. ">Wade 1999</a>). Moreover, benzodiazepines alone may not be effective in treating panic disorder co‐morbid with depression (<a href="./references#CD011567-bbs2-0088" title="BallengerJC , DavidsonJR , LecrubierY , NuttDJ , BaldwinDS , denBoerJA , et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. Journal of Clinical Psychiatry1998;59(Suppl 8):47‐54. ">Ballenger 1998</a>), and have less favourable long‐term outcomes (<a href="./references#CD011567-bbs2-0121" title="National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: Management in primary, secondary and community care. NICE guidelines [CG113]. Published date: January 2011. Available from http://www.nice.org.uk/guidance/cg113/chapter/guidance. ">NICE 2011</a>). In spite of these caveats, it appears that benzodiazepines continue to be widely prescribed for the treatment of panic disorder (<a href="./references#CD011567-bbs2-0096" title="BruceSE , VasileRG , GoismanRM , SalzmanC , SpencerM , MachanJT , et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?. American Journal of Psychiatry2003;160:1432‐8. ">Bruce 2003</a>). </p> </section> <section id="CD011567-sec-0033"> <h3 class="title" id="CD011567-sec-0033">How the intervention might work</h3> <p>The main classes with evidence of efficacy in panic disorder are antidepressant drugs that augment the function of the monoamines serotonin and/or noradrenaline. With regard to the serotonergic antidepressants (SSRIs such as fluoxetine, paroxetine, sertraline and citalopram), these drugs promote the transmission of the neurotransmitter serotonin across brain synapses; most notably in the dorsal raphe nucleus (<a href="./references#CD011567-bbs2-0095" title="BrileyM , MoretC . Neurobiological mechanisms involved in antidepressant therapies. Clinical Neuropharmacology1993;16:387‐400. ">Briley 1993</a>). They prevent reuptake of serotonin into nerve terminals by inhibiting serotonin transporters, thus allowing more to be available for neurotransmission. In panic disorder, imaging studies have showed reduced expression of the 5H1A receptor (<a href="./references#CD011567-bbs2-0120" title="NashJR , SargentPA , RabinerEA , HoodSD , ArgyropoulosSV , PotokarJP , et al. Serotonin 5‐HT1A receptor binding in people with panic disorder: positron emission tomography study. British Journal of Psychiatry2008;1993:229‐34. ">Nash 2008</a>), which has an inhibitory function, so the increased serotonin throughput may in part serve to overcome this deficit of inhibition. Noradrenergic antidepressants can similarly increase transmission of the catecholamine noradrenaline. Some antidepressants such as the serotonin‐norepinephrine reuptake inhibitors (SNRIs) (e.g. venlafaxine, duloxetine) and TCAs can enhance both serotonin and noradrenaline transmission by inhibiting both transporters. </p> <p>Benzodiazepines moderate the gamma‐aminobutyric acid (GABA) neurotransmitter system, which is the brain's main inhibitory neurotransmitter. They act as agonists at the GABA‐A benzodiazepines receptor. This complex contains a chloride channel which can be opened by agonists and ultimately produces an anxiolytic effect and sedation. It is known through imaging studies that the inhibitory GABA system is deficient in panic disorder (<a href="./references#CD011567-bbs2-0118" title="MaliziaAL , CunninghamVJ , BellCJ , LiddlePF , JonesT , NuttDJ . Decreased brain GABA(A)‐benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Archives of General Psychiatry1998;55:715‐20. ">Malizia 1998</a>; <a href="./references#CD011567-bbs2-0099" title="CameronOG , HuangGC , NicholsT , KoeppeRA , MinoshimaS , RoseD , et al. Reduced gamma‐aminobutyric acid(A)‐benzodiazepine binding sites in insular cortex of individuals with panic disorder. Archives of General Psychiatry2007;64:793‐800. ">Cameron 2007</a>), and thus the ability of benzodiazepines to act as agonists at the GABA‐A benzodiazepine receptor can counteract this. It is likely that both monoamine‐based systems and GABA‐based systems converge allowing both antidepressants and benzodiazepines to have efficacy in panic disorder despite their differing actions on neurotransmitter systems. One possibility is via serotonergic neurons that modulate GABA input to the periaqueductal grey matter. </p> </section> <section id="CD011567-sec-0034"> <h3 class="title" id="CD011567-sec-0034">Why it is important to do this review</h3> <p>Antidepressants and benzodiazepines are widely used in panic disorder. Published randomised controlled trials (RCTs) have shown some evidence of efficacy. However, no systematic review that includes comparisons between antidepressants and benzodiazepines in panic disorder has been conducted recently, to our knowledge. A meta‐analysis published in 2007 focused on combined psychotherapy and antidepressants in panic disorder (<a href="./references#CD011567-bbs2-0106" title="FurukawaTA , WatanabeN , ChurchillR . Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD004364.pub2] ">Furukawa 2007</a>), and a more recent systematic review focused on psychological treatments only (<a href="./references#CD011567-bbs2-0125" title="Sánchez‐MecaJ , Rosa‐AlcázarAI , Marín‐MartínezF , Gómez‐ConesaA . Psychological treatment of panic disorder with or without agoraphobia: a meta‐analysis. Clinical Psychology Review2010;30:37‐50. ">Sanchez‐Meca 2010</a>). One meta‐analysis of interventions for panic disorder has been published in recent years, focusing on combined psychotherapy and benzodiazepines in panic disorder (<a href="./references#CD011567-bbs2-0130" title="WatanabeN , ChurchillR , FurukawaTA . Combined psychotherapy plus benzodiazepines for panic disorder. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD005335.pub2] ">Watanabe 2009</a>). <a href="./references#CD011567-bbs2-0106" title="FurukawaTA , WatanabeN , ChurchillR . Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD004364.pub2] ">Furukawa 2007</a> concluded that either combined psychotherapy or psychotherapy alone may be chosen as first‐line treatment for panic disorder. <a href="./references#CD011567-bbs2-0125" title="Sánchez‐MecaJ , Rosa‐AlcázarAI , Marín‐MartínezF , Gómez‐ConesaA . Psychological treatment of panic disorder with or without agoraphobia: a meta‐analysis. Clinical Psychology Review2010;30:37‐50. ">Sanchez‐Meca 2010</a> reported that exposure, relaxation training and breathing retraining have the most robust evidence. A network meta‐analysis was also performed to compare different psychological therapies for panic disorder (<a href="./references#CD011567-bbs2-0124" title="PompoliA , FurukawaTA , ImaiH , TajikaA , EfthimiouO , SalantiG . Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta‐analysis. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD011004.pub2] ">Pompoli 2016</a>). To our knowledge, the most recent meta‐analysis specifically focused on antidepressants in panic disorder was published in 2002 (<a href="./references#CD011567-bbs2-0087" title="BakkerA , vanBalkomAJ , SpinhovenP . SSRIs vs. TCAs in the treatment of panic disorder: a meta‐analysis. Acta Psychiatrica Scandinavica2002;106:163‐7. ">Bakker 2002</a>), and included 43 studies comparing SSRIs and TCAs. The authors concluded that SSRIs and TCAs were of equal efficacy in the treatment of panic disorder, with a better tolerability profile for SSRIs. Benzodiazepines are widely used in panic disorder. Available RCTs have shown some evidence of efficacy (<a href="./references#CD011567-bbs2-0091" title="BatelaanNM , VanBalkomAJ , SteinDJ . Evidence‐based pharmacotherapy of panic disorder: an update. International Journal of Neuropsychopharmacology2012;15(3):403‐15. ">Batelaan 2012</a>). The last meta‐analysis specifically focused on benzodiazepines in panic disorder was published in 1991 (<a href="./references#CD011567-bbs2-0132" title="WilkinsonG , BalestrieriM , RuggeriM , BellantuonoC . Meta‐analysis of double‐blind placebo‐controlled trials of antidepressants and benzodiazepines for patients with panic disorders. Psychological Medicine1991;21:991‐8. ">Wilkinson 1991</a>), and included 19 double‐blind, placebo‐controlled trials. This meta‐analysis compared antidepressants and benzodiazepines with placebo. The authors concluded that active treatment had a 25% greater success rate than placebo over 14 weeks. Another meta‐analysis has been recently published (<a href="./references#CD011567-bbs2-0122" title="OffidaniE , GuidiJ , TombaE , FavaGA . Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta‐analysis. Psychotherapy and Psychosomatics2013;82:355‐62. ">Offidani 2013</a>), including 22 studies comparing benzodiazepines and antidepressants in various anxiety disorders including panic disorder. The authors found that benzodiazepines were more effective in reducing the number of panic attacks, than TCAs. Additionally, benzodiazepines were better tolerated than TCAs and they were as effective as the newer antidepressants. The authors concluded that the role of benzodiazepines should be reappraised. The review mostly focused on tricyclic antidepressants and did not include studies comparing benzodiazepines with SSRIs. </p> <p>An up‐to‐date systematic review is needed to help practitioners identify the relative efficacy of antidepressants and benzodiazepines, compared to each other, in order to be better guided in the choice of the pharmacological agent. </p> <p>Two other Cochrane reviews in patients with panic disorder, one on antidepressants versus placebo and one on benzodiazepines versus placebo, respectively, are in progress, which will be of further help to identify effective treatments in panic disorder (<a href="./references#CD011567-bbs2-0110" title="GuaianaG , BarbuiC , ChiodoD , CiprianiA , DaviesSJC , KoestersM . Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD010677] ">Guaiana 2013a</a>; <a href="./references#CD011567-bbs2-0111" title="GuaianaG , BarbuiC , ChiodoD , CiprianiA , DaviesSJC , KoestersM . Antidepressants versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD010676] ">Guaiana 2013b</a>). A Cochrane network meta‐analysis of psychopharmacological treatment in panic disorder is in progress (<a href="./references#CD011567-bbs2-0112" title="GuaianaG , BarbuiC , CaldwellD , DaviesSJC , FurukawaT , ImaiH , et al. Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta‐analysis. Cochrane Database of Systematic Reviews2014 (Data on file). ">Guaiana 2014</a>). </p> <p>This review followed the methods set out in the protocol (<a href="./references#CD011567-bbs2-0133" title="GuaianaG , BarbuiC , BighelliI , TrespidiC , ChiodoD , CiprianiA , et al. Antidepressants and benzodiazepines for panic disorder in adults. Cochrane Database of Systematic Reviews2015, Issue Issue 3. [DOI: 10.1002/14651858.CD011567] ">Guaiana 2015</a>) </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011567-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011567-sec-0035"></div> <p>To assess the effects of antidepressants or benzodiazepines for panic disorder in adults, specifically: </p> <p> <ol id="CD011567-list-0002"> <li> <p>to determine the efficacy of antidepressants and benzodiazepines in alleviating symptoms of panic disorder, with or without agoraphobia, in comparison to other antidepressants and other benzodiazepines; </p> </li> <li> <p>to review the acceptability of antidepressants and benzodiazepines in panic disorder, with or without agoraphobia, in comparison to other antidepressants and other benzodiazepines; and </p> </li> <li> <p>to investigate the adverse effects of antidepressants and benzodiazepines in panic disorder, with or without agoraphobia, including the general prevalence of adverse effects, compared to other antidepressants and other benzodiazepines. </p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011567-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011567-sec-0036"></div> <section id="CD011567-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011567-sec-0038"> <h4 class="title">Types of studies</h4> <p>Double‐blind randomised controlled trials (RCTs) using a parallel‐group design that compare antidepressants as monotherapy with benzodiazepines as monotherapy, antidepressants with antidepressants and benzodiazepines with benzodiazepines. We included one cross‐over trial, and RCTs with more than two arms. Cluster‐RCTs were eligible for inclusion but none were identified. </p> <p>We excluded quasi‐randomised trials, such as those allocated by using alternate days of the week. </p> </section> <section id="CD011567-sec-0039"> <h4 class="title">Types of participants</h4> <section id="CD011567-sec-0040"> <h5 class="title">Participants</h5> <p>Participants aged 18 years or older.</p> </section> <section id="CD011567-sec-0041"> <h5 class="title">Diagnosis</h5> <p>Patient with primary diagnosis of panic disorder, with or without agoraphobia, diagnosed according to any of the following criteria: Feighner criteria, Research Diagnostic Criteria, Diagnostic and Statistical Manual of Mental Disorders (DSM‐III, DSM‐III‐R, DSM‐IV, DSM‐V) or International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD‐10). In cases where study eligibility focused on agoraphobia, rather than panic disorder, we included studies if operationally diagnosed according to the above‐named criteria and when it was possible to safely assume that some of the participants were suffering from panic disorder as defined by the above criteria. In other words, we excluded studies that focused on agoraphobia without panic disorder. There is evidence that over 95% of patients with agoraphobia seen clinically suffer from panic disorder as well (<a href="./references#CD011567-bbs2-0107" title="GoismanRM , WarshawMG , SteketeeGS , FiermanEJ , RogersMP , GoldenbergI , et al. DSM‐IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis. American Journal of Psychiatry1995;152:1438‐43. ">Goisman 1995</a>). However, we planned to further examine the effects of the inclusion of these studies (i.e. studies in which some, but possibly not all, of the patients had panic disorder) in a sensitivity analysis (<a href="#CD011567-sec-0077">Sensitivity analysis</a>). </p> </section> <section id="CD011567-sec-0042"> <h5 class="title">Co‐morbidities</h5> <p>We excluded participants with serious co‐morbid physical disorders (e.g. myocardial infarction, chronic obstructive pulmonary disorder, uncontrolled diabetes, electrolyte disturbances) as they may confound treatment effectiveness and tolerability. Studies where panic is induced were excluded. We included participants with co‐morbid mental disorders, but the effect of including these participants was examined in sensitivity analyses (<a href="#CD011567-sec-0077">Sensitivity analysis</a>). </p> </section> <section id="CD011567-sec-0043"> <h5 class="title">Settings</h5> <p>We included all types of settings (inpatient, outpatient, primary care). We included only studies recruiting patients acutely ill. Long‐term, relapse prevention studies were therefore excluded. </p> </section> </section> <section id="CD011567-sec-0044"> <h4 class="title">Types of interventions</h4> <p>Trials comparing antidepressants as monotherapy with benzodiazepines as monotherapy, antidepressants with antidepressants, and benzodiazepines with benzodiazepines in the treatment of panic disorder, with or without agoraphobia. </p> <p>We included only acute treatment studies treating participants for less than six months. If a study treated participants for more than six months but reported outcome data within six months, we included the data. </p> <p>We included the following antidepressants as classified by the World Health Organization (WHO) Anatomical, Therapeutic and Chemical (ATC) classification system and the Defined Daily Dose (DDD) (WHO ATC/DDD) system (<a href="./references#CD011567-bbs2-0131" title="World Health Organization. Introduction to drug utilization research. WHO International Working Group for Drug Statistics Methodology; WHO Collaborating Centre for Drug Statistics Methodology; WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. 2003. Available from http://www.who.int/medicines/areas/quality_safety/safety_efficacy/utilization/en/. ">WHO 2003</a>). </p> <p> <ol id="CD011567-list-0003"> <li> <p>Tricyclic antidepressants (TCAs): amitriptyline, amoxapine, clomipramine, desipramine, dosulepin/dothiepin, doxepin, imipramine, iofepramine, maprotiline, nortriptyline, protriptyline , trimipramine, any other agent. </p> </li> <li> <p>Selective serotonin reuptake inhibitors (SSRIs): fluoxetine, fluvoxamine, sertraline, citalopram, paroxetine, escitalopram, any other agent. </p> </li> <li> <p>Monomine oxidase inhibitors (MAOIs: phenelzine, isocarboxazide, tranylcypromine, moclobemide, brofaromine, any other agent. </p> </li> <li> <p>Serotonin‐noradrenaline reuptake Inhibitors (SNRIs): venlafaxine, desvenlafaxine, duloxetine, milnacipran, any other agent. </p> </li> <li> <p>Noradrenergic and specific serotonergic antidepressants (NaSSAs): mirtazapine, any other agent </p> </li> <li> <p>Noradrenergic and dopaminergic reuptake inhibitors: bupropion, any other agent.</p> </li> <li> <p>Noradrenergic reuptake inhibitors: reboxetine, any other agent.</p> </li> <li> <p>Others: agomelatine, trazodone, nefazodone, mianserin, maprotiline, any other agent classified as antidepressants according to the WHO ATC/DDD system of non‐conventional herbal products (e.g. <i>Hypericum</i>). </p> </li> </ol> </p> <p>We included the following benzodiazepines: alprazolam, bretazenil, bromazepam, chlordiazepoxide, cinolazepam, clonazepam, cloxazolam, clorazepate, diazepam, estazolam, fludiazepam, flunitrazepam, flurazepam, flutoprazepam, halazepam, ketazolam, loprazolam, lorazepam, medazepam, nimatazepam, nitrazepam, nodazepam, oxazepam, phenazepam, pinazepam, prazepam, premazepam, quazepam, temazepam, tetrazepam, triazolam. </p> <p>We excluded studies in which regular use of benzodiazepines was allowed in addition to the study medications; studies where irregular use of benzodiazepines was allowed were included, but the effect of including these participants was examined in sensitivity analyses (<a href="#CD011567-sec-0077">Sensitivity analysis</a>). We applied no restrictions on dose, frequency, intensity or duration.   </p> <p>We also excluded studies administering psychosocial therapies targeted at panic disorder delivered concurrently with medication. </p> </section> <section id="CD011567-sec-0045"> <h4 class="title">Types of outcome measures</h4> <section id="CD011567-sec-0046"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011567-list-0004"> <li> <p>Failure to respond, i.e. lacking of substantial improvement from baseline as defined by the original investigators. Examples of improvement would be “very much or much improved” according to the Clinical Global Impressions Scale, more than 40% reduction in the Panic Disorder Severity Scale score (which is considered as equivalent to "very much or much improved" on the Clinical Global Impression of Improvement Scale (<a href="./references#CD011567-bbs2-0051" title="FurukawaTA , Katherine ShearM , BarlowDH , GormanJM , WoodsSW , MoneyR , et al. Evidence‐based guidelines for interpretation of the Panic Disorder Severity Scale. Depression and Anxiety2009;26(10):922‐9. ">Furukawa 2009</a>), and more than 50% reduction in the Fear Questionnaire Agoraphobia Subscale (which is considered as an appropriate rate of response according to <a href="./references#CD011567-bbs2-0089" title="BandelowB , BaldwinDS , DolbergOT , AndersenHF , SteinDJ . What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?. Journal of Clinical Psychiatry2006;67:1428‐34. ">Bandelow 2006</a>). For this outcome we calculated the number of patients who fail to meet these improvement criteria. </p> </li> <li> <p>Total number of dropouts for any reason as a proxy measure of treatment acceptability.</p> </li> </ol> </p> </section> <section id="CD011567-sec-0047"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011567-list-0005"> <li> <p>Failure to remit, i.e. lacking of satisfactory end‐state as defined by global judgment of the original investigators. Examples of satisfactory end‐state would be "panic free" and "no or minimal symptoms" according to the Clinical Global Impression Severity Scale. For this outcome, we calculated the number of patients who failed to meet these remission criteria. </p> </li> <li> <p>Panic symptom scales and global judgment on a continuous scale. Examples include Panic Disorder Severity Scale (PDSS) total score (0 to 28), Clinical Global Impression Severity Scale (CGI‐S) (1 to 7), and Clinical Global Impression Change Scale (1 to 7). When multiple measures are used, preference was given in the order as above, with preference given to panic symptom scales. The actual measure entered into meta‐analyses will be indicated at the top of the listings in the 'Characteristics of included studies' section </p> </li> <li> <p>Frequency of panic attacks, as recorded, for example, by a panic diary</p> </li> <li> <p>Agoraphobia, as measured, for example, by the Fear Questionnaire (FQ), Mobility Inventory, or behavioural avoidance test </p> </li> <li> <p>General anxiety, as measured, for example, by the Hamilton Rating Scale for Anxiety (HAMA), Beck Anxiety Inventory, State‐Trait Anxiety Index, Sheehan Patient‐Rated Anxiety Scale, or Anxiety Subscale of Symptom Checklist‐90‐Revised (SCL‐90‐R) </p> </li> <li> <p>Depression, as measured, for example, by the Hamilton Rating Scale for Depression (HRSD), Beck Depression Inventory (BDI), or Depression Subscale of SCL‐90‐R </p> </li> <li> <p>Social functioning, as measured, for example, by the Sheehan Disability Scale (SDS), Global Assessment Scale, or Social Adjustment Scale‐Self Report </p> </li> <li> <p>Quality of life, as measured for example by the 36‐Item Short Form Health Survey (SF‐36) or the 12‐Item Short Form Health Survey (SF‐12) </p> </li> <li> <p>Patient satisfaction with treatment</p> </li> <li> <p>Economic costs</p> </li> <li> <p>Number of dropouts due to adverse effects</p> </li> <li> <p>Number of patients experiencing at least one adverse effect</p> </li> </ol> </p> <section id="CD011567-sec-0048"> <h6 class="title">Timing of outcome assessment</h6> <p>All outcomes are short‐term outcomes, which we defined as acute phase treatment which normally would last two to six months. </p> <p>When studies reported outcome data at different time points within two to six months, the time point closest to 12 weeks was given preference. </p> </section> <section id="CD011567-sec-0049"> <h6 class="title">Hierarchy of outcome measures</h6> <p>When multiple measures were used, preference was given in the order listed above for each outcome. </p> </section> </section> </section> </section> <section id="CD011567-sec-0050"> <h3 class="title">Search methods for identification of studies</h3> <p>The Cochrane Common Mental Disorders Group maintains a specialised register of randomised controlled trials, the CCMDCTR. This register contains over 40,000 reference records (reports of RCTs) for anxiety disorders, depression, bipolar disorder, eating disorders, self‐harm and other mental disorders within the scope of this Group. The CCMDCTR is a partially studies based register with &gt;50% of reference records tagged to c12,500 individually PICO coded study records. Reports of trials for inclusion in the register are collated from (weekly) generic searches of MEDLINE (1950‐), Embase (1974‐) and PsycINFO (1967‐), quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and review specific searches of additional databases. Reports of trials are also sourced from international trial registries, drug companies, the hand‐searching of key journals, conference proceedings and other (non‐Cochrane) systematic reviews and meta‐analyses. Details of <a href="http://cmd.cochrane.org/search-strategies-identification-studies" target="_blank">CCMD's core search strategies</a> (used to identify RCTs) can be found on the Group's web site with an example of the core MEDLINE search displayed in <a href="./appendices#CD011567-sec-0440">Appendix 1</a>. </p> <section id="CD011567-sec-0051"> <h4 class="title">Electronic searches</h4> <section id="CD011567-sec-0052"> <h5 class="title">Cochrane Common Mental Disorders Group's specialised register (CCMDCTR)</h5> <p>The Group's Information Specialist searched the CCMDCTR (Studies and References) register to 11 September 2015, using the following search strategy: </p> <p><i>CCDANCTR‐Studies</i> <br/> Diagnosis = panic </p> <p>Records were screened for randomised‐controlled trials comparing antidepressants with benzodiazepines, antidepressants with antidepressants or benzodiazepine with benzodiazepine in this population. </p> <p><i>CCDANCTR‐References</i> <br/> A search of the references register (to identify additional untagged, uncoded reports of RCTs) included a comprehensive list of terms for panic, anxiety disorders not otherwise specified (ADNOS), antidepressants and benzodiazepines, (<a href="./appendices#CD011567-sec-0441">Appendix 2</a>). </p> <p>We screened all abstracts for 'antidepressants' as classified by the WHO ATC/DDD system as well as relevant benzodiazepine trials. We obtained full‐text articles, where necessary. </p> </section> <section id="CD011567-sec-0053"> <h5 class="title">National and international trials registers</h5> <p>We conducted complementary searches on the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) and <a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> </p> </section> </section> <section id="CD011567-sec-0054"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all included studies, non‐Cochrane systematic reviews and major textbooks of affective disorders (written in English), for published reports and citations of unpublished research. We also pursued a citation search via Web of Science (included studies only) to identify additional works. We also contacted experts in the field. </p> </section> </section> <section id="CD011567-sec-0055"> <h3 class="title" id="CD011567-sec-0055">Data collection and analysis</h3> <section id="CD011567-sec-0056"> <h4 class="title">Selection of studies</h4> <p>Two review authors (IB (clinical expertise), CT (methodological expertise)) independently selected studies for inclusion in this systematic review. </p> <p>Review authors IB and CT inspected the search results by reading the titles and abstracts to see if they met the inclusion criteria. Disagreement was resolved by consultation with the other co‐authors. We obtained full‐text articles for the potentially relevant studies located in the search and both review authors independently assessed them for inclusion and, in the case of discordance, resolution was sought by discussion between all review authors. Where it was not be possible to evaluate the study because of language problems or missing information, we categorised the study as 'study awaiting classification' until a translation or further information could be obtained. We reported the reasons for the exclusion of trials in the <a href="./references#CD011567-sec-0451" title="">Characteristics of excluded studies</a> table. </p> <p>We documented and presented all decisions made during the selection process, with numbers of studies and references, in a Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) flow diagram (<a href="./references#CD011567-bbs2-0119" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA group. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: The PRISMA Statement. PLoS Medicine2009;6(6):e1000097. ">Moher 2009</a>) (<a href="#CD011567-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011567-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011567-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011567-sec-0057"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (IB and CT) used a standardised data extraction form to independently extract data from included studies concerning participant characteristics (age, sex, study setting), intervention details (dosage, duration of study, sponsorship), study characteristics (blinding, allocation etc) and outcome measures of interest. We first piloted this data extraction sheet on a sample of 10% of the included studies. Again, any disagreement was resolved by consensus or by consulting a third review author (CB). If necessary, we contacted authors of studies to obtain clarification. </p> <p>Our comparisons were as follows (<a href="#CD011567-sec-0044">Types of interventions</a>): </p> <p>A. antidepressants versus benzodiazepines;</p> <p>B. antidepressants versus antidepressants;</p> <p>C. individual benzodiazepines versus another benzodiazepine.</p> <p>We stratified comparison A by class of antidepressant, as per the categories provided in <a href="#CD011567-sec-0044">Types of interventions</a>. We also included comparisons of antidepressant classes versus benzodiazepines, to allow the presentation of data about individual antidepressants of each class versus benzodiazepines. For the second comparison, we made the decision to conduct separate comparisons for each class of antidepressant rather than stratify an overall comparison of antidepressant versus antidepressant according to class of drug. For the second comparison we also included individual antidepressants versus another antidepressant of the same class (see <a href="#CD011567-sec-0447">Differences between protocol and review</a>.) </p> </section> <section id="CD011567-sec-0058"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (IB and CT) independently assessed the risk of bias in included studies using the Cochrane Collaboration's tool for assessing risk of bias as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011567-bbs2-0113" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). This tool encourages consideration of the following domains: </p> <p> <ol id="CD011567-list-0006"> <li> <p>random sequence generation and allocation concealment (selection bias);</p> </li> <li> <p>blinding of participants and personnel (performance bias);</p> </li> <li> <p>blinding of outcome assessors (detection bias);</p> </li> <li> <p>incomplete outcome data reporting (attrition bias);</p> </li> <li> <p>selective reporting (reporting bias);</p> </li> <li> <p>other bias (within this domain we will consider things like sponsorship bias).</p> </li> </ol> </p> <p>We assessed and categorised risk of bias, in each domain and overall, as follows:</p> <p> <ol id="CD011567-list-0007"> <li> <p>low risk of bias, plausible bias unlikely to seriously alter the results;</p> </li> <li> <p>high risk of bias, plausible bias that seriously weakens confidence in the results;</p> </li> <li> <p>unclear risk of bias, plausible bias that raises some doubt about the results.</p> </li> </ol> </p> <p>In case of disagreement, the final rating was made by consensus, if needed with the involvement of a third author (CB). Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain further information. Non‐concurrence in assessment of bias was also reported. </p> </section> <section id="CD011567-sec-0059"> <h4 class="title">Measures of treatment effect</h4> <p>Our main outcome measure is reduction of severity of panic and agoraphobia symptoms. Symptomatic improvement was usually presented as a change in a panic disorder scale(s) (mean and standard deviation) or as a dichotomous outcome (responder or non‐responder, remitted or not‐remitted), or both. </p> <section id="CD011567-sec-0060"> <h5 class="title">Dichotomous data</h5> <p>For binary or dichotomous outcomes, we calculated a standard estimation of the risk ratios (RRs) and the corresponding 95% confidence intervals (CIs) using a random‐effects model. It has been shown that a random‐effects model has a good generalisability (<a href="./references#CD011567-bbs2-0103" title="FurukawaTA , GuyattGH , GriffithLE . Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta‐analyses. International Journal of Epidemiology2002;31:72‐6. ">Furukawa 2002</a>), and that RRs are easier to understand than odds ratios (ORs) (<a href="./references#CD011567-bbs2-0094" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. Comparison of the indices and their use. Therapie1999;54:405‐11. ">Boissel 1999</a>). Furthermore, ORs tend to be interpreted as RRs by clinicians (<a href="./references#CD011567-bbs2-0100" title="DeeksJJ . Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomes. Statistics in Medicine2002;21(11):1575‐600. ">Deeks 2002</a>). This may lead to an overestimation of the impression of the effect (<a href="./references#CD011567-bbs2-0113" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). For all primary outcomes, we calculated the number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH) and their 95% CIs using Visual Rx (<a href="http://www.nntonline.net/" target="_blank">www.nntonline.net/</a>), taking account of the event rate in the control group. </p> </section> <section id="CD011567-sec-0061"> <h5 class="title">Continuous data</h5> <section id="CD011567-sec-0062"> <h6 class="title">Summary statistics</h6> <p>We assumed a priori that the included studies used varied rating scales; therefore we used standardised mean differences (SMDs). If all included studies used the same measuring instrument, we used mean differences (MDs). We also calculated 95% CIs for each continuous measure. </p> </section> <section id="CD011567-sec-0063"> <h6 class="title">Endpoint versus change data</h6> <p>Trials usually report results either using endpoint means and standard deviation of scales or using change in mean values from baseline of assessment rating scales. We prefer to use scale endpoint data, which typically cannot have negative values and are easier to interpret from a clinical point of view. If endpoint data were unavailable, we used the change data in separate analyses. In the case we used MDs, we pooled results based on change data and endpoint data in the same analysis. </p> </section> </section> </section> <section id="CD011567-sec-0064"> <h4 class="title">Unit of analysis issues</h4> <section id="CD011567-sec-0065"> <h5 class="title">Cross‐over trials</h5> <p>Cross‐over trials are trials in which all participants receive both the control and intervention treatment but in a different order. The major problem is a carry‐over effect from the first phase to the second phase of the study, especially if the condition of interest is unstable (<a href="./references#CD011567-bbs2-0102" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31:140‐9. ">Elbourne 2002</a>). As this is the case with panic disorder, we planned to include cross‐over studies, but to use only data up to the point of first cross‐over phase. </p> </section> <section id="CD011567-sec-0066"> <h5 class="title">Studies with multiple treatment groups</h5> <p>Where a study involved more than two treatment arms, when there were two appropriate dose groups of the same drug, we pooled different dose arms and considered them as one. If the arms involved one or more benzodiazepine arms and/or two or more arms of different classes of antidepressants, we planned to compare each arm separately. To avoid the of unit‐of‐analysis error by double counting the patients of the shared group (<a href="./references#CD011567-bbs2-0113" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), we planned to divide the shared group evenly among the treatment arms. In accordance to the recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011567-bbs2-0113" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), we divided events and number of patients for dichotomous outcomes, while only divided the number of patients for continuous outcomes. </p> </section> <section id="CD011567-sec-0067"> <h5 class="title">Cluster‐randomised trials</h5> <p>In cluster‐randomised trials, groups of individuals rather than individuals are randomised to different interventions. Had we identified cluster‐RCTs, we planned to use the generic inverse variance technique. We would have checked if such trials have been appropriately analysed taking into account intraclass correlation coefficients to adjust for cluster effects. If trialists have not adjusted for the effects of clustering, we would have attempted to do this by obtaining an intracluster correlation coefficient and then following the guidance given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011567-bbs2-0113" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> </section> <section id="CD011567-sec-0068"> <h4 class="title">Dealing with missing data</h4> <p>We tried to contact the study authors for all relevant missing data.</p> <section id="CD011567-sec-0069"> <h5 class="title">Dichotomous outcomes</h5> <p>We calculated response, or remission on treatment, using an intention‐to‐treat analysis. We followed the principle of 'once randomised always analysed'. Where participants left the study before the intended endpoint, it was assumed that they would have experienced the negative outcome. The validity of the above assumption was planned to be tested by sensitivity analysis, applying worst and best case scenarios. When dichotomous outcomes were not reported, but the baseline mean and standard deviation on a panic disorder scale were reported, we calculated the number of responding or remitted participants according to a validated imputation method (<a href="./references#CD011567-bbs2-0104" title="FurukawaTA , CiprianiA , BarbuiC , BrambillaP , WatanabeN . Imputing response rates from means and standard deviations in meta‐analysis. International Clinical Psychopharmacology2005;20:49‐52. ">Furukawa 2005</a>). We analysed the validity of the above approach by sensitivity analysis (<a href="#CD011567-sec-0077">Sensitivity analysis</a>). If necessary, we contacted authors of studies to obtain data and/or clarification. </p> </section> <section id="CD011567-sec-0070"> <h5 class="title">Continuous outcomes</h5> <p>Concerning continuous data, the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> recommends avoiding imputation of continuous data and suggests using the data as presented by the original authors (<a href="./references#CD011567-bbs2-0113" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Where intention‐to‐treat data were available, they have been preferred to 'per‐protocol analysis'. If necessary, we contacted authors of studies to obtain data and/or clarification. </p> </section> <section id="CD011567-sec-0071"> <h5 class="title">Skewed or qualitative data</h5> <p>We planned to present skewed and qualitative data descriptively. We considered several strategies for skewed data. If papers reported a mean and standard deviation and there was also an absolute minimum possible value for the outcome, we planned to divide the mean by the standard deviation. If this was less than two then we concluded that there was some indication of skewness. If it was less than one (that is the standard deviation was bigger than the mean), then there was almost certainly skewness. If papers had not reported the skewness and simply reported means, standard deviations and sample sizes, these numbers were used. Because there was a possibility that these data might not have been properly analysed, and could also be misleading, they were descriptively reported in the results. If the data had been log‐transformed for analysis, and the geometric means were reported, skewness was reduced. This is the recommended method of analysis of skewed data (<a href="./references#CD011567-bbs2-0113" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). If studies used non‐parametric tests and described averages using medians, they could not be formally pooled in the analysis. We followed the recommendation made in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> that results of these studies should be reported in a table in our review, along with all other papers. This means that the data were not lost from the review and the results could be considered when drawing conclusions, even if they could not be formally pooled in the analyses. </p> </section> <section id="CD011567-sec-0072"> <h5 class="title">Missing statistics</h5> <p>When only P or standard error values were reported, we calculated standard deviations (<a href="./references#CD011567-bbs2-0081" title="AltmanDG , BlandMJ . Detecting skewness for summary information. BMJ1996;313:1200. ">Altman 1996</a>). In the absence of supplementary data after requests to the authors, we calculated the standard deviations according to a validated imputation method (<a href="./references#CD011567-bbs2-0105" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2000;59:7‐10. ">Furukawa 2006</a>). We examined the validity of these imputations in the sensitivity analyses. </p> </section> </section> <section id="CD011567-sec-0073"> <h4 class="title">Assessment of heterogeneity</h4> <p>We quantified heterogeneity using the I² statistic as per the guidance by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011567-bbs2-0113" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We interpreted the I² as follows: </p> <p> <ol id="CD011567-list-0008"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ol> </p> <p>We also used the Chi² test and its P value to determine the direction and magnitude of the treatment effects. In a meta‐analysis of few trials, Chi² will be underpowered to detect heterogeneity, if it exists. A P value of &lt;0.10 was used as a threshold of statistical significance for the ChI²<sup>²</sup> test. We also visually assessed the forest plots for evidence of heterogeneity. </p> </section> <section id="CD011567-sec-0074"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD011567-bbs2-0113" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). A funnel plot is usually used to investigate publication bias. However, it has a limited role when there are only few studies of similar size. Secondly, asymmetry of a funnel plot does not always reflect publication bias. We visually inspected funnel plots to assess publication bias as well as performed statistical test for funnel plot asymmetry as proposed by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011567-bbs2-0113" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We did not use funnel plots for outcomes if there were 10 or fewer studies included in the meta‐analysis in question, or if all studies were of similar size. </p> </section> <section id="CD011567-sec-0075"> <h4 class="title">Data synthesis</h4> <p>We used a random‐effects model to calculate the treatment effects. We preferred the random‐effects model as it takes into account differences between studies even when there is no evidence of statistical heterogeneity It gives a more conservative estimate than the fixed‐effect model. We noted that the random‐effects model gives added weight to small studies, which can either increase or decrease the effect size. We applied a fixed‐effect model, on primary outcomes only, to see whether it markedly changed the effect size. </p> </section> <section id="CD011567-sec-0076"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analyses are often exploratory in nature and should be interpreted cautiously: firstly, because they often involve multiple analyses leading to false positive results; and secondly, these analyses lack power and are more likely to result in false positive results. Keeping in mind these reservations, and also taking into account the number of available studies, we planned to perform the following subgroup analyses: </p> <p> <ol id="CD011567-list-0009"> <li> <p>participants with agoraphobia versus participants without agoraphobia (because the same treatment may have differential effectiveness with regard to panic and agoraphobia); </p> </li> <li> <p>acute phase treatment studies that lasted for less than four months versus those that lasted for four months or more. </p> </li> </ol> </p> </section> <section id="CD011567-sec-0077"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct the following sensitivity analyses for the primary outcomes only in order to examine if the results changed and check for the robustness of the observed findings. </p> <p> <ol id="CD011567-list-0010"> <li> <p>Excluding trials with high risk of bias (i.e. trials with inadequate allocation concealment and blinding, with incomplete data reporting and/or with high probability of selective reporting). </p> </li> <li> <p>Excluding trials with dropout rates greater than 20%.</p> </li> <li> <p>Excluding studies funded by the pharmaceutical company marketing each antidepressant or benzodiazepine (This sensitivity analysis is particularly important in view of the repeated findings that funding strongly affects outcomes of research studies (<a href="./references#CD011567-bbs2-0080" title="Als‐NielsenB , ChenW , GluudC , KjaergardLL . Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. JAMA2003;290:921‐8. ">Als‐Nielsen 2003</a>; <a href="./references#CD011567-bbs2-0117" title="LexchinJ , BeroLA , DjulbegovicB , ClarkO . Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ2003;326:1167‐70. ">Lexchin 2003</a>; <a href="./references#CD011567-bbs2-0092" title="BhandariM , BusseJW , JackowskiD , MontoriVM , SchünemannH , SpragueS , et al. Association between industry funding and statistically significant pro‐industry findings in medical and surgical randomized trials. Canadian Medical Association Journal2004;170:477‐80. ">Bhandari 2004</a>), and because industry sponsorship and authorship of clinical trial reports have increased over the last 20 years (<a href="./references#CD011567-bbs2-0097" title="BuchkowskySS , JewessonPJ . Industry sponsorship and authorship of clinical trials over 20 years. Annals of Pharmacotherapy2004;38:579‐85. ">Buchkowsky 2004</a>)). </p> </li> <li> <p>Excluding studies whose participants clearly have significant psychiatric co‐morbidities including primary or secondary depressive disorders. </p> </li> <li> <p>Excluding studies mostly focused on agoraphobia.</p> </li> <li> <p>Applying best and worst case scenarios to studies where participants left the study before the endpoint. </p> </li> <li> <p>Excluding studies where responding or remitted participants are calculated according to an imputation method. </p> </li> <li> <p>Excluding studies where irregular benzodiazepine use was allowed after the first 15 days after random allocation. </p> </li> </ol> </p> <section id="CD011567-sec-0078"> <h5 class="title">Summary of findings</h5> <p>We summarised the findings using a 'Summary of findings' table, applying the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<a href="./references#CD011567-bbs2-0113" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>We included the following outcomes in the 'Summary of findings' tables:</p> <p> <ol id="CD011567-list-0011"> <li> <p>response;</p> </li> <li> <p>total number of dropouts;</p> </li> <li> <p>remission;</p> </li> <li> <p>panic symptom scales and global judgment on a continuous scale;</p> </li> <li> <p>number of dropouts due to adverse effects.</p> </li> </ol> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011567-sec-0079" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011567-sec-0079"></div> <section id="CD011567-sec-0080"> <h3 class="title">Description of studies</h3> <section id="CD011567-sec-0081"> <h4 class="title">Results of the search</h4> <p>The number of references identified by the searches (last update September 2015) was 1489, of which 1488 remained after de‐duplication. We excluded 1341 references after assessment of titles and abstracts. We retrieved 147 full‐text articles for full inspection, describing 79 randomised controlled trials (RCTs). Of these, 43 studies were excluded, and one study was placed in the awaiting assessment group. Finally, 35 studies including 6785 participants, 5365 for the arms of interest (described in 84 reports) were included in the review. In case of missing information, we contacted authors of the included studies for additional information, and three of them responded (Drs. Bandelow, Lavori, and Stahl). See <a href="#CD011567-fig-0001">Figure 1</a> for a PRISMA flow diagram (<a href="./references#CD011567-bbs2-0119" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA group. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: The PRISMA Statement. PLoS Medicine2009;6(6):e1000097. ">Moher 2009</a>) depicting the study selection process. </p> </section> <section id="CD011567-sec-0082"> <h4 class="title">Included studies</h4> <p>Thirty‐five studies were included in this review, with characteristics as follows (see also <a href="./references#CD011567-sec-0450" title="">Characteristics of included studies</a>). </p> <section id="CD011567-sec-0083"> <h5 class="title">Design</h5> <p>Thirty‐four of the 35 included studies were parallel‐group, individually‐randomised controlled trials. One study (<a href="./references#CD011567-bbs2-0024" title="SassonY , IancuI , FuxM , TaubM , DannonP , ZoharJ . A double‐blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. European Neuropsychopharmacology1999;9:191‐6. ">Sasson 1999</a>) with a cross‐over design reported only aggregated results on the two active treatment phases (before and after cross‐over); therefore these data could not be included in the meta‐analysis. </p> </section> <section id="CD011567-sec-0084"> <h5 class="title">Sample sizes</h5> <p>The sample sizes ranged between seven (<a href="./references#CD011567-bbs2-0026" title="SheikhJI , SwalesPJ . Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo. International Journal of Psychiatry in Medicine1999;29(1):107‐17. ">Sheikh 1999</a>) and 391 (<a href="./references#CD011567-bbs2-0006" title="AlbusM , LecrubierY , MaierW , BullerR , RosenbergR , HippiusH . Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatrica Scandinavica1990;82(5):359‐65. AlbusM , MaierW , SheraD , BechP . Consistencies and discrepancies in self‐ and observer‐rated anxiety scales. A comparison between the self‐ and observer‐rated Marks‐Sheehan scales. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):96‐102. AnderschS , HansonL , HallstromT . Panic disorder: a five‐year follow‐up study in 52 patients. European Journal of Psychiatry1997;11(3):145‐55. AnderschS , HettaJ . A 15‐year follow‐up study of patients with panic disorder. European Psychiatry2003;18(8):401‐08. AnderschS , RosenbergNK , KullingsjöH , OttossonJO , BechP , Bruun‐HansenJ , et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatrica Scandinavica. Supplementum1991;365:18‐27. BerlangaC , CanettiA , ChavezE , De LaFuenteR , delCarmen LaraM , LeonC , et al. Pharmacologic treatment of panic disorders: Comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study [Tratamiento farmacologico de las crisis de angustia Reporte comparativo de la eficacia y seguridad del alprazolam y la imipramina en un estudio controlado]. Salud Mental1991;14(1):1‐5. BullerR , MaierW , GoldenbergIM , LavoriPW , BenkertO . Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross‐National Collaborative Panic Study. European Archives of Psychiatry and Clinical Neuroscience1991;240(3):163‐8. CassanoGB , ToniC , PetraccaA , DeltitoJ , BenkertO , CurtisG , et al. Adverse effects associated with the short‐term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology1994;4(1):47‐53. Cross National Collaborative Panic Study Second Phase Investigators. Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. British Journal of Psychiatry1992;160:191‐202. CurtisGC , MassanaJ , UdinaC , AyusoJL , CassanoGB , PerugiG . Maintenance drug therapy of panic disorder. Journal of Psychiatry Research1993;27(Suppl 1):127‐42. DeltitoJA , ArgyleN , BullerR , NutzingerD , OttossonJO , BrandonS , et al. The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(2):120‐9. DeltitoJA , ArgyleN , KlermanGL . Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Journal of Clinical Psychiatry1991;52(3):121‐7. GreenMA , CurtisGC . Personality disorders in panic patients: Response to termination of antipanic medication. Journal of Personality Disorders1988;2(4):303‐14. KatschnigH , AmeringM , StolkJM , KlermanGL , BallengerJC , BriggsA , et al. Long‐term follow‐up after a drug trial for panic disorder. British Journal of Psychiatry1995;167(4):487‐94. KlermanGL . Depression and panic anxiety: the effect of depressive co‐morbidity on response to drug treatment of patients with panic disorder and agoraphobia. Journal of Psychiatric Research1990;24(Suppl 2):27‐41. KlermanGL , ColemanJH , PurpuraRP . The design and conduct of the Upjohn Cross‐National Collaborative Panic Study. Psychopharmacology Bulletin1986;22(1):59‐64. LavoriPW , DawsonR , SheraD . A multiple imputation strategy for clinical trials with truncation of patient data. Statistics in Medicine1995;14(17):1913‐25. LeónCA , DeArangoMV , ArevaloW , CalvoA , MontoyaA , LeónA . Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia [Comparacion del efecto del alprazolam, la imipramina y placebo en el tratamiento del trastorno de panico en Cali, Colombia]. Acta Psiquiatrica y Psicologica de America Latina1990;36(1‐2):59‐72. MaierW , AlbusM , BullerR , NutzingerD , SheraD , BechP . Self‐ and observer assessment in anxiolytic drug trials: a comparison of their validity. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):103‐8. MaierW , RothSM , ArgyleN , BullerR , LavoriP , BrandonS , et al. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?. European Archives of Psychiatry and Clinical Neuroscience1991;241(3):151‐8. MaierWA , RothM , BullerR , ArgyleN , RosenbergR , SydneyB , et al. Agoraphobia in panic disorder: An indicator of the severity of panic disorder or a distinct diagnostic entity?. Psychiatric Annals1991;21(6):374‐81. RifkinA . The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(6):559‐60. RosenbergNK , MellergårdM , RosenbergR , BeckP , OttossonJO . Characteristics of panic disorder patients responding to placebo. Acta Psychiatrica Scandinavica Supplementum1991;365:33‐8. RosenbergR , BechP , MellergårdM , OttossonJO . Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response. Acta Psychiatrica Scandinavica. Supplementum1991;365:46‐52. SwobodaH , AmeringM , WindhaberJ , KatschnigH . The long‐term course of panic disorder‐‐an 11 year follow‐up. Journal of Anxiety Disorders2003;17(2):223‐32. ">CNCPS 1992</a>) participants in each arm. Fifteen studies included overall sample sizes over 100: <a href="./references#CD011567-bbs2-0004" title="BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , DombrowskiA , et al. Sertraline versus paroxetine in the treatment of panic disorder: a multinational randomized double‐blind 15 week study. European Neuropsychopharmacology2002;12(Suppl 3):S363. BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , GoebelC , et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double‐blind noninferiority comparison. Journal of Clinical Psychiatry2004;65(3):405‐13. ">Bandelow 2004</a> (n = 225), <a href="./references#CD011567-bbs2-0006" title="AlbusM , LecrubierY , MaierW , BullerR , RosenbergR , HippiusH . Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatrica Scandinavica1990;82(5):359‐65. AlbusM , MaierW , SheraD , BechP . Consistencies and discrepancies in self‐ and observer‐rated anxiety scales. A comparison between the self‐ and observer‐rated Marks‐Sheehan scales. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):96‐102. AnderschS , HansonL , HallstromT . Panic disorder: a five‐year follow‐up study in 52 patients. European Journal of Psychiatry1997;11(3):145‐55. AnderschS , HettaJ . A 15‐year follow‐up study of patients with panic disorder. European Psychiatry2003;18(8):401‐08. AnderschS , RosenbergNK , KullingsjöH , OttossonJO , BechP , Bruun‐HansenJ , et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatrica Scandinavica. Supplementum1991;365:18‐27. BerlangaC , CanettiA , ChavezE , De LaFuenteR , delCarmen LaraM , LeonC , et al. Pharmacologic treatment of panic disorders: Comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study [Tratamiento farmacologico de las crisis de angustia Reporte comparativo de la eficacia y seguridad del alprazolam y la imipramina en un estudio controlado]. Salud Mental1991;14(1):1‐5. BullerR , MaierW , GoldenbergIM , LavoriPW , BenkertO . Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross‐National Collaborative Panic Study. European Archives of Psychiatry and Clinical Neuroscience1991;240(3):163‐8. CassanoGB , ToniC , PetraccaA , DeltitoJ , BenkertO , CurtisG , et al. Adverse effects associated with the short‐term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology1994;4(1):47‐53. Cross National Collaborative Panic Study Second Phase Investigators. Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. British Journal of Psychiatry1992;160:191‐202. CurtisGC , MassanaJ , UdinaC , AyusoJL , CassanoGB , PerugiG . Maintenance drug therapy of panic disorder. Journal of Psychiatry Research1993;27(Suppl 1):127‐42. DeltitoJA , ArgyleN , BullerR , NutzingerD , OttossonJO , BrandonS , et al. The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(2):120‐9. DeltitoJA , ArgyleN , KlermanGL . Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Journal of Clinical Psychiatry1991;52(3):121‐7. GreenMA , CurtisGC . Personality disorders in panic patients: Response to termination of antipanic medication. Journal of Personality Disorders1988;2(4):303‐14. KatschnigH , AmeringM , StolkJM , KlermanGL , BallengerJC , BriggsA , et al. Long‐term follow‐up after a drug trial for panic disorder. British Journal of Psychiatry1995;167(4):487‐94. KlermanGL . Depression and panic anxiety: the effect of depressive co‐morbidity on response to drug treatment of patients with panic disorder and agoraphobia. Journal of Psychiatric Research1990;24(Suppl 2):27‐41. KlermanGL , ColemanJH , PurpuraRP . The design and conduct of the Upjohn Cross‐National Collaborative Panic Study. Psychopharmacology Bulletin1986;22(1):59‐64. LavoriPW , DawsonR , SheraD . A multiple imputation strategy for clinical trials with truncation of patient data. Statistics in Medicine1995;14(17):1913‐25. LeónCA , DeArangoMV , ArevaloW , CalvoA , MontoyaA , LeónA . Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia [Comparacion del efecto del alprazolam, la imipramina y placebo en el tratamiento del trastorno de panico en Cali, Colombia]. Acta Psiquiatrica y Psicologica de America Latina1990;36(1‐2):59‐72. MaierW , AlbusM , BullerR , NutzingerD , SheraD , BechP . Self‐ and observer assessment in anxiolytic drug trials: a comparison of their validity. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):103‐8. MaierW , RothSM , ArgyleN , BullerR , LavoriP , BrandonS , et al. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?. European Archives of Psychiatry and Clinical Neuroscience1991;241(3):151‐8. MaierWA , RothM , BullerR , ArgyleN , RosenbergR , SydneyB , et al. Agoraphobia in panic disorder: An indicator of the severity of panic disorder or a distinct diagnostic entity?. Psychiatric Annals1991;21(6):374‐81. RifkinA . The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(6):559‐60. RosenbergNK , MellergårdM , RosenbergR , BeckP , OttossonJO . Characteristics of panic disorder patients responding to placebo. Acta Psychiatrica Scandinavica Supplementum1991;365:33‐8. RosenbergR , BechP , MellergårdM , OttossonJO . Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response. Acta Psychiatrica Scandinavica. Supplementum1991;365:46‐52. SwobodaH , AmeringM , WindhaberJ , KatschnigH . The long‐term course of panic disorder‐‐an 11 year follow‐up. Journal of Anxiety Disorders2003;17(2):223‐32. ">CNCPS 1992</a> (n = 1168), <a href="./references#CD011567-bbs2-0011" title="GSK . A double‐blind, multicenter, flexible‐dose study of paroxetine, alprazolam and placebo in the treatment of panic disorder. GSK Clinical Studies Register [http://www.gsk‐clinicalstudyregister.com/]. ">GSK‐29060/1</a> (n = 226), <a href="./references#CD011567-bbs2-0013" title="HollandR , MuschB , HindmarchI . Specific effects of benzodiazepines and tricyclic antidepressants in panic disorder: comparisons of clomipramine with alprazolam SR and adinazolam SR. Human Psychopharmacology Clinical Experimental1999;14:119‐24. ">Holland 1999</a> (n = 315), <a href="./references#CD011567-bbs2-0014" title="KruegerMB , DahlAA . The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. European Archives of Psychiatry and Clinical Neuroscience1999;249(Suppl 1):S19‐S24. ">Krueger 1999</a> (n = 135), <a href="./references#CD011567-bbs2-0015" title="GlaxoSmithKline . A double‐blind placebo controlled comparative study of paroxetine and clomipramine in the treatment of panic disorder. GSK‐ClinicalStudy Register (www.gsk‐clinicalstudyregister.com) 1993/11/12. LecrubierY , BakkerA , DunbarG , Judge R and the Collaborative Panic Study Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatrica Scandinavica1997;95:145‐52. LecrubierY , Judge R and the Collaborative Paroxetine Panic Study Investigators. Long‐term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatrica Scandinavica1997;95:153‐60. ">Lecrubier 1997</a> (n = 368), <a href="./references#CD011567-bbs2-0018" title="BakishD , HooperCL , FilteauMJ , CharbonneauY , FraserG , WestDL , et al. A double‐blind placebo‐controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacology Bulletin1996;32(1):135‐41. NairNP , BakishD , SaxenaB , AminM , SchwartzG , WestTE . Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety1996;2(4):192‐8. ">Nair 1996</a> (n = 148), <a href="./references#CD011567-bbs2-0019" title="CoryellW , NoyesRJr , SchlechteJ . The significance of HPA axis disturbance in panic disorder. Biological Psychiatry1989;25(8):989‐1002. LopezAL , KatholRG , NoyesRJr . Reduction in urinary free cortisol during benzodiazepine treatment of panic disorder. Psychoneuroendocrinology1990;15(1):23‐8. NoyesRJr , BurrowsGD , ReichJH , JuddFK , GarveyMJ , NormanTR , et al. Diazepam versus alprazolam for the treatment of panic disorder. Journal of Clinical Psychiatry1996;57(8):349‐55. NoyesRJr , GarveyMJ , CookB , SuelzerM . Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. American Journal of Psychiatry1991;148(4):517‐23. ">Noyes 1996</a> (n = 238), <a href="./references#CD011567-bbs2-0020" title="Pfizer . A randomized, double‐blind, multicenter study of sertraline compared with paroxetine In the treatment of panic disorder. http://clinicaltrials.gov/show/NCT006773522008. ">Pfizer 2008</a> (n = 319), <a href="./references#CD011567-bbs2-0021" title="PollackM , ManganoR , EntsuahR , TzanisE , SimonNM . A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology2007;194:233‐42. PollackM , WhitakerT , ManganoR , GaoB . A comparison of venlafaxine XR and paroxetine in the treatment of outpatients with panic disorder. ACNP 2004 Annual MeetingS201‐S202. ">Pollack 2007a</a> (n = 653), <a href="./references#CD011567-bbs2-0022" title="PollackMH , LepolaU , KoponenH , SimonNM , WorthingtonJJ , EmilienG , et al. A double‐blind study of the efficacy of venlafaxine extended‐release, paroxetine and placebo in the treatment of panic disorder. Depression and Anxiety2007;24:1‐14. ">Pollack 2007b</a> (n = 663), <a href="./references#CD011567-bbs2-0025" title="RickelsK , SchweizerE . Panic disorder: Long‐term pharmacotherapy and discontinuation. Journal of Clinical Psychopharmacology1998;18(6 Suppl 2):12‐8. RickelsK , SchweizerE , WeissS , ZavodnickS . Maintenance drug treatment for panic disorder. II. Short‐ and long‐term outcome after drug taper. Archives of General Psychiatry1993;50:61‐8. SchweizerE , RickelsK , WeissS , ZavodnickS . Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo‐controlled comparison of alprazolam and imipramine. Archives of General Psychiatry1993;50:51‐60. ">Schweizer 1993</a> (n = 106); <a href="./references#CD011567-bbs2-0027" title="BandelowB , SteinDJ , DolbergOT , AndersenHF , BaldwinDS . Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry2007;40:152‐6. ForestLaboratories . Flexible‐dose comparison of the safety and efficacy of Lu 26‐054 (escitalopram), citalopram and placebo in the treatment of panic disorder. Forest Laboratories Clinical Study Register [www.forestclinicaltrials.com]. StahlS , GergelI , LiD . Escitalopram in the treatment of panic disorder: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2003;64:1322‐7. ">Stahl 2003</a> (n = 380), <a href="./references#CD011567-bbs2-0030" title="TillerJWG , BouwerC , BehnkeK . Moclobemide and fluoxetine for panic disorder. European Archives of Psychiatry and Clinical Neuroscience1999;249(Suppl1):S7‐S10. ">Tiller 1999</a> (n = 366), <a href="./references#CD011567-bbs2-0033" title="LeinonenE , LepolaU , KoponenH , TurtonenJ , WadeA , LehtoH . Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. Journal of Psychiatry and Neuroscience2000;25(1):24‐32. LepolaU , WadeAG , LeinonenEV , KoponenHJ , FrazerJ , SjoedinI , et al. A controlled, prospective, 1‐year trial of citalopram in the treatment of panic disorder. Journal of Clinical Psychiatry1998;59:528‐34. WadeA , OvereKF , LemmingO . Weight monitoring during two long‐term trials of citalopram. European Neuropsychopharmacology1999;9 Suppl 5:S221. WadeAG , LepolaU , KoponenHJ , PedersenV , PedersenT . The effect of citalopram in panic disorder. British Journal of Psychiatry1997;170:549‐53. ">Wade 1997</a> (n = 379). </p> </section> <section id="CD011567-sec-0085"> <h5 class="title">Setting</h5> <p>A total of 19 trials enrolled only outpatients, one trial enrolled only inpatients, and both inpatients and outpatients were enrolled in three trials. For the remaining 12 trials the setting was unclear. Nine trials were conducted in the USA, four in the Netherlands, three in Italy, two in Canada, two in Brazil, two in China, one in UK, one in Finland, one in Japan, and one in Israel; seven trials were multinational, and two did not provide information about the country. </p> </section> <section id="CD011567-sec-0086"> <h5 class="title">Participants</h5> <p>The proportion of women ranged from 36% to 92%. Mean age ranged from 30.5 to 61.6 years. </p> </section> <section id="CD011567-sec-0087"> <h5 class="title">Interventions</h5> <p>Eighteen studies included two arms, while the remaining studies had three or more arms. Nine trials included a comparison between antidepressants and benzodiazepines, 22 between individual antidepressants (including four comparisons between antidepressants of the same class), and four trials between individual benzodiazepines. Fifteen studies had a placebo arm. </p> <p>Duration of the intervention ranged from three to 24 weeks.</p> </section> <section id="CD011567-sec-0088"> <h5 class="title">Outcomes</h5> <p>Seventeen studies reported data on response rates, while the number of dropout for any reason was reported in 28 studies. Fourteen studies reported on remission rates. Sixteen studies reported data on panic symptoms (using Panic and Anticipatory Anxiety Scale (PAAS), Panic Disorder Severity Scale (PDSS), Clinical Global Impression Severity of Illness Score (CGI‐S)), 15 on frequency of panic attacks, 10 on agoraphobia (using Fear Questionnaire (FQ) and Marks‐Sheehan Phobia Scale), 26 on general anxiety (using Hamilton Anxiety Rating Scale (HAS) and Hamilton Rating Scale for Anxiety (HAMA)), 17 on depression (using Hamilton Rating Scale for Depression (HRSD), Beck Depression Inventory (BDI), Montgomery–Åsberg Depression Rating Scale (MADRS)). SIx studies reported data on social functioning (using Sheehan Disability Scale (SDS)), three on quality of life. None of the studies reported on patient satisfaction and economic costs. Twenty‐one studies had data on dropouts due to adverse effects, and 11 on the number of patients experiencing at least one adverse effect. </p> </section> </section> <section id="CD011567-sec-0089"> <h4 class="title">Excluded studies</h4> <p>See: <a href="./references#CD011567-sec-0451" title="">Characteristics of excluded studies</a>. </p> <p>Sixty‐seven articles, initially selected (corresponding to 43 studies), did not meet our inclusion criteria and were excluded, for the following reasons: 19 had a wrong study design; four trials included patients who were not primarily diagnosed with panic disorder; five studies included participants with anxiety disorders in general, but the randomisation was not stratified by the presence of panic disorder; 15 studies had a wrong comparison group. </p> <section id="CD011567-sec-0090"> <h5 class="title">Ongoing studies</h5> <p>See: Characteristics of ongoing studies.</p> <p>Our search identified no ongoing studies.</p> </section> <section id="CD011567-sec-0091"> <h5 class="title">Studies awaiting classification</h5> <p>See <a href="./references#CD011567-sec-0452" title="">Characteristics of studies awaiting classification</a>. </p> <p>Only one study (<a href="./references#CD011567-bbs2-0079" title="MinutentagNW , BernikMA . Comparative study of citalopram and imipramine in the treatment of panic disorder [Estudo comparativo entre o citalopram e a imiprimina no tratamento do transtorno de panico]. Revista de Psiquiatria Clinica2001;28(2):44‐51. ">Minutentag 2001</a>) was classified as "awaiting classification". </p> </section> </section> </section> <section id="CD011567-sec-0092"> <h3 class="title">Risk of bias in included studies</h3> <p>For details of the 'Risk of bias' judgements for each study, see <a href="./references#CD011567-sec-0450" title="">Characteristics of included studies</a>. Graphical representations of the overall risk of bias in included studies are presented in <a href="#CD011567-fig-0002">Figure 2</a> and <a href="#CD011567-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD011567-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011567-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD011567-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011567-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD011567-sec-0093"> <h4 class="title">Allocation</h4> <p><b>Random sequence generation</b> </p> <p>Thirty‐four of the studies did not report the methods of random sequence generation; only one study (<a href="./references#CD011567-bbs2-0023" title="RibeiroL , BusnelloJV , Kauer‐Sant'AnnaM , MadrugaM , QuevedoJ , BusnelloEAD , et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. Brazilian Journal of Medical and Biological Research2001;34:1303‐7. ">Ribeiro 2001</a>) specified this information, and it was classified as "low risk". </p> <p><b>Allocation concealment</b> </p> <p>Only one study (<a href="./references#CD011567-bbs2-0023" title="RibeiroL , BusnelloJV , Kauer‐Sant'AnnaM , MadrugaM , QuevedoJ , BusnelloEAD , et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. Brazilian Journal of Medical and Biological Research2001;34:1303‐7. ">Ribeiro 2001</a>) reported details on allocation concealment and was classified as "low risk". </p> </section> <section id="CD011567-sec-0094"> <h4 class="title">Blinding</h4> <p>Twenty‐five RCTs were reported to be double‐blind, without providing any further detail; 10 RCTs reported details on strategies to ensure blinding of participants and key study personnel, and were classified as "low risk". </p> </section> <section id="CD011567-sec-0095"> <h4 class="title">Incomplete outcome data</h4> <p>Eleven trials were rated as adequate in terms of addressing incomplete outcome data, while 20 studies were classified as "unclear risk" and four as "high risk". </p> </section> <section id="CD011567-sec-0096"> <h4 class="title">Selective reporting</h4> <p>The study protocol was not available for almost all studies so it is difficult to make a judgment on the possibility of outcome reporting bias. However, in 16 studies results were consistent with the outcomes pre‐specified in the methods section, and they were evaluated as "low risk"; using the same criterion, 11 studies were judged to be at "high risk". </p> </section> <section id="CD011567-sec-0097"> <h4 class="title">Other potential sources of bias</h4> <p>Nineteen of the included studies were funded by the pharmaceutical industry, and they did not report details on the role of the funder in planning, conducting and writing the study; for this reason they were rated as "high risk". Fifteen did not specify the source of funding. One study (<a href="./references#CD011567-bbs2-0010" title="GentilV , Lotufo‐NetoF , AndradeL , CordásT , BernikM , RamosR , et al. Clomipramine, a better reference drug for panic/agoraphobia. I. Effectiveness comparison with imipramine. Journal of Psychopharmacology1993;7(4):316‐24. MarcourakisT , GorensteinC , GentilV . Clomipramine, a better reference drug for panic/agoraphobia. II. Psychomotor and cognitive effects. Journal of Psychopharmacology1993;7(4):325‐30. ">Gentil 1993</a>) was classified as "low risk". </p> </section> </section> <section id="CD011567-sec-0098"> <h3 class="title" id="CD011567-sec-0098">Effects of interventions</h3> <p>See: <a href="./full#CD011567-tbl-0001"><b>Summary of findings for the main comparison</b> Antidepressants compared to benzodiazepines for adults with panic disorder</a>; <a href="./full#CD011567-tbl-0002"><b>Summary of findings 2</b> TCAs compared to benzodiazepines for adults with panic disorder</a>; <a href="./full#CD011567-tbl-0003"><b>Summary of findings 3</b> SSRIs compared to benzodiazepines for adults with panic disorder</a>; <a href="./full#CD011567-tbl-0004"><b>Summary of findings 4</b> TCAs compared to SSRI for adults with panic disorder</a>; <a href="./full#CD011567-tbl-0005"><b>Summary of findings 5</b> TCA compared to MAOI for adults with panic disorder</a>; <a href="./full#CD011567-tbl-0006"><b>Summary of findings 6</b> SSRIs compared to MAOIs for adults with panic disorder</a>; <a href="./full#CD011567-tbl-0007"><b>Summary of findings 7</b> SSRIs compared to SNRIs for adults with panic disorder</a>; <a href="./full#CD011567-tbl-0008"><b>Summary of findings 8</b> SSRIs compared to NaSSAs for adults with panic disorder</a> </p> <section id="CD011567-sec-0099"> <h4 class="title">A: Antidepressants versus benzodiazepines</h4> <p>We found data only for the comparisons reported below.</p> </section> <section id="CD011567-sec-0100"> <h4 class="title">Comparison 1: Antidepressants versus benzodiazepines</h4> <p>Eight studies including 2055 participants (<a href="./references#CD011567-bbs2-0006" title="AlbusM , LecrubierY , MaierW , BullerR , RosenbergR , HippiusH . Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatrica Scandinavica1990;82(5):359‐65. AlbusM , MaierW , SheraD , BechP . Consistencies and discrepancies in self‐ and observer‐rated anxiety scales. A comparison between the self‐ and observer‐rated Marks‐Sheehan scales. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):96‐102. AnderschS , HansonL , HallstromT . Panic disorder: a five‐year follow‐up study in 52 patients. European Journal of Psychiatry1997;11(3):145‐55. AnderschS , HettaJ . A 15‐year follow‐up study of patients with panic disorder. European Psychiatry2003;18(8):401‐08. AnderschS , RosenbergNK , KullingsjöH , OttossonJO , BechP , Bruun‐HansenJ , et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatrica Scandinavica. Supplementum1991;365:18‐27. BerlangaC , CanettiA , ChavezE , De LaFuenteR , delCarmen LaraM , LeonC , et al. Pharmacologic treatment of panic disorders: Comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study [Tratamiento farmacologico de las crisis de angustia Reporte comparativo de la eficacia y seguridad del alprazolam y la imipramina en un estudio controlado]. Salud Mental1991;14(1):1‐5. BullerR , MaierW , GoldenbergIM , LavoriPW , BenkertO . Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross‐National Collaborative Panic Study. European Archives of Psychiatry and Clinical Neuroscience1991;240(3):163‐8. CassanoGB , ToniC , PetraccaA , DeltitoJ , BenkertO , CurtisG , et al. Adverse effects associated with the short‐term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology1994;4(1):47‐53. Cross National Collaborative Panic Study Second Phase Investigators. Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. British Journal of Psychiatry1992;160:191‐202. CurtisGC , MassanaJ , UdinaC , AyusoJL , CassanoGB , PerugiG . Maintenance drug therapy of panic disorder. Journal of Psychiatry Research1993;27(Suppl 1):127‐42. DeltitoJA , ArgyleN , BullerR , NutzingerD , OttossonJO , BrandonS , et al. The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(2):120‐9. DeltitoJA , ArgyleN , KlermanGL . Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Journal of Clinical Psychiatry1991;52(3):121‐7. GreenMA , CurtisGC . Personality disorders in panic patients: Response to termination of antipanic medication. Journal of Personality Disorders1988;2(4):303‐14. KatschnigH , AmeringM , StolkJM , KlermanGL , BallengerJC , BriggsA , et al. Long‐term follow‐up after a drug trial for panic disorder. British Journal of Psychiatry1995;167(4):487‐94. KlermanGL . Depression and panic anxiety: the effect of depressive co‐morbidity on response to drug treatment of patients with panic disorder and agoraphobia. Journal of Psychiatric Research1990;24(Suppl 2):27‐41. KlermanGL , ColemanJH , PurpuraRP . The design and conduct of the Upjohn Cross‐National Collaborative Panic Study. Psychopharmacology Bulletin1986;22(1):59‐64. LavoriPW , DawsonR , SheraD . A multiple imputation strategy for clinical trials with truncation of patient data. Statistics in Medicine1995;14(17):1913‐25. LeónCA , DeArangoMV , ArevaloW , CalvoA , MontoyaA , LeónA . Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia [Comparacion del efecto del alprazolam, la imipramina y placebo en el tratamiento del trastorno de panico en Cali, Colombia]. Acta Psiquiatrica y Psicologica de America Latina1990;36(1‐2):59‐72. MaierW , AlbusM , BullerR , NutzingerD , SheraD , BechP . Self‐ and observer assessment in anxiolytic drug trials: a comparison of their validity. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):103‐8. MaierW , RothSM , ArgyleN , BullerR , LavoriP , BrandonS , et al. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?. European Archives of Psychiatry and Clinical Neuroscience1991;241(3):151‐8. MaierWA , RothM , BullerR , ArgyleN , RosenbergR , SydneyB , et al. Agoraphobia in panic disorder: An indicator of the severity of panic disorder or a distinct diagnostic entity?. Psychiatric Annals1991;21(6):374‐81. RifkinA . The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(6):559‐60. RosenbergNK , MellergårdM , RosenbergR , BeckP , OttossonJO . Characteristics of panic disorder patients responding to placebo. Acta Psychiatrica Scandinavica Supplementum1991;365:33‐8. RosenbergR , BechP , MellergårdM , OttossonJO . Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response. Acta Psychiatrica Scandinavica. Supplementum1991;365:46‐52. SwobodaH , AmeringM , WindhaberJ , KatschnigH . The long‐term course of panic disorder‐‐an 11 year follow‐up. Journal of Anxiety Disorders2003;17(2):223‐32. ">CNCPS 1992</a>; <a href="./references#CD011567-bbs2-0011" title="GSK . A double‐blind, multicenter, flexible‐dose study of paroxetine, alprazolam and placebo in the treatment of panic disorder. GSK Clinical Studies Register [http://www.gsk‐clinicalstudyregister.com/]. ">GSK‐29060/1</a>; <a href="./references#CD011567-bbs2-0013" title="HollandR , MuschB , HindmarchI . Specific effects of benzodiazepines and tricyclic antidepressants in panic disorder: comparisons of clomipramine with alprazolam SR and adinazolam SR. Human Psychopharmacology Clinical Experimental1999;14:119‐24. ">Holland 1999</a>; <a href="./references#CD011567-bbs2-0016" title="LepolaU , HeikkinenH , RimonR , RiekkinenP . Clinical evaluation of alprazolam in patients with panic disorder; a double‐blind comparison with imipramine. Human Psychopharmacology1990;5:159‐63. RimonR . Spectral electroencephalogram and clinical follow‐up during alprazolam and imipramine treatment in panic disorder. Nordic Journal of Psychiatry1998;52(3):245‐9. ">Lepola 1990</a>; <a href="./references#CD011567-bbs2-0025" title="RickelsK , SchweizerE . Panic disorder: Long‐term pharmacotherapy and discontinuation. Journal of Clinical Psychopharmacology1998;18(6 Suppl 2):12‐8. RickelsK , SchweizerE , WeissS , ZavodnickS . Maintenance drug treatment for panic disorder. II. Short‐ and long‐term outcome after drug taper. Archives of General Psychiatry1993;50:61‐8. SchweizerE , RickelsK , WeissS , ZavodnickS . Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo‐controlled comparison of alprazolam and imipramine. Archives of General Psychiatry1993;50:51‐60. ">Schweizer 1993</a>; <a href="./references#CD011567-bbs2-0026" title="SheikhJI , SwalesPJ . Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo. International Journal of Psychiatry in Medicine1999;29(1):107‐17. ">Sheikh 1999</a>; <a href="./references#CD011567-bbs2-0028" title='ClarkDB , TaylorCB , RothWT , HaywardC , EhlersA , MargrafJ , et al. Surreptitious drug use by patients in a panic disorder study. American Journal of Psychiatry1990;147(4):507‐9. MargrafJ , EhlersA , RothWT , ClarkDB , SheikhJ , AgrasWS , et al. How "blind" are double‐blind studies?. Journal of Consulting and Clinical Psychology1991;59(1):184‐7. TaylorCB , HaywardC , KingR , EhlersA , MargrafJ , MaddockR , et al. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double‐blind, placebo‐controlled trial. Journal of Clinical Psychopharmacology1990;10(2):112‐8. '>Taylor 1990</a>; <a href="./references#CD011567-bbs2-0031" title="UhlenhuthEH , MatuzasW , GlassRM , EastonC . Response of panic disorder to fixed doses of alprazolam or imipramine. Journal of Affective Disorders1989;17(3):261‐70. ">Uhlenhuth 1989</a>) provided data for at least one outcome for this comparison. See also: <a href="./full#CD011567-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011567-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011567-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD011567-sec-0101"> <h5 class="title">Primary outcomes</h5> <section id="CD011567-sec-0102"> <h6 class="title">1.1 Failure to respond</h6> <p>We found low‐quality evidence that cannot inform us as to whether there is a difference between antidepressants and benzodiazepines in terms of response rate. Confidence interval ranges from appreciable benefit with antidepressants to appreciable benefit with benzodiazepines (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.67 to 1.47; participants = 215; studies = 2; I<sup>2</sup> = 0%) (<a href="./references#CD011567-fig-0006" title="">Analysis 1.1</a>). There was consistency between study results. Risk of bias was considered unclear for this outcome. Additionally, the comparisons of tricyclic antidepressants (TCAs) versus benzodiazepines (RR 1.02, 95% CI 0.63 to 1.67; participants = 61; studies = 1; very low‐quality evidence) and selective serotonin reuptake inhibitors (SSRIs) versus benzodiazepines (RR 0.93, 95% CI 0.48 to 1.80; participants = 154; studies = 1; very low‐quality evidence) did not show any difference (<a href="#CD011567-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD011567-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antidepressants versus benzodiazepines, outcome: 1.1 Failure to respond." data-id="CD011567-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antidepressants versus benzodiazepines, outcome: 1.1 Failure to respond. </p> </div> </div> </div> </section> <section id="CD011567-sec-0103"> <h6 class="title">1.2 Total number of dropouts</h6> <p>In terms of participants who dropped out due to any cause, very low‐quality evidence suggested a benefit of benzodiazepines compared to antidepressants. However, the wide confidence interval ranges from almost no difference to benefit with benzodiazepines (RR 1.64, 95% CI 1.03 to 2.63; participants = 1449; studies = 7), and the degree of heterogeneity in the studies considered was considerable (I<sup>2</sup> = 75%) (<a href="./references#CD011567-fig-0007" title="">Analysis 1.2</a>). In comparison with benzodiazepines, more participants receiving the SSRIs dropped out due to any cause (RR 1.71, 95% CI 1.03 to 2.84; participants = 154; studies = 1; very low‐quality evidence) (the magnitude of effect corresponds to a NNTH of 7, 95% CI 152 to 3), while no difference was detected between TCAs and benzodiazepines (RR 1.67, 95% CI 0.93 to 2.99; participants = 1295; studies = 6; very low‐quality evidence), with a considerable heterogeneity (I² = 79%), (<a href="./references#CD011567-fig-0007" title="">Analysis 1.2</a>). Risk of bias was considered unclear for this outcome, but the majority of the studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies (<a href="#CD011567-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD011567-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antidepressants versus benzodiazepines, outcome: 1.2 Total number of dropouts." data-id="CD011567-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antidepressants versus benzodiazepines, outcome: 1.2 Total number of dropouts. </p> </div> </div> </div> </section> </section> <section id="CD011567-sec-0104"> <h5 class="title">Secondary outcomes</h5> <section id="CD011567-sec-0105"> <h6 class="title">1.3 Failure to remit</h6> <p>We found moderate‐quality evidence suggesting no difference in terms of remission rate between antidepressants and benzodiazepines (RR 1.18, 95% CI 1.01 to 1.37; participants = 1002; studies = 3), TCAs and benzodiazepines (RR 1.19, 95% CI 1.00 to 1.41; participants = 848; studies = 2 moderate‐quality evidence) and SSRIs versus benzodiazepines (RR 1.12, 95% CI 0.79 to 1.59; participants = 154; studies = 1; I² = 0%, very low‐quality evidence) (<a href="./references#CD011567-fig-0008" title="">Analysis 1.3</a>). Risk of bias was considered unclear for this outcome, but the majority of the studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0106"> <h6 class="title">1.4 Panic symptoms ‐ endpoint score</h6> <p>We found very low‐quality evidence suggesting no difference between antidepressants and benzodiazepines (mean difference (MD) ‐0.13, 95% CI ‐1.06 to 0.80; participants = 1144; studies = 3), with a substantial degree of heterogeneity (I² = 95%), no difference between TCAs and benzodiazepines (mean difference (MD) ‐0.25, 95% CI ‐1.72 to 1.22; participants = 998; studies = 2; I<sup>2</sup> = 97%, low‐quality evidence) and between SSRIs and benzodiazepines (mean difference (MD) 0.10, 95% CI ‐0.34 to 0.54; participants = 146; studies = 1, low‐quality evidence) (<a href="./references#CD011567-fig-0009" title="">Analysis 1.4</a>). Risk of bias was considered between unclear and high for this outcome, with two studies rated as high risk for "other bias" because they were funded by pharmaceutical companies. For one study included in the analysis there was some indication of skewness (<a href="./references#CD011567-bbs2-0013" title="HollandR , MuschB , HindmarchI . Specific effects of benzodiazepines and tricyclic antidepressants in panic disorder: comparisons of clomipramine with alprazolam SR and adinazolam SR. Human Psychopharmacology Clinical Experimental1999;14:119‐24. ">Holland 1999</a>). </p> </section> <section id="CD011567-sec-0107"> <h6 class="title">1.5 Panic symptoms ‐ mean change</h6> <p>We found low‐quality evidence showing a benefit for benzodiazepines over placebo in reducing panic symptoms measured as change from baseline on a continuous measure (MD 0.40, 95% CI ‐0.83 to 1.63; participants = 44; studies = 1) (<a href="./references#CD011567-fig-0010" title="">Analysis 1.5</a>). The only study contributing to this analysis was about TCAs. </p> </section> <section id="CD011567-sec-0108"> <h6 class="title">1.6 Frequency of panic attacks</h6> <p>We did not find any difference between antidepressants and benzodiazepines (MD 0.33, 95% CI ‐0.72 to 1.38; participants = 595; studies = 7) , with a substantial heterogeneity (I² = 65%), TCAs and benzodiazepines (MD 0.30, 95% CI ‐0.81 to 1.41; participants = 458; studies = 6) , also with substantial heterogeneity (I² = 71%), SSRIs and benzodiazepines (MD 1.20, 95% CI ‐3.31 to 5.71; participants = 137; studies = 1) in terms of frequency of panic attacks (<a href="./references#CD011567-fig-0011" title="">Analysis 1.6</a>). Risk of bias was considered unclear for this outcome, but the majority of the studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. For some studies included in the analysis there was some indication of skewness (<a href="./references#CD011567-bbs2-0013" title="HollandR , MuschB , HindmarchI . Specific effects of benzodiazepines and tricyclic antidepressants in panic disorder: comparisons of clomipramine with alprazolam SR and adinazolam SR. Human Psychopharmacology Clinical Experimental1999;14:119‐24. ">Holland 1999</a>; <a href="./references#CD011567-bbs2-0016" title="LepolaU , HeikkinenH , RimonR , RiekkinenP . Clinical evaluation of alprazolam in patients with panic disorder; a double‐blind comparison with imipramine. Human Psychopharmacology1990;5:159‐63. RimonR . Spectral electroencephalogram and clinical follow‐up during alprazolam and imipramine treatment in panic disorder. Nordic Journal of Psychiatry1998;52(3):245‐9. ">Lepola 1990</a>; <a href="./references#CD011567-bbs2-0025" title="RickelsK , SchweizerE . Panic disorder: Long‐term pharmacotherapy and discontinuation. Journal of Clinical Psychopharmacology1998;18(6 Suppl 2):12‐8. RickelsK , SchweizerE , WeissS , ZavodnickS . Maintenance drug treatment for panic disorder. II. Short‐ and long‐term outcome after drug taper. Archives of General Psychiatry1993;50:61‐8. SchweizerE , RickelsK , WeissS , ZavodnickS . Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo‐controlled comparison of alprazolam and imipramine. Archives of General Psychiatry1993;50:51‐60. ">Schweizer 1993</a>; <a href="./references#CD011567-bbs2-0026" title="SheikhJI , SwalesPJ . Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo. International Journal of Psychiatry in Medicine1999;29(1):107‐17. ">Sheikh 1999</a>; <a href="./references#CD011567-bbs2-0031" title="UhlenhuthEH , MatuzasW , GlassRM , EastonC . Response of panic disorder to fixed doses of alprazolam or imipramine. Journal of Affective Disorders1989;17(3):261‐70. ">Uhlenhuth 1989</a>). </p> </section> <section id="CD011567-sec-0109"> <h6 class="title">1.7 Agoraphobia</h6> <p>For this outcome, we observed no difference between antidepressants and benzodiazepines (SMD 0.04, 95% CI ‐0.08 to 0.16; participants = 1061; studies = 5; I<sup>2</sup> = 0%) (<a href="./references#CD011567-fig-0012" title="">Analysis 1.7</a>). Risk of bias was considered unclear for this outcome, but all the studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0110"> <h6 class="title">1.8 General anxiety</h6> <p>We found no difference between antidepressants and benzodiazepines (SMD 0.06, 95% CI ‐0.25 to 0.37; participants = 1365; studies = 8), TCAs and benzodiazepines (SMD 0.08, 95% CI ‐0.28 to 0.45; participants = 1238; studies = 7), SSRIs and benzodiazepines (SMD ‐0.08, 95% CI ‐0.42 to 0.27; participants = 127; studies = 1) on general anxiety (<a href="./references#CD011567-fig-0013" title="">Analysis 1.8</a>). Heterogeneity for antidepressants compared to benzodiazepines and TCAs compared to benzodiazepines was considerable (I² = 81% and I² = 83%). Risk of bias was considered unclear for this outcome, but the majority of the studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. For some studies included in the analysis, there was some indication of skewness (<a href="./references#CD011567-bbs2-0006" title="AlbusM , LecrubierY , MaierW , BullerR , RosenbergR , HippiusH . Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatrica Scandinavica1990;82(5):359‐65. AlbusM , MaierW , SheraD , BechP . Consistencies and discrepancies in self‐ and observer‐rated anxiety scales. A comparison between the self‐ and observer‐rated Marks‐Sheehan scales. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):96‐102. AnderschS , HansonL , HallstromT . Panic disorder: a five‐year follow‐up study in 52 patients. European Journal of Psychiatry1997;11(3):145‐55. AnderschS , HettaJ . A 15‐year follow‐up study of patients with panic disorder. European Psychiatry2003;18(8):401‐08. AnderschS , RosenbergNK , KullingsjöH , OttossonJO , BechP , Bruun‐HansenJ , et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatrica Scandinavica. Supplementum1991;365:18‐27. BerlangaC , CanettiA , ChavezE , De LaFuenteR , delCarmen LaraM , LeonC , et al. Pharmacologic treatment of panic disorders: Comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study [Tratamiento farmacologico de las crisis de angustia Reporte comparativo de la eficacia y seguridad del alprazolam y la imipramina en un estudio controlado]. Salud Mental1991;14(1):1‐5. BullerR , MaierW , GoldenbergIM , LavoriPW , BenkertO . Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross‐National Collaborative Panic Study. European Archives of Psychiatry and Clinical Neuroscience1991;240(3):163‐8. CassanoGB , ToniC , PetraccaA , DeltitoJ , BenkertO , CurtisG , et al. Adverse effects associated with the short‐term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology1994;4(1):47‐53. Cross National Collaborative Panic Study Second Phase Investigators. Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. British Journal of Psychiatry1992;160:191‐202. CurtisGC , MassanaJ , UdinaC , AyusoJL , CassanoGB , PerugiG . Maintenance drug therapy of panic disorder. Journal of Psychiatry Research1993;27(Suppl 1):127‐42. DeltitoJA , ArgyleN , BullerR , NutzingerD , OttossonJO , BrandonS , et al. The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(2):120‐9. DeltitoJA , ArgyleN , KlermanGL . Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Journal of Clinical Psychiatry1991;52(3):121‐7. GreenMA , CurtisGC . Personality disorders in panic patients: Response to termination of antipanic medication. Journal of Personality Disorders1988;2(4):303‐14. KatschnigH , AmeringM , StolkJM , KlermanGL , BallengerJC , BriggsA , et al. Long‐term follow‐up after a drug trial for panic disorder. British Journal of Psychiatry1995;167(4):487‐94. KlermanGL . Depression and panic anxiety: the effect of depressive co‐morbidity on response to drug treatment of patients with panic disorder and agoraphobia. Journal of Psychiatric Research1990;24(Suppl 2):27‐41. KlermanGL , ColemanJH , PurpuraRP . The design and conduct of the Upjohn Cross‐National Collaborative Panic Study. Psychopharmacology Bulletin1986;22(1):59‐64. LavoriPW , DawsonR , SheraD . A multiple imputation strategy for clinical trials with truncation of patient data. Statistics in Medicine1995;14(17):1913‐25. LeónCA , DeArangoMV , ArevaloW , CalvoA , MontoyaA , LeónA . Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia [Comparacion del efecto del alprazolam, la imipramina y placebo en el tratamiento del trastorno de panico en Cali, Colombia]. Acta Psiquiatrica y Psicologica de America Latina1990;36(1‐2):59‐72. MaierW , AlbusM , BullerR , NutzingerD , SheraD , BechP . Self‐ and observer assessment in anxiolytic drug trials: a comparison of their validity. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):103‐8. MaierW , RothSM , ArgyleN , BullerR , LavoriP , BrandonS , et al. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?. European Archives of Psychiatry and Clinical Neuroscience1991;241(3):151‐8. MaierWA , RothM , BullerR , ArgyleN , RosenbergR , SydneyB , et al. Agoraphobia in panic disorder: An indicator of the severity of panic disorder or a distinct diagnostic entity?. Psychiatric Annals1991;21(6):374‐81. RifkinA . The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(6):559‐60. RosenbergNK , MellergårdM , RosenbergR , BeckP , OttossonJO . Characteristics of panic disorder patients responding to placebo. Acta Psychiatrica Scandinavica Supplementum1991;365:33‐8. RosenbergR , BechP , MellergårdM , OttossonJO . Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response. Acta Psychiatrica Scandinavica. Supplementum1991;365:46‐52. SwobodaH , AmeringM , WindhaberJ , KatschnigH . The long‐term course of panic disorder‐‐an 11 year follow‐up. Journal of Anxiety Disorders2003;17(2):223‐32. ">CNCPS 1992</a>; <a href="./references#CD011567-bbs2-0011" title="GSK . A double‐blind, multicenter, flexible‐dose study of paroxetine, alprazolam and placebo in the treatment of panic disorder. GSK Clinical Studies Register [http://www.gsk‐clinicalstudyregister.com/]. ">GSK‐29060/1</a>; <a href="./references#CD011567-bbs2-0013" title="HollandR , MuschB , HindmarchI . Specific effects of benzodiazepines and tricyclic antidepressants in panic disorder: comparisons of clomipramine with alprazolam SR and adinazolam SR. Human Psychopharmacology Clinical Experimental1999;14:119‐24. ">Holland 1999</a>; <a href="./references#CD011567-bbs2-0016" title="LepolaU , HeikkinenH , RimonR , RiekkinenP . Clinical evaluation of alprazolam in patients with panic disorder; a double‐blind comparison with imipramine. Human Psychopharmacology1990;5:159‐63. RimonR . Spectral electroencephalogram and clinical follow‐up during alprazolam and imipramine treatment in panic disorder. Nordic Journal of Psychiatry1998;52(3):245‐9. ">Lepola 1990</a>; <a href="./references#CD011567-bbs2-0025" title="RickelsK , SchweizerE . Panic disorder: Long‐term pharmacotherapy and discontinuation. Journal of Clinical Psychopharmacology1998;18(6 Suppl 2):12‐8. RickelsK , SchweizerE , WeissS , ZavodnickS . Maintenance drug treatment for panic disorder. II. Short‐ and long‐term outcome after drug taper. Archives of General Psychiatry1993;50:61‐8. SchweizerE , RickelsK , WeissS , ZavodnickS . Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo‐controlled comparison of alprazolam and imipramine. Archives of General Psychiatry1993;50:51‐60. ">Schweizer 1993</a>; <a href="./references#CD011567-bbs2-0031" title="UhlenhuthEH , MatuzasW , GlassRM , EastonC . Response of panic disorder to fixed doses of alprazolam or imipramine. Journal of Affective Disorders1989;17(3):261‐70. ">Uhlenhuth 1989</a>). </p> </section> <section id="CD011567-sec-0111"> <h6 class="title">1.9 Depression</h6> <p>The analyses did not show a difference in favour of antidepressants over benzodiazepines (SMD ‐0.14, 95% CI ‐0.29 to 0.02; participants = 892; studies = 6; I<sup>2</sup> = 7%). . The SSRIs were more effective than benzodiazepines (SMD ‐0.46, 95% CI ‐0.81 to ‐0.11; participants = 127; studies = 1) in terms of depressive measures, while the TCAs were not different from benzodiazepines (SMD ‐0.08, 95% CI ‐0.22 to 0.06; participants = 765; studies = 5; I² = 0%) (<a href="./references#CD011567-fig-0014" title="">Analysis 1.9</a>). Risk of bias was considered unclear for this outcome, but the majority of the studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. For some studies included in the analysis there was some indication of skewness (<a href="./references#CD011567-bbs2-0006" title="AlbusM , LecrubierY , MaierW , BullerR , RosenbergR , HippiusH . Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatrica Scandinavica1990;82(5):359‐65. AlbusM , MaierW , SheraD , BechP . Consistencies and discrepancies in self‐ and observer‐rated anxiety scales. A comparison between the self‐ and observer‐rated Marks‐Sheehan scales. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):96‐102. AnderschS , HansonL , HallstromT . Panic disorder: a five‐year follow‐up study in 52 patients. European Journal of Psychiatry1997;11(3):145‐55. AnderschS , HettaJ . A 15‐year follow‐up study of patients with panic disorder. European Psychiatry2003;18(8):401‐08. AnderschS , RosenbergNK , KullingsjöH , OttossonJO , BechP , Bruun‐HansenJ , et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatrica Scandinavica. Supplementum1991;365:18‐27. BerlangaC , CanettiA , ChavezE , De LaFuenteR , delCarmen LaraM , LeonC , et al. Pharmacologic treatment of panic disorders: Comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study [Tratamiento farmacologico de las crisis de angustia Reporte comparativo de la eficacia y seguridad del alprazolam y la imipramina en un estudio controlado]. Salud Mental1991;14(1):1‐5. BullerR , MaierW , GoldenbergIM , LavoriPW , BenkertO . Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross‐National Collaborative Panic Study. European Archives of Psychiatry and Clinical Neuroscience1991;240(3):163‐8. CassanoGB , ToniC , PetraccaA , DeltitoJ , BenkertO , CurtisG , et al. Adverse effects associated with the short‐term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology1994;4(1):47‐53. Cross National Collaborative Panic Study Second Phase Investigators. Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. British Journal of Psychiatry1992;160:191‐202. CurtisGC , MassanaJ , UdinaC , AyusoJL , CassanoGB , PerugiG . Maintenance drug therapy of panic disorder. Journal of Psychiatry Research1993;27(Suppl 1):127‐42. DeltitoJA , ArgyleN , BullerR , NutzingerD , OttossonJO , BrandonS , et al. The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(2):120‐9. DeltitoJA , ArgyleN , KlermanGL . Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Journal of Clinical Psychiatry1991;52(3):121‐7. GreenMA , CurtisGC . Personality disorders in panic patients: Response to termination of antipanic medication. Journal of Personality Disorders1988;2(4):303‐14. KatschnigH , AmeringM , StolkJM , KlermanGL , BallengerJC , BriggsA , et al. Long‐term follow‐up after a drug trial for panic disorder. British Journal of Psychiatry1995;167(4):487‐94. KlermanGL . Depression and panic anxiety: the effect of depressive co‐morbidity on response to drug treatment of patients with panic disorder and agoraphobia. Journal of Psychiatric Research1990;24(Suppl 2):27‐41. KlermanGL , ColemanJH , PurpuraRP . The design and conduct of the Upjohn Cross‐National Collaborative Panic Study. Psychopharmacology Bulletin1986;22(1):59‐64. LavoriPW , DawsonR , SheraD . A multiple imputation strategy for clinical trials with truncation of patient data. Statistics in Medicine1995;14(17):1913‐25. LeónCA , DeArangoMV , ArevaloW , CalvoA , MontoyaA , LeónA . Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia [Comparacion del efecto del alprazolam, la imipramina y placebo en el tratamiento del trastorno de panico en Cali, Colombia]. Acta Psiquiatrica y Psicologica de America Latina1990;36(1‐2):59‐72. MaierW , AlbusM , BullerR , NutzingerD , SheraD , BechP . Self‐ and observer assessment in anxiolytic drug trials: a comparison of their validity. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):103‐8. MaierW , RothSM , ArgyleN , BullerR , LavoriP , BrandonS , et al. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?. European Archives of Psychiatry and Clinical Neuroscience1991;241(3):151‐8. MaierWA , RothM , BullerR , ArgyleN , RosenbergR , SydneyB , et al. Agoraphobia in panic disorder: An indicator of the severity of panic disorder or a distinct diagnostic entity?. Psychiatric Annals1991;21(6):374‐81. RifkinA . The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(6):559‐60. RosenbergNK , MellergårdM , RosenbergR , BeckP , OttossonJO . Characteristics of panic disorder patients responding to placebo. Acta Psychiatrica Scandinavica Supplementum1991;365:33‐8. RosenbergR , BechP , MellergårdM , OttossonJO . Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response. Acta Psychiatrica Scandinavica. Supplementum1991;365:46‐52. SwobodaH , AmeringM , WindhaberJ , KatschnigH . The long‐term course of panic disorder‐‐an 11 year follow‐up. Journal of Anxiety Disorders2003;17(2):223‐32. ">CNCPS 1992</a>; <a href="./references#CD011567-bbs2-0011" title="GSK . A double‐blind, multicenter, flexible‐dose study of paroxetine, alprazolam and placebo in the treatment of panic disorder. GSK Clinical Studies Register [http://www.gsk‐clinicalstudyregister.com/]. ">GSK‐29060/1</a>; <a href="./references#CD011567-bbs2-0016" title="LepolaU , HeikkinenH , RimonR , RiekkinenP . Clinical evaluation of alprazolam in patients with panic disorder; a double‐blind comparison with imipramine. Human Psychopharmacology1990;5:159‐63. RimonR . Spectral electroencephalogram and clinical follow‐up during alprazolam and imipramine treatment in panic disorder. Nordic Journal of Psychiatry1998;52(3):245‐9. ">Lepola 1990</a>; <a href="./references#CD011567-bbs2-0026" title="SheikhJI , SwalesPJ . Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo. International Journal of Psychiatry in Medicine1999;29(1):107‐17. ">Sheikh 1999</a>; <a href="./references#CD011567-bbs2-0031" title="UhlenhuthEH , MatuzasW , GlassRM , EastonC . Response of panic disorder to fixed doses of alprazolam or imipramine. Journal of Affective Disorders1989;17(3):261‐70. ">Uhlenhuth 1989</a>). This analysis found a substantial subgroup difference (I² = 73.7%, P = 0.05) between TCAs and SSRIs. </p> </section> <section id="CD011567-sec-0112"> <h6 class="title">1.10 Social functioning</h6> <p>We found no difference between antidepressants and benzodiazepines in this outcome, with a moderate heterogeneity (I² = 57%) (SMD 0.16, 95% CI ‐0.12 to 0.44; participants = 1007; studies = 4). In terms of drug classes, benzodiazepines were more effective than TCAs (SMD 0.23, 95% CI 0.03 to 0.42; participants = 882; studies = 3; I<sup>2</sup> = 14%), while SSRIs were not different from benzodiazepines (SMD ‐0.22, 95% CI ‐0.57 to 0.13; participants = 125; studies = 1) (<a href="./references#CD011567-fig-0015" title="">Analysis 1.10</a>). Risk of bias was considered unclear for this outcome, but all the studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. This analysis found a substantial subgroup difference (I² = 73.4%, P = 0.05) between TCAs and SSRIs. </p> </section> <section id="CD011567-sec-0113"> <h6 class="title">1.11 Quality of life</h6> <p>No studies provided data for this outcome.</p> </section> <section id="CD011567-sec-0114"> <h6 class="title">1.12 Patient satisfaction</h6> <p>No studies provided data for this outcome.</p> </section> <section id="CD011567-sec-0115"> <h6 class="title">1.13 Economic costs</h6> <p>No studies provided data for this outcome.</p> </section> <section id="CD011567-sec-0116"> <h6 class="title">1.14 Number of dropouts due to adverse effects</h6> <p>In terms of dropouts due to adverse effects, we found low‐quality evidence that benzodiazepines were better tolerated than antidepressants as a whole (RR 1.72, 95% CI 1.03 to 2.87; participants = 1002; studies = 3; I² = 13%). The magnitude of effect corresponds to a NNTH of 27 (95% CI 642 to 11). In addition, low‐quality evidence suggested that the TCAs were better tolerated than benzodiazepines (RR 2.10, 95% CI 1.13 to 3.93; participants = 848; studies = 2; I² = 8%), with a magnitude of effect of NNTH = 24 (95% CI 203 to 9), while the SSRIs were similarly tolerated in comparison with benzodiazepines (RR 1.20, 95% CI 0.55 to 2.61; participants = 154; studies = 1; I² = 0%, very low‐quality evidence) (<a href="./references#CD011567-fig-0016" title="">Analysis 1.14</a>). Risk of bias was considered unclear for this outcome, but all the studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0117"> <h6 class="title">1.15 Number of patients experiencing at least one adverse effect</h6> <p>Only one study provided data for this outcome, showing no difference between antidepressants (SSRIs) and benzodiazepines (RR 1.03, 95% CI 0.92 to 1.15; participants = 154; studies = 1) (<a href="./references#CD011567-fig-0017" title="">Analysis 1.15</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> </section> </section> <section id="CD011567-sec-0118"> <h4 class="title">Comparison 2: TCAs versus benzodiazepines</h4> <p>Seven studies including 1829 participants provided data for this comparison. Six studies compared imipramine with alprazolam (<a href="./references#CD011567-bbs2-0006" title="AlbusM , LecrubierY , MaierW , BullerR , RosenbergR , HippiusH . Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatrica Scandinavica1990;82(5):359‐65. AlbusM , MaierW , SheraD , BechP . Consistencies and discrepancies in self‐ and observer‐rated anxiety scales. A comparison between the self‐ and observer‐rated Marks‐Sheehan scales. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):96‐102. AnderschS , HansonL , HallstromT . Panic disorder: a five‐year follow‐up study in 52 patients. European Journal of Psychiatry1997;11(3):145‐55. AnderschS , HettaJ . A 15‐year follow‐up study of patients with panic disorder. European Psychiatry2003;18(8):401‐08. AnderschS , RosenbergNK , KullingsjöH , OttossonJO , BechP , Bruun‐HansenJ , et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatrica Scandinavica. Supplementum1991;365:18‐27. BerlangaC , CanettiA , ChavezE , De LaFuenteR , delCarmen LaraM , LeonC , et al. Pharmacologic treatment of panic disorders: Comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study [Tratamiento farmacologico de las crisis de angustia Reporte comparativo de la eficacia y seguridad del alprazolam y la imipramina en un estudio controlado]. Salud Mental1991;14(1):1‐5. BullerR , MaierW , GoldenbergIM , LavoriPW , BenkertO . Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross‐National Collaborative Panic Study. European Archives of Psychiatry and Clinical Neuroscience1991;240(3):163‐8. CassanoGB , ToniC , PetraccaA , DeltitoJ , BenkertO , CurtisG , et al. Adverse effects associated with the short‐term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology1994;4(1):47‐53. Cross National Collaborative Panic Study Second Phase Investigators. Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. British Journal of Psychiatry1992;160:191‐202. CurtisGC , MassanaJ , UdinaC , AyusoJL , CassanoGB , PerugiG . Maintenance drug therapy of panic disorder. Journal of Psychiatry Research1993;27(Suppl 1):127‐42. DeltitoJA , ArgyleN , BullerR , NutzingerD , OttossonJO , BrandonS , et al. The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(2):120‐9. DeltitoJA , ArgyleN , KlermanGL . Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Journal of Clinical Psychiatry1991;52(3):121‐7. GreenMA , CurtisGC . Personality disorders in panic patients: Response to termination of antipanic medication. Journal of Personality Disorders1988;2(4):303‐14. KatschnigH , AmeringM , StolkJM , KlermanGL , BallengerJC , BriggsA , et al. Long‐term follow‐up after a drug trial for panic disorder. British Journal of Psychiatry1995;167(4):487‐94. KlermanGL . Depression and panic anxiety: the effect of depressive co‐morbidity on response to drug treatment of patients with panic disorder and agoraphobia. Journal of Psychiatric Research1990;24(Suppl 2):27‐41. KlermanGL , ColemanJH , PurpuraRP . The design and conduct of the Upjohn Cross‐National Collaborative Panic Study. Psychopharmacology Bulletin1986;22(1):59‐64. LavoriPW , DawsonR , SheraD . A multiple imputation strategy for clinical trials with truncation of patient data. Statistics in Medicine1995;14(17):1913‐25. LeónCA , DeArangoMV , ArevaloW , CalvoA , MontoyaA , LeónA . Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia [Comparacion del efecto del alprazolam, la imipramina y placebo en el tratamiento del trastorno de panico en Cali, Colombia]. Acta Psiquiatrica y Psicologica de America Latina1990;36(1‐2):59‐72. MaierW , AlbusM , BullerR , NutzingerD , SheraD , BechP . Self‐ and observer assessment in anxiolytic drug trials: a comparison of their validity. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):103‐8. MaierW , RothSM , ArgyleN , BullerR , LavoriP , BrandonS , et al. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?. European Archives of Psychiatry and Clinical Neuroscience1991;241(3):151‐8. MaierWA , RothM , BullerR , ArgyleN , RosenbergR , SydneyB , et al. Agoraphobia in panic disorder: An indicator of the severity of panic disorder or a distinct diagnostic entity?. Psychiatric Annals1991;21(6):374‐81. RifkinA . The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(6):559‐60. RosenbergNK , MellergårdM , RosenbergR , BeckP , OttossonJO . Characteristics of panic disorder patients responding to placebo. Acta Psychiatrica Scandinavica Supplementum1991;365:33‐8. RosenbergR , BechP , MellergårdM , OttossonJO . Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response. Acta Psychiatrica Scandinavica. Supplementum1991;365:46‐52. SwobodaH , AmeringM , WindhaberJ , KatschnigH . The long‐term course of panic disorder‐‐an 11 year follow‐up. Journal of Anxiety Disorders2003;17(2):223‐32. ">CNCPS 1992</a>; <a href="./references#CD011567-bbs2-0016" title="LepolaU , HeikkinenH , RimonR , RiekkinenP . Clinical evaluation of alprazolam in patients with panic disorder; a double‐blind comparison with imipramine. Human Psychopharmacology1990;5:159‐63. RimonR . Spectral electroencephalogram and clinical follow‐up during alprazolam and imipramine treatment in panic disorder. Nordic Journal of Psychiatry1998;52(3):245‐9. ">Lepola 1990</a>; <a href="./references#CD011567-bbs2-0025" title="RickelsK , SchweizerE . Panic disorder: Long‐term pharmacotherapy and discontinuation. Journal of Clinical Psychopharmacology1998;18(6 Suppl 2):12‐8. RickelsK , SchweizerE , WeissS , ZavodnickS . Maintenance drug treatment for panic disorder. II. Short‐ and long‐term outcome after drug taper. Archives of General Psychiatry1993;50:61‐8. SchweizerE , RickelsK , WeissS , ZavodnickS . Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo‐controlled comparison of alprazolam and imipramine. Archives of General Psychiatry1993;50:51‐60. ">Schweizer 1993</a>; <a href="./references#CD011567-bbs2-0026" title="SheikhJI , SwalesPJ . Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo. International Journal of Psychiatry in Medicine1999;29(1):107‐17. ">Sheikh 1999</a>; <a href="./references#CD011567-bbs2-0028" title='ClarkDB , TaylorCB , RothWT , HaywardC , EhlersA , MargrafJ , et al. Surreptitious drug use by patients in a panic disorder study. American Journal of Psychiatry1990;147(4):507‐9. MargrafJ , EhlersA , RothWT , ClarkDB , SheikhJ , AgrasWS , et al. How "blind" are double‐blind studies?. Journal of Consulting and Clinical Psychology1991;59(1):184‐7. TaylorCB , HaywardC , KingR , EhlersA , MargrafJ , MaddockR , et al. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double‐blind, placebo‐controlled trial. Journal of Clinical Psychopharmacology1990;10(2):112‐8. '>Taylor 1990</a>; <a href="./references#CD011567-bbs2-0031" title="UhlenhuthEH , MatuzasW , GlassRM , EastonC . Response of panic disorder to fixed doses of alprazolam or imipramine. Journal of Affective Disorders1989;17(3):261‐70. ">Uhlenhuth 1989</a>), and one study compared clomipramine with adinazolam (<a href="./references#CD011567-bbs2-0013" title="HollandR , MuschB , HindmarchI . Specific effects of benzodiazepines and tricyclic antidepressants in panic disorder: comparisons of clomipramine with alprazolam SR and adinazolam SR. Human Psychopharmacology Clinical Experimental1999;14:119‐24. ">Holland 1999</a>). See also: <a href="./full#CD011567-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD011567-sec-0119"> <h5 class="title">Primary outcomes</h5> <section id="CD011567-sec-0120"> <h6 class="title">2.1 Failure to respond</h6> <p>The comparison between imipramine and benzodiazepines did not show a difference in terms of response rate (RR 1.02, 95% CI 0.63 to 1.67; participants = 61; studies = 1) (<a href="./references#CD011567-fig-0018" title="">Analysis 2.1</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0121"> <h6 class="title">2.2 Total number of dropouts</h6> <p>Imipramine was less well tolerated than benzodiazepines (RR 1.87, 95% CI 1.47 to 2.37; participants = 980; studies = 5; I² = 0%) (NNTH = 7, 95% CI 13 to 5), while there was a difference favouring clomipramine over benzodiazepines for this outcome (RR 0.69, 95% CI 0.49 to 0.98; participants = 315; studies = 1; I² = 0%) (NNTH = 10, 95% CI 6 to 143) (<a href="./references#CD011567-fig-0019" title="">Analysis 2.2</a>). Risk of bias was considered unclear for this outcome, but the majority of the studies were rated as high risk for "other bias" because of funding by pharmaceutical companies. </p> </section> </section> <section id="CD011567-sec-0122"> <h5 class="title">Secondary outcomes</h5> <section id="CD011567-sec-0123"> <h6 class="title">2.3 Failure to remit</h6> <p>The analysis failed to detect a difference between imipramine and benzodiazepines on remission rates (RR 1.19, 95% CI 1.00 to 1.41; participants = 848; studies = 2; I² = 0%). Risk of bias was considered unclear for this outcome, but the studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0124"> <h6 class="title">2.4 Panic symptoms ‐ endpoint score</h6> <p>One study showed a benefit for benzodiazepines over imipramine in reducing panic symptoms measured as endpoint scores (MD 0.50, 95% CI 0.21 to 0.79; participants = 777), whereas one study showed a benefit for clomipramine over benzodiazepines (MD ‐1.00, 95% CI ‐1.37 to ‐0.63; participants = 221) (<a href="./references#CD011567-fig-0021" title="">Analysis 2.4</a>). Risk of bias was considered unclear for this outcome. </p> </section> <section id="CD011567-sec-0125"> <h6 class="title">2.5 Panic symptoms ‐ mean change</h6> <p>Measuring mean change in panic symptoms, we found no difference between imipramine and benzodiazepines (MD 0.40, 95% CI ‐0.83 to 1.63; participants = 44; studies = 1) (<a href="./references#CD011567-fig-0022" title="">Analysis 2.5</a>). Risk of bias was considered high for this outcome, and the study was rated as high risk for "other bias" because of funding from a pharmaceutical company. </p> </section> <section id="CD011567-sec-0126"> <h6 class="title">2.6 Frequency of panic attacks</h6> <p>We found no difference in this outcome for the comparisons between imipramine and benzodiazepines, with a substantial heterogeneity (I² = 67%) (MD 0.75, 95% CI ‐0.44 to 1.94; participants = 237; studies = 5), while clomipramine was more effective than benzodiazepines for this outcome (MD ‐1.60, 95% CI ‐3.17 to ‐0.03; participants = 221; studies = 1) (<a href="./references#CD011567-fig-0023" title="">Analysis 2.6</a>). Risk of bias was considered unclear for this outcome, but the majority of the studies were rated as high risk for "other bias" because of funding by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0127"> <h6 class="title">2.7 Agoraphobia</h6> <p>In terms of agoraphobia, we found no difference between imipramine and benzodiazepines (SMD 0.04, 95% CI ‐0.08 to 0.17; participants = 949; studies = 4; I² = 0%) (<a href="./references#CD011567-fig-0024" title="">Analysis 2.7</a>). Risk of bias was considered unclear for this outcome, but all the studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0128"> <h6 class="title">2.8 General anxiety</h6> <p>For this outcome, we found a difference in favour of benzodiazepines over imipramine (SMD 0.22, 95% CI 0.10 to 0.35; participants = 1017; studies = 6; I² = 0%), and in favour of clomipramine over benzodiazepines (SMD ‐0.67, 95% CI ‐0.94 to ‐0.40; participants = 221; studies = 1) (<a href="./references#CD011567-fig-0025" title="">Analysis 2.8</a>). Risk of bias was considered unclear for this outcome, but the majority of the studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0129"> <h6 class="title">2.9 Depression</h6> <p>We did not find any difference between imipramine and benzodiazepines in this outcome (SMD ‐0.08, 95% CI ‐0.22 to 0.06; participants = 765; studies = 5; I² = 0%) (<a href="./references#CD011567-fig-0026" title="">Analysis 2.9</a>). Risk of bias was considered unclear for this outcome, but the majority of the studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0130"> <h6 class="title">2.10 Social functioning</h6> <p>We found a difference in favour of benzodiazepines over imipramine for this outcome (MD 0.25, 95% CI 0.09 to 0.42; participants = 882; studies = 3; I² = 0%) (<a href="./references#CD011567-fig-0027" title="">Analysis 2.10</a>). Risk of bias was considered between unclear and high for this outcome, and the studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0131"> <h6 class="title">2.11 Quality of life</h6> <p>No studies provided data for this outcome.</p> </section> <section id="CD011567-sec-0132"> <h6 class="title">2.12 Patient satisfaction</h6> <p>No studies provided data for this outcome.</p> </section> <section id="CD011567-sec-0133"> <h6 class="title">2.13 Economic costs</h6> <p>No studies provided data for this outcome.</p> </section> <section id="CD011567-sec-0134"> <h6 class="title">2.14 Number of dropouts due to adverse effects</h6> <p>We found that benzodiazepines were better tolerated than imipramine (RR 2.10, 95% CI 1.13 to 3.93; participants = 848; studies = 2; I² = 8%) (<a href="./references#CD011567-fig-0028" title="">Analysis 2.14</a>). Risk of bias was considered unclear for this outcome, but all the studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0135"> <h6 class="title">2.15 Number of patients experiencing at least one adverse effect</h6> <p>No studies provided data for this outcome.</p> </section> </section> </section> <section id="CD011567-sec-0136"> <h4 class="title">Comparison 3: SSRIs versus benzodiazepines</h4> <p>One study including 226 participants (<a href="./references#CD011567-bbs2-0011" title="GSK . A double‐blind, multicenter, flexible‐dose study of paroxetine, alprazolam and placebo in the treatment of panic disorder. GSK Clinical Studies Register [http://www.gsk‐clinicalstudyregister.com/]. ">GSK‐29060/1</a>) provided data for this comparison. The trial compared paroxetine versus alprazolam. See also: <a href="./full#CD011567-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD011567-sec-0137"> <h5 class="title">Primary outcomes</h5> <section id="CD011567-sec-0138"> <h6 class="title">3.1 Failure to respond</h6> <p>This comparison did not show any difference in terms of response rate (RR 0.93, 95% CI 0.48 to 1.80; participants = 154; studies = 1) (<a href="./references#CD011567-fig-0029" title="">Analysis 3.1</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0139"> <h6 class="title">3.2 Total number of dropouts</h6> <p>There was evidence that paroxetine is less well tolerated than benzodiazepines (RR 1.71, 95% CI 1.03 to 2.84; participants = 154; studies = 1) (<a href="./references#CD011567-fig-0030" title="">Analysis 3.2</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> </section> <section id="CD011567-sec-0140"> <h5 class="title">Secondary outcomes</h5> <section id="CD011567-sec-0141"> <h6 class="title">3.3 Failure to remit</h6> <p>We did not find any difference in terms of remission rate between paroxetine and benzodiazepines (RR 1.12, 95% CI 0.79 to 1.59; participants = 154; studies = 1) (<a href="./references#CD011567-fig-0031" title="">Analysis 3.3</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0142"> <h6 class="title">3.4 Panic symptoms</h6> <p>We did not find any difference in terms of panic symptoms between paroxetine and benzodiazepines (MD 0.10, 95% CI ‐0.34 to 0.54; participants = 146; studies = 1) (<a href="./references#CD011567-fig-0032" title="">Analysis 3.4</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0143"> <h6 class="title">3.5 Frequency of panic attacks</h6> <p>We did not find any difference in this outcome between paroxetine and benzodiazepines (MD 1.20, 95% CI ‐3.31 to 5.71; participants = 137; studies = 1) (<a href="./references#CD011567-fig-0033" title="">Analysis 3.5</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0144"> <h6 class="title">3.6 Agoraphobia</h6> <p>We did not find any difference in this outcome between paroxetine and benzodiazepines (SMD 0.00, 95% CI ‐0.37 to 0.37; participants = 112; studies = 1) (<a href="./references#CD011567-fig-0034" title="">Analysis 3.6</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0145"> <h6 class="title">3.7 General anxiety</h6> <p>We did not find any difference in terms of general anxiety between paroxetine and benzodiazepines (MD ‐0.60, 95% CI ‐3.35 to 2.15; participants = 127; studies = 1) (<a href="./references#CD011567-fig-0035" title="">Analysis 3.7</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0146"> <h6 class="title">3.8 Depression</h6> <p>We found a difference favouring paroxetine over benzodiazepines in terms of depression (MD ‐3.60, 95% CI ‐6.36 to ‐0.84; participants = 127; studies = 1) (<a href="./references#CD011567-fig-0036" title="">Analysis 3.8</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0147"> <h6 class="title">3.9 Social functioning</h6> <p>We did not find any difference in this outcome between paroxetine and benzodiazepines (MD ‐3.40, 95% CI ‐8.81 to 2.01; participants = 125; studies = 1) (<a href="./references#CD011567-fig-0037" title="">Analysis 3.9</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0148"> <h6 class="title">3.10 Quality of life</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0149"> <h6 class="title">3.11 Patient satisfaction</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0150"> <h6 class="title">3.12 Economic costs</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0151"> <h6 class="title">3.13 Number of dropouts due to adverse effects</h6> <p>We did not find any difference in terms of dropouts due to adverse effects between paroxetine and benzodiazepines (RR 1.20, 95% CI 0.55 to 2.61; participants = 154; studies = 1) (<a href="./references#CD011567-fig-0038" title="">Analysis 3.13</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0152"> <h6 class="title">3.14 Number of patients experiencing at least one adverse effect</h6> <p>We did not find any difference in this outcome between paroxetine and benzodiazepines (RR 1.03, 95% CI 0.92 to 1.15; participants = 154; studies = 1) (<a href="./references#CD011567-fig-0039" title="">Analysis 3.14</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> </section> </section> <section id="CD011567-sec-0153"> <h4 class="title">B: Antidepressants versus antidepressants</h4> <p>We found data only for the comparisons reported below.</p> </section> <section id="CD011567-sec-0154"> <h4 class="title">Comparison 4: TCAs versus SSRIs</h4> <p>Nine studies including 1290 participants (<a href="./references#CD011567-bbs2-0001" title="AmoreM , MagnaniK , CerisoliM , CasagrandeC , FerrariG . Panic disorder. A long‐term treatment study: fluoxetine vs imipramine. Human Psychopharmacology: Clinical and Experimental1999;14(6):429‐34. ">Amore 1999</a>; <a href="./references#CD011567-bbs2-0005" title="BystritskyA , RosenRM , MurphyKJ , BohnP , KeysSA , VapnikT . Double‐blind pilot trial of desipramine versus fluoxetine in panic patients. Anxiety 1994‐1995;1(6):287‐90. ">Bystritsky 1995</a>; <a href="./references#CD011567-bbs2-0007" title="DenBoerJA , WestenbergHGM . Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double‐blind comparative study with fluvoxamine and maprotiline. International Clinical Psychopharmacology1988;3(1):59‐74. ">Den Boer 1988</a>; <a href="./references#CD011567-bbs2-0012" title="GSK . A double blind, multicenter randomized drug‐controlled study to assess the efficacy and tolerance of paroxetine compared with clomipramine in treatment of panic disorder. GSK Clinical Studies Register [http://www.gsk‐clinicalstudyregister.com/]. ">GSK‐29060/525</a>; <a href="./references#CD011567-bbs2-0015" title="GlaxoSmithKline . A double‐blind placebo controlled comparative study of paroxetine and clomipramine in the treatment of panic disorder. GSK‐ClinicalStudy Register (www.gsk‐clinicalstudyregister.com) 1993/11/12. LecrubierY , BakkerA , DunbarG , Judge R and the Collaborative Panic Study Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatrica Scandinavica1997;95:145‐52. LecrubierY , Judge R and the Collaborative Paroxetine Panic Study Investigators. Long‐term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatrica Scandinavica1997;95:153‐60. ">Lecrubier 1997</a>; <a href="./references#CD011567-bbs2-0018" title="BakishD , HooperCL , FilteauMJ , CharbonneauY , FraserG , WestDL , et al. A double‐blind placebo‐controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacology Bulletin1996;32(1):135‐41. NairNP , BakishD , SaxenaB , AminM , SchwartzG , WestTE . Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety1996;2(4):192‐8. ">Nair 1996</a>; <a href="./references#CD011567-bbs2-0033" title="LeinonenE , LepolaU , KoponenH , TurtonenJ , WadeA , LehtoH . Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. Journal of Psychiatry and Neuroscience2000;25(1):24‐32. LepolaU , WadeAG , LeinonenEV , KoponenHJ , FrazerJ , SjoedinI , et al. A controlled, prospective, 1‐year trial of citalopram in the treatment of panic disorder. Journal of Clinical Psychiatry1998;59:528‐34. WadeA , OvereKF , LemmingO . Weight monitoring during two long‐term trials of citalopram. European Neuropsychopharmacology1999;9 Suppl 5:S221. WadeAG , LepolaU , KoponenHJ , PedersenV , PedersenT . The effect of citalopram in panic disorder. British Journal of Psychiatry1997;170:549‐53. ">Wade 1997</a>; <a href="./references#CD011567-bbs2-0034" title="WestenbergHG , denBoerJA . Selective monoamine uptake inhibitors and a serotonin antagonist in the treatment of panic disorder. Psychopharmacology Bulletin1989;25(1):119‐23. ">Westenberg 1989</a>; <a href="./references#CD011567-bbs2-0035" title="ZhangHY , ZhaoQP , MaC . Paroxetine versus clomipramine for the treatment of panic disorders: a double‐blind randomised study. Chinese Mental Health Journal2000;14(6):410‐3. ">Zhang 2000</a>) provided data for this comparison. See also: <a href="./full#CD011567-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD011567-sec-0155"> <h5 class="title">Primary outcomes</h5> <section id="CD011567-sec-0156"> <h6 class="title">4.1 Failure to respond</h6> <p>There was low‐quality evidence suggesting no difference between TCAs and SSRIs on response rate, with moderate heterogeneity (I² = 61%) (RR 1.08, 95% CI 0.71 to 1.66; participants = 438; studies = 4) (<a href="./references#CD011567-fig-0040" title="">Analysis 4.1</a>). Risk of bias was considered unclear for this outcome, but the majority of studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0157"> <h6 class="title">4.2 Total number of dropouts</h6> <p>We found low‐quality evidence suggesting no difference in terms of dropouts between TCAs and SSRIs, with moderate heterogeneity (I² = 47%) (RR 0.98, 95% CI 0.65 to 1.48; participants = 928; studies = 7) (<a href="./references#CD011567-fig-0041" title="">Analysis 4.2</a>). Risk of bias was considered unclear for this outcome, but the majority of studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> </section> <section id="CD011567-sec-0158"> <h5 class="title">Secondary outcomes</h5> <section id="CD011567-sec-0159"> <h6 class="title">4.3 Failure to remit</h6> <p>We found moderate‐quality evidence suggesting no difference in terms of remission rate between TCAs and SSRIs, with moderate heterogeneity (I² = 58%) (RR 0.89, 95% CI 0.63 to 1.26; participants = 475; studies = 5) (<a href="./references#CD011567-fig-0042" title="">Analysis 4.3</a>). Risk of bias was considered unclear for this outcome, but many studies were rated as high risk for "other bias" because of funding by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0160"> <h6 class="title">4.4 Panic symptoms</h6> <p>There was very low‐quality evidence suggesting no difference between TCAs and SSRIs on this outcome, with moderate heterogeneity (I² = 50%) (MD ‐0.20, 95% CI ‐0.88 to 0.48; participants = 243; studies = 4) (<a href="./references#CD011567-fig-0043" title="">Analysis 4.4</a>). Risk of bias was considered unclear for this outcome, but the majority of studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0161"> <h6 class="title">4.5 Frequency of panic attacks</h6> <p>No difference was found between SSRIs and TCAs in terms of frequency of panic attacks, with moderate heterogeneity (I² = 66%) (MD 2.30, 95% CI ‐0.11 to 4.71; participants = 329; studies = 3) (<a href="./references#CD011567-fig-0044" title="">Analysis 4.5</a>). Risk of bias was considered between unclear and high for this outcome, and the majority of studies were rated as high risk for "other bias" because of funding by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0162"> <h6 class="title">4.6 Agoraphobia</h6> <p>One study with 226 patients found no difference in this outcome between TCAs and SSRIs (MD 0.10, 95% CI ‐0.68 to 0.88) (<a href="./references#CD011567-fig-0045" title="">Analysis 4.6</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0163"> <h6 class="title">4.7 General anxiety ‐ endpoint score</h6> <p>We did not find any difference between TCAs and SSRIs on efficacy measured as endpoint scores (SMD 0.09, 95% CI ‐0.27 to 0.45; participants = 668; studies = 7). The degree of heterogeneity was substantial (I² = 71%) (<a href="./references#CD011567-fig-0046" title="">Analysis 4.7</a>). Risk of bias was considered unclear for this outcome, and some studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0164"> <h6 class="title">4.8 General anxiety ‐ mean change</h6> <p>We did not find any difference between TCAs and SSRIs on efficacy measured as mean change scores (MD 0.99, 95% CI ‐1.39 to 3.36; participants = 309; studies = 2; I² = 0%) (<a href="./references#CD011567-fig-0047" title="">Analysis 4.8</a>). Risk of bias was considered unclear for this outcome, but all the studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0165"> <h6 class="title">4.9 Depression ‐ endpoint score</h6> <p>We did not find any difference between TCAs and SSRIs on efficacy measured as endpoint scores (SMD ‐0.04, 95% CI ‐0.26 to 0.17; participants = 597; studies = 5; I² = 20%) (<a href="./references#CD011567-fig-0048" title="">Analysis 4.9</a>). Risk of bias was considered unclear for this outcome, but some studies were rated as high risk for "other bias" because of funding by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0166"> <h6 class="title">4.10 Depression ‐ mean change</h6> <p>We did not find any difference between TCAs and SSRIs on efficacy measured as mean change scores (SMD ‐0.04, 95% CI ‐0.31 to 0.23; participants = 212; studies = 1; I² = 0%) (<a href="./references#CD011567-fig-0049" title="">Analysis 4.10</a>). Risk of bias was considered between unclear and high for this outcome, and the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0167"> <h6 class="title">4.11 Social functioning</h6> <p>No studies provided data for this outcome.</p> </section> <section id="CD011567-sec-0168"> <h6 class="title">4.12 Quality of life</h6> <p>No studies provided data for this outcome.</p> </section> <section id="CD011567-sec-0169"> <h6 class="title">4.13 Patient satisfaction</h6> <p>No studies provided data for this outcome.</p> </section> <section id="CD011567-sec-0170"> <h6 class="title">4.14 Economic costs</h6> <p>No studies provided data for this outcome.</p> </section> <section id="CD011567-sec-0171"> <h6 class="title">4.15 Number of dropouts due to adverse effects</h6> <p>There was low‐quality evidence suggesting no difference between TCAs and SSRIs on dropouts due to adverse effects (RR 1.43, 95% CI 0.82 to 2.48; participants = 476; studies = 5; I² = 11%) (<a href="./references#CD011567-fig-0050" title="">Analysis 4.15</a>). Risk of bias was considered unclear for this outcome, but the majority of studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0172"> <h6 class="title">4.16 Number of patients experiencing at least one adverse effect</h6> <p>Considering tolerability as the number of patients who experienced at least one adverse effect, we found a difference in favour of SSRIs compared to TCAs (RR 1.29, 95% CI 1.02 to 1.65; participants = 489; studies = 4) (NNTH = 6, 95% CI 84 to 3), with a substantial degree of heterogeneity between the studies included in the analysis (I² = 78%) (<a href="./references#CD011567-fig-0051" title="">Analysis 4.16</a>). Risk of bias was considered unclear for this outcome, but all the studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> </section> </section> <section id="CD011567-sec-0173"> <h4 class="title">Comparison 5: TCAs versus MAOIs</h4> <p>Two studies including 228 participants provided data for this comparison. One compared brofaromine with clomipramine (<a href="./references#CD011567-bbs2-0003" title="BakishD , SaxenaBM , BowenR , D'SouzaJ . Reversible monoamine oxidase‐A inhibitors in panic disorder. Clinical Neuropharmacology1993;16(Suppl 2):S77‐S82. SaxenaB , BakishD , BowenR , D'SouzaJ . Brofaromine and clomipramine in panic disorder: a double‐blind study. Clinical Neuropharmacology1992;15(1 Pt B):60. ">Bakish 1993</a>), and one compared moclobemide with clomipramine (<a href="./references#CD011567-bbs2-0014" title="KruegerMB , DahlAA . The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. European Archives of Psychiatry and Clinical Neuroscience1999;249(Suppl 1):S19‐S24. ">Krueger 1999</a>). See also: <a href="./full#CD011567-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD011567-sec-0174"> <h5 class="title">Primary outcomes</h5> <section id="CD011567-sec-0175"> <h6 class="title">5.1 Failure to respond</h6> <p>The comparison between TCAs and MAOIs did not find any difference in response rate (RR 0.59, 95% CI 0.28 to 1.26; participants = 135; studies = 1; low‐quality evidence) (<a href="./references#CD011567-fig-0052" title="">Analysis 5.1</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0176"> <h6 class="title">5.2 Total number of dropouts</h6> <p>We found moderate‐quality evidence suggesting no difference between TCAs and MAOIs in terms of number of dropouts (RR 0.84, 95% CI 0.61 to 1.17; participants = 228; studies = 2; I² = 0%) (<a href="./references#CD011567-fig-0053" title="">Analysis 5.2</a>). Risk of bias was considered between unclear and high for this outcome, with one study rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> </section> <section id="CD011567-sec-0177"> <h5 class="title">Secondary outcomes</h5> <section id="CD011567-sec-0178"> <h6 class="title">5.3 Failure to remit</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0179"> <h6 class="title">5.4 Panic symptoms</h6> <p>We found low‐quality evidence suggesting no difference between TCAs and MAOIs on this outcome (MD ‐0.20, 95% CI ‐0.75 to 0.35; participants = 135; studies = 1) (<a href="./references#CD011567-fig-0054" title="">Analysis 5.4</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0180"> <h6 class="title">5.5 Frequency of panic attacks</h6> <p>We found no difference between TCAs and MAOIs for this outcome (MD ‐0.30, 95% CI ‐3.35 to 2.75; participants = 135; studies = 1) (<a href="./references#CD011567-fig-0055" title="">Analysis 5.5</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0181"> <h6 class="title">5.6 Agoraphobia</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0182"> <h6 class="title">5.7 General anxiety</h6> <p>The comparison between TCAs and MAOIs did not find any difference in general anxiety (MD 0.30, 95% CI ‐3.03 to 3.63; participants = 135; studies = 1) (<a href="./references#CD011567-fig-0056" title="">Analysis 5.7</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0183"> <h6 class="title">5.8 Depression</h6> <p>We found a difference in favour of TCAs over MAOIs for depression measured on a continuous scale (MD ‐4.10, 95% CI ‐8.14 to ‐0.06; participants = 135; studies = 1) (<a href="./references#CD011567-fig-0057" title="">Analysis 5.8</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0184"> <h6 class="title">5.9 Social functioning</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0185"> <h6 class="title">5.10 Quality of life</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0186"> <h6 class="title">5.11 Patient satisfaction</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0187"> <h6 class="title">5.12 Economic costs</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0188"> <h6 class="title">5.13 Number of dropouts due to adverse effects</h6> <p>The comparison between TCAs and MAOIs did not show any difference in terms of dropouts due to adverse effects (RR 1.27, 95% CI 0.50 to 3.21; participants = 135; studies = 1; low‐quality evidence) (<a href="./references#CD011567-fig-0058" title="">Analysis 5.13</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0189"> <h6 class="title">5.14 Number of patients experiencing at least one adverse effect</h6> <p>We found a difference in favour of MAOIs over TCAs in tolerability in terms of number of patients who experienced at least one adverse effect (RR 1.24, 95% CI 1.06 to 1.45; participants = 135; studies = 1) (<a href="./references#CD011567-fig-0059" title="">Analysis 5.14</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> </section> </section> <section id="CD011567-sec-0190"> <h4 class="title">Comparison 6: SSRIs versus MAOIs</h4> <p>Two studies including 396 participants; provided data for this comparison. One study compared moclobemide with fluoxetine (<a href="./references#CD011567-bbs2-0030" title="TillerJWG , BouwerC , BehnkeK . Moclobemide and fluoxetine for panic disorder. European Archives of Psychiatry and Clinical Neuroscience1999;249(Suppl1):S7‐S10. ">Tiller 1999</a>), and the other compared brofaromine with fluvoxamine (<a href="./references#CD011567-bbs2-0032" title="SlaapBR , vanVlietIM , WestenbergHGM , denBoerJA . Phobic symptoms as predictors of nonresponse to drug therapy in panic disorder patients (a preliminary report). Journal of Affective Disorders1995;33(1):31‐8. vanVlietIM , denBoerJA , WestenbergHGM , SlaapBR . A double‐blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. Journal of Clinical Psychopharmacology1996;16(4):299‐306. ">Van Vliet 1996</a>). See also: <a href="./full#CD011567-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD011567-sec-0191"> <h5 class="title">Primary outcomes</h5> <section id="CD011567-sec-0192"> <h6 class="title">6.1 Failure to respond</h6> <p>We found moderate‐quality evidence suggesting no difference in terms of response rate between SSRIs and MAOIs (RR 1.12, 95% CI 0.83 to 1.52; participants = 396; studies = 2; I² = 0%) (<a href="./references#CD011567-fig-0060" title="">Analysis 6.1</a>). Risk of bias was considered between unclear and high for this outcome, with one study rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0193"> <h6 class="title">6.2 Total number of dropouts</h6> <p>We found low‐quality evidence suggesting no difference between SSRIs and MAOIs in terms of the number of dropouts (RR 1.00, 95% CI 0.07 to 14.55; participants = 30; studies = 1) (<a href="./references#CD011567-fig-0061" title="">Analysis 6.2</a>). Risk of bias was considered between unclear and high for this outcome. </p> </section> </section> <section id="CD011567-sec-0194"> <h5 class="title">Secondary outcomes</h5> <section id="CD011567-sec-0195"> <h6 class="title">6.3 Failure to remit</h6> <p>We found moderate‐quality evidence suggesting no difference between SSRIs and MAOIs for this outcome (RR 0.93, 95% CI 0.74 to 1.17; participants = 366; studies = 1) (<a href="./references#CD011567-fig-0062" title="">Analysis 6.3</a>). Risk of bias was considered between unclear and high for this outcome, as the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0196"> <h6 class="title">6.4 Panic symptoms</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0197"> <h6 class="title">6.5 Frequency of panic attacks</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0198"> <h6 class="title">6.6 Agoraphobia</h6> <p>There was no evidence of a difference between SSRIs and MAOIs in this outcome (MD 1.50, 95% CI ‐4.47 to 7.47; participants = 30; studies = 1) (<a href="./references#CD011567-fig-0063" title="">Analysis 6.6</a>). Risk of bias was considered between unclear and high for this outcome. </p> </section> <section id="CD011567-sec-0199"> <h6 class="title">6.7 General anxiety</h6> <p>We found a difference in favour of SSRIs over MAOIs in terms of efficacy on general anxiety (MD ‐0.60, 95% CI ‐1.10 to ‐0.10; participants = 30; studies = 1) (<a href="./references#CD011567-fig-0064" title="">Analysis 6.7</a>). Risk of bias was considered between unclear and high for this outcome. </p> </section> <section id="CD011567-sec-0200"> <h6 class="title">6.8 Depression</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0201"> <h6 class="title">6.9 Social functioning</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0202"> <h6 class="title">6.10 Quality of life</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0203"> <h6 class="title">6.11 Patient satisfaction</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0204"> <h6 class="title">6.12 Economic costs</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0205"> <h6 class="title">6.13 Number of dropouts due to adverse effects</h6> <p>The comparison between SSRIs and MAOIs did not find any difference in terms of dropouts due to adverse effects (RR 1.26, 95% CI 0.59 to 2.70; participants = 366; studies = 1, low‐quality evidence) (<a href="./references#CD011567-fig-0065" title="">Analysis 6.13</a>). Risk of bias was considered between unclear and high for this outcome, with the study rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0206"> <h6 class="title">6.14 Number of patients experiencing at least one adverse effect</h6> <p>We found no difference between SSRIs and MAOIs for this outcome (RR 1.09, 95% CI 0.94 to 1.27; participants = 366; studies = 1) (<a href="./references#CD011567-fig-0066" title="">Analysis 6.14</a>). Risk of bias was considered between unclear and high for this outcome, with the study rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> </section> </section> <section id="CD011567-sec-0207"> <h4 class="title">Comparison 7: SSRIs versus SNRIs</h4> <p>Two studies including 1316 participants (<a href="./references#CD011567-bbs2-0021" title="PollackM , ManganoR , EntsuahR , TzanisE , SimonNM . A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology2007;194:233‐42. PollackM , WhitakerT , ManganoR , GaoB . A comparison of venlafaxine XR and paroxetine in the treatment of outpatients with panic disorder. ACNP 2004 Annual MeetingS201‐S202. ">Pollack 2007a</a>; <a href="./references#CD011567-bbs2-0022" title="PollackMH , LepolaU , KoponenH , SimonNM , WorthingtonJJ , EmilienG , et al. A double‐blind study of the efficacy of venlafaxine extended‐release, paroxetine and placebo in the treatment of panic disorder. Depression and Anxiety2007;24:1‐14. ">Pollack 2007b</a>) provided data for this comparison. Both studies compared venlafaxine and paroxetine. See also: <a href="./full#CD011567-tbl-0007">summary of findings Table 7</a>. </p> <section id="CD011567-sec-0208"> <h5 class="title">Primary outcomes</h5> <section id="CD011567-sec-0209"> <h6 class="title">7.1 Failure to respond</h6> <p>We found high‐quality evidence suggesting no difference between SSRIs and serotonin‐norepinephrine reuptake inhibitors (SNRIs) in terms of response rate (RR 0.96, 95% CI 0.75 to 1.23; participants = 991; studies = 2; I² = 1%) (<a href="./references#CD011567-fig-0067" title="">Analysis 7.1</a>). Risk of bias was considered unclear for this outcome, but both studies were rated as high risk for "other bias" because they were funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0210"> <h6 class="title">7.2 Total number of dropouts</h6> <p>We found low‐quality evidence suggesting no difference between SSRIs and SNRIs in terms of total number of dropouts (RR 1.11, 95% CI 0.74 to 1.65; participants = 991; studies = 2), with moderate heterogeneity (I² = 53%) (<a href="./references#CD011567-fig-0068" title="">Analysis 7.2</a>). Risk of bias was considered unclear for this outcome, but both studies were rated as high risk for "other bias" because they were funded by a pharmaceutical company. </p> </section> </section> <section id="CD011567-sec-0211"> <h5 class="title">Secondary outcomes</h5> <section id="CD011567-sec-0212"> <h6 class="title">7.3 Failure to remit</h6> <p>We found high‐quality evidence suggesting no difference between SSRIs and SNRIs in terms of remission rate (RR 1.05, 95% CI 0.91 to 1.21; participants = 991; studies = 2; I<sup>2</sup> = 42%) (<a href="./references#CD011567-fig-0069" title="">Analysis 7.3</a>). Risk of bias was considered unclear for this outcome, but both studies were rated as high risk for "other bias" because they were funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0213"> <h6 class="title">7.4 Panic symptoms</h6> <p>We found no difference between SSRIs and SNRIs in terms of panic symptoms (MD ‐0.12, 95% CI ‐0.33 to 0.10; participants = 945; studies = 2; I² = 0%, high‐quality evidence) (<a href="./references#CD011567-fig-0070" title="">Analysis 7.4</a>). Risk of bias was considered unclear for this outcome, but both studies were rated as high risk for "other bias" because they were funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0214"> <h6 class="title">7.5 Frequency of panic attacks</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0215"> <h6 class="title">7.6 Agoraphobia</h6> <p>One study showed no difference between SSRIs and SNRIs on agoraphobia (SMD 0.00, 95% CI ‐0.19 to 0.19; participants = 478; studies = 1) (<a href="./references#CD011567-fig-0071" title="">Analysis 7.6</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0216"> <h6 class="title">7.7 General anxiety</h6> <p>No difference was found between SSRIs and SNRIs for this outcome (MD ‐0.25, 95% CI ‐1.83 to 1.33; participants = 478; studies = 1) (<a href="./references#CD011567-fig-0072" title="">Analysis 7.7</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0217"> <h6 class="title">7.8 Depression</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0218"> <h6 class="title">7.9 Social functioning</h6> <p>One study showed no difference between SSRIs and SNRIs for this outcome (MD 0.15, 95% CI ‐0.71 to 1.01; participants = 478; studies = 1) (<a href="./references#CD011567-fig-0073" title="">Analysis 7.9</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0219"> <h6 class="title">7.10 Quality of life</h6> <p>One study showed no difference between SSRIs and SNRIs for this outcome (MD 0.06, 95% CI ‐2.11 to 2.23; participants = 478; studies = 1) (<a href="./references#CD011567-fig-0074" title="">Analysis 7.10</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by pharmaceutical company. </p> </section> <section id="CD011567-sec-0220"> <h6 class="title">7.11 Patient satisfaction</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0221"> <h6 class="title">7.12 Economic costs</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0222"> <h6 class="title">7.13 Number of dropouts due to adverse effects</h6> <p>We found low‐quality evidence that failed to reveal a difference between SSRIs and SNRIs in this outcome (RR 1.86, 95% CI 0.49 to 7.05; participants = 991; studies = 2; I<sup>2</sup> = 76%) (<a href="./references#CD011567-fig-0075" title="">Analysis 7.13</a>). Risk of bias was considered unclear for this outcome, but both studies were rated as high risk for "other bias" because they were funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0223"> <h6 class="title">7.14 Number of patients experiencing at least one adverse effect</h6> <p>We found no difference between SSRIs and SNRIs in this outcome (RR 0.97, 95% CI 0.88 to 1.08; participants = 991; studies = 2) with moderate heterogeneity (I² = 51%) (<a href="./references#CD011567-fig-0076" title="">Analysis 7.14</a>). Risk of bias was considered unclear for this outcome, but both studies were rated as high risk for "other bias" because of funding by a pharmaceutical company. </p> </section> </section> </section> <section id="CD011567-sec-0224"> <h4 class="title">Comparison 8: SSRIs versus NaSSAs</h4> <p>One study including 30 participants (<a href="./references#CD011567-bbs2-0023" title="RibeiroL , BusnelloJV , Kauer‐Sant'AnnaM , MadrugaM , QuevedoJ , BusnelloEAD , et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. Brazilian Journal of Medical and Biological Research2001;34:1303‐7. ">Ribeiro 2001</a>) provided data for this comparison, comparing mirtazapine and fluoxetine. See also: <a href="./full#CD011567-tbl-0008">summary of findings Table 8</a>. </p> <section id="CD011567-sec-0225"> <h5 class="title">Primary outcomes</h5> <section id="CD011567-sec-0226"> <h6 class="title">8.1 Failure to respond</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0227"> <h6 class="title">8.2 Total number of dropouts</h6> <p>We found low‐quality evidence suggesting no difference between SSRIs and noradrenergic and specific serotonergic antidepressant (NaSSAs) in terms of dropouts due to any cause (RR 1.50, 95% CI 0.29 to 7.73; participants = 30; studies = 1; I² = 0%) (<a href="./references#CD011567-fig-0077" title="">Analysis 8.2</a>). Risk of bias was considered between low and unclear for this outcome. </p> </section> </section> <section id="CD011567-sec-0228"> <h5 class="title">Secondary outcomes</h5> <section id="CD011567-sec-0229"> <h6 class="title">8.3 Failure to remit</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0230"> <h6 class="title">8.4 Panic symptoms</h6> <p>We found low‐quality evidence suggesting no difference between SSRIs and NaSSAs for this outcome (MD 0.30, 95% CI ‐0.49 to 1.09; participants = 22; studies = 1) (<a href="./references#CD011567-fig-0078" title="">Analysis 8.4</a>). Risk of bias was considered between low and unclear for this outcome. </p> </section> <section id="CD011567-sec-0231"> <h6 class="title">8.5 Frequency of panic attacks</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0232"> <h6 class="title">8.6 Agoraphobia</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0233"> <h6 class="title">8.7 General anxiety</h6> <p>No difference was found between SSRIs and NaSSAs on this outcome (MD 1.10, 95% CI ‐6.04 to 8.24; participants = 27; studies = 1) (<a href="./references#CD011567-fig-0079" title="">Analysis 8.7</a>). Risk of bias was considered between low and unclear for this outcome. </p> </section> <section id="CD011567-sec-0234"> <h6 class="title">8.8 Depression</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0235"> <h6 class="title">8.9 Social functioning</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0236"> <h6 class="title">8.10 Quality of life</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0237"> <h6 class="title">8.11 Patient satisfaction</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0238"> <h6 class="title">8.12 Economic costs</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0239"> <h6 class="title">8.13 Number of dropouts due to adverse effects</h6> <p>We found low‐quality evidence suggesting no difference between SSRIs and NaSSAs in terms of dropouts due to adverse effects (RR 1.50, 95% CI 0.29 to 7.73; participants = 30; studies = 1) (<a href="./references#CD011567-fig-0080" title="">Analysis 8.13</a>). Risk of bias was considered between low and unclear for this outcome. </p> </section> <section id="CD011567-sec-0240"> <h6 class="title">8.14 Number of patients experiencing at least one adverse effect</h6> <p>The study did not provide data for this outcome.</p> </section> </section> </section> <section id="CD011567-sec-0241"> <h4 class="title">Comparison 9: SSRIs versus Other Antidepressants</h4> <p>One study including 59 participants (<a href="./references#CD011567-bbs2-0008" title="DenBoerJA , WestenbergHGM . Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology1990;102:85‐94. WestenbergHG , denBoerJA . Selective monoamine uptake inhibitors and a serotonin antagonist in the treatment of panic disorder. Psychopharmacology Bulletin1989;25(1):119‐23. ">Den Boer 1990</a>) provided data for this comparison, comparing fluvoxamine and ritanserin. </p> <section id="CD011567-sec-0242"> <h5 class="title">Primary outcomes</h5> <section id="CD011567-sec-0243"> <h6 class="title">9.1 Failure to respond</h6> <p>We found a difference favouring SSRIs over other antidepressants in terms of response rates (RR 0.28, 95% CI 0.13 to 0.60; participants = 40; studies = 1) (<a href="./references#CD011567-fig-0081" title="">Analysis 9.1</a>). Risk of bias was considered between unclear for this outcome. </p> </section> <section id="CD011567-sec-0244"> <h6 class="title">9.2 Total number of dropouts</h6> <p>The study reports that no patients left the study early in both groups, therefore it was not possible to calculate a RR (dropouts were n = 0 in 20 patients in both the fluvoxamine and ritanserin group). </p> </section> </section> <section id="CD011567-sec-0245"> <h5 class="title">Secondary outcomes</h5> <section id="CD011567-sec-0246"> <h6 class="title">9.3 Failure to remit</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0247"> <h6 class="title">9.4 Panic symptoms</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0248"> <h6 class="title">9.5 Frequency of panic attacks</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0249"> <h6 class="title">9.6 Agoraphobia</h6> <p>We found a difference in favour of SSRIs over other antidepressants (ritanserin) in terms of efficacy on agoraphobia (MD ‐7.35, 95% CI ‐13.73 to ‐0.97; participants = 40; studies = 1) (<a href="./references#CD011567-fig-0083" title="">Analysis 9.6</a>). Risk of bias was considered unclear for this outcome. </p> </section> <section id="CD011567-sec-0250"> <h6 class="title">9.7 General anxiety</h6> <p>We found a difference in favour of SSRIs over other antidepressants (ritanserin) in terms of efficacy on general anxiety (MD ‐3.55, 95% CI ‐5.07 to ‐2.03; participants = 40; studies = 1) (<a href="./references#CD011567-fig-0084" title="">Analysis 9.7</a>). Risk of bias was considered unclear for this outcome. </p> </section> <section id="CD011567-sec-0251"> <h6 class="title">9.8 Depression</h6> <p>We found a difference in favour of SSRIs over other antidepressant (ritanserin) (MD ‐5.38, 95% CI ‐7.90 to ‐2.86; participants = 40; studies = 1) (<a href="./references#CD011567-fig-0085" title="">Analysis 9.8</a>). Risk of bias was considered unclear for this outcome. </p> </section> <section id="CD011567-sec-0252"> <h6 class="title">9.9 Social functioning</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0253"> <h6 class="title">9.10 Quality of life</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0254"> <h6 class="title">9.11 Patient satisfaction</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0255"> <h6 class="title">9.12 Economic costs</h6> <p>The study did not provide data for this outcome.</p> </section> <section id="CD011567-sec-0256"> <h6 class="title">9.13 Number of dropouts due to adverse effects</h6> <p>The study reports that no patients left the study early in both groups, therefore it was not possible to calculate a RR (dropouts were n= 0 in patients in both the fluvoxamine and ritanserin group). </p> </section> <section id="CD011567-sec-0257"> <h6 class="title">9.14 Number of patients experiencing at least one adverse effect</h6> <p>The study did not provide data for this outcome.</p> </section> </section> </section> <section id="CD011567-sec-0258"> <h4 class="title">Comparison 10: Individual antidepressants versus another antidepressant within the same class </h4> <p>Five studies including 1026 participants (<a href="./references#CD011567-bbs2-0002" title="AmoreM , MagnaniK , CerisoliM , FerrariG . Short‐term and long‐term evaluation of selective serotonin reuptake inhibitors in the treatment of panic disorder: fluoxetine vs citalopram. Human Psychopharmacology: Clinical and Experimental1999;14(6):435‐40. ">Amore 1999 bis</a>; <a href="./references#CD011567-bbs2-0004" title="BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , DombrowskiA , et al. Sertraline versus paroxetine in the treatment of panic disorder: a multinational randomized double‐blind 15 week study. European Neuropsychopharmacology2002;12(Suppl 3):S363. BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , GoebelC , et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double‐blind noninferiority comparison. Journal of Clinical Psychiatry2004;65(3):405‐13. ">Bandelow 2004</a>; <a href="./references#CD011567-bbs2-0010" title="GentilV , Lotufo‐NetoF , AndradeL , CordásT , BernikM , RamosR , et al. Clomipramine, a better reference drug for panic/agoraphobia. I. Effectiveness comparison with imipramine. Journal of Psychopharmacology1993;7(4):316‐24. MarcourakisT , GorensteinC , GentilV . Clomipramine, a better reference drug for panic/agoraphobia. II. Psychomotor and cognitive effects. Journal of Psychopharmacology1993;7(4):325‐30. ">Gentil 1993</a>; <a href="./references#CD011567-bbs2-0020" title="Pfizer . A randomized, double‐blind, multicenter study of sertraline compared with paroxetine In the treatment of panic disorder. http://clinicaltrials.gov/show/NCT006773522008. ">Pfizer 2008</a>; <a href="./references#CD011567-bbs2-0027" title="BandelowB , SteinDJ , DolbergOT , AndersenHF , BaldwinDS . Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry2007;40:152‐6. ForestLaboratories . Flexible‐dose comparison of the safety and efficacy of Lu 26‐054 (escitalopram), citalopram and placebo in the treatment of panic disorder. Forest Laboratories Clinical Study Register [www.forestclinicaltrials.com]. StahlS , GergelI , LiD . Escitalopram in the treatment of panic disorder: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2003;64:1322‐7. ">Stahl 2003</a>) provided data for this comparison. </p> <section id="CD011567-sec-0259"> <h5 class="title">Primary outcomes</h5> <section id="CD011567-sec-0260"> <h6 class="title">10.1 Failure to respond</h6> <p>We found no difference between escitalopram and citalopram in terms of response rate (RR 0.92, 95% CI 0.79 to 1.06; participants = 255; studies = 1). The comparison between fluoxetine and citalopram (RR 0.57, 95% CI 0.20 to 1.66; participants = 42; studies = 1), as well as the one between sertraline and paroxetine (RR 0.97, 95% CI 0.80 to 1.17; participants = 546; studies = 2; I² = 0%) did not show any difference (<a href="./references#CD011567-fig-0087" title="">Analysis 10.1</a>). Risk of bias was considered unclear for this outcome, but the majority of studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0261"> <h6 class="title">10.2 Total number of dropouts</h6> <p>We found a difference in favour of sertraline over paroxetine in terms of dropouts due to any cause (RR 0.74, 95% CI 0.55 to 0.99; participants = 546; studies = 2; I² = 2%) (NNTH = 14, 95% CI 8 to 351), while there was no difference for the other comparisons (<a href="./references#CD011567-fig-0088" title="">Analysis 10.2</a>). Risk of bias was considered unclear for this outcome, but the majority of studies were rated as high risk for "other bias" because of funding by pharmaceutical companies. </p> </section> </section> <section id="CD011567-sec-0262"> <h5 class="title">Secondary outcomes</h5> <section id="CD011567-sec-0263"> <h6 class="title">10.3 Failure to remit</h6> <p>We found no difference between escitalopram and citalopram in terms of remission rates (RR 0.90, 95% CI 0.71 to 1.15; participants = 255; studies = 1) (<a href="./references#CD011567-fig-0089" title="">Analysis 10.3</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0264"> <h6 class="title">10.4 Panic symptoms</h6> <p>No difference was found between escitalopram and citalopram for this outcome (SMD ‐0.09, 95% CI ‐0.35 to 0.16; participants = 237; studies = 1), as well as between sertraline and paroxetine (SMD ‐0.05, 95% CI ‐0.23 to 0.13; participants = 473; studies = 2; I² = 0%) (<a href="./references#CD011567-fig-0090" title="">Analysis 10.4</a>). Risk of bias was considered unclear for this outcome, but all the studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0265"> <h6 class="title">10.5 Frequency of panic attacks</h6> <p>We found no difference between sertraline and paroxetine for this outcome (MD 0.48, 95% CI ‐1.02 to 1.98; participants = 461; studies = 2; I² = 0%) (<a href="./references#CD011567-fig-0091" title="">Analysis 10.5</a>). Risk of bias was considered unclear for this outcome, but both studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0266"> <h6 class="title">10.6 Agoraphobia</h6> <p>In terms of agoraphobia, we found no difference between escitalopram and citalopram (MD ‐1.10, 95% CI ‐3.46 to 1.26; participants = 237; studies = 1) (<a href="./references#CD011567-fig-0092" title="">Analysis 10.6</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0267"> <h6 class="title">10.7 General anxiety</h6> <p>In terms of general anxiety, the comparison between escitalopram and citalopram did not show any difference (MD ‐1.20, 95% CI ‐3.14 to 0.74; participants = 237; studies = 1), as well as between sertraline and paroxetine (MD ‐0.72, 95% CI ‐2.42 to 0.99; participants = 454; studies = 2; I² = 0%) (<a href="./references#CD011567-fig-0093" title="">Analysis 10.7</a>). Risk of bias was considered unclear for this outcome, but all the studies were rated as high risk for "other bias" because of funding by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0268"> <h6 class="title">10.8 Depression</h6> <p>We found no difference between escitalopram and citalopram for this outcome (SMD ‐0.11, 95% CI ‐0.36 to 0.15; participants = 237; studies = 1), and between sertraline and paroxetine (SMD 0.00, 95% CI ‐0.28 to 0.29; participants = 189; studies = 1) (<a href="./references#CD011567-fig-0094" title="">Analysis 10.8</a>). Risk of bias was considered unclear for this outcome, but both studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0269"> <h6 class="title">10.9 Social functioning</h6> <p>No studies provided data for this outcome.</p> </section> <section id="CD011567-sec-0270"> <h6 class="title">10.10 Quality of life</h6> <p>We found no difference between escitalopram and citalopram for this outcome (MD 1.40, 95% CI ‐1.51 to 4.31; participants = 237; studies = 1) (<a href="./references#CD011567-fig-0095" title="">Analysis 10.10</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0271"> <h6 class="title">10.11 Patient satisfaction</h6> <p>No studies provided data for this outcome.</p> </section> <section id="CD011567-sec-0272"> <h6 class="title">10.12 Economic costs</h6> <p>No studies provided data for this outcome.</p> </section> <section id="CD011567-sec-0273"> <h6 class="title">10.13 Number of dropouts due to adverse effects</h6> <p>In terms of dropouts due to adverse effects there was no difference between sertraline and paroxetine (RR 0.66, 95% CI 0.42 to 1.04; participants = 546; studies = 2; I² = 0%). We found no difference between escitalopram and citalopram (RR 0.78, 95% CI 0.32 to 1.92; participants = 255; studies = 1), as well as between fluoxetine and citalopram (RR 1.00, 95% CI 0.07 to 14.95; participants = 42; studies = 1) and imipramine versus clomipramine (RR 0.33, 95% CI 0.08 to 1.46; participants = 40; studies = 1) (<a href="./references#CD011567-fig-0096" title="">Analysis 10.13</a>). Risk of bias was considered unclear for this outcome, but the majority of studies were rated as high risk for "other bias" because they were funded by pharmaceutical companies. </p> </section> <section id="CD011567-sec-0274"> <h6 class="title">10.14 Number of patients experiencing at least one adverse effect</h6> <p>We found no difference between escitalopram and citalopram (RR 0.95, 95% CI 0.85 to 1.06; participants = 255; studies = 1), as well as between sertraline and paroxetine (RR 0.99, 95% CI 0.89 to 1.10; participants = 321; studies = 1) (<a href="./references#CD011567-fig-0097" title="">Analysis 10.14</a>). Risk of bias was considered unclear for this outcome, but both studies were rated as high risk for "other bias" because of funding by pharmaceutical companies. </p> </section> </section> </section> <section id="CD011567-sec-0275"> <h4 class="title">C: Individual benzodiazepines versus another benzodiazepine</h4> </section> <section id="CD011567-sec-0276"> <h4 class="title">Comparison 11: Individual benzodiazepines versus another benzodiazepine</h4> <p>Two studies including 310 participants provided data for this comparison, one comparing diazepam with alprazolam (<a href="./references#CD011567-bbs2-0019" title="CoryellW , NoyesRJr , SchlechteJ . The significance of HPA axis disturbance in panic disorder. Biological Psychiatry1989;25(8):989‐1002. LopezAL , KatholRG , NoyesRJr . Reduction in urinary free cortisol during benzodiazepine treatment of panic disorder. Psychoneuroendocrinology1990;15(1):23‐8. NoyesRJr , BurrowsGD , ReichJH , JuddFK , GarveyMJ , NormanTR , et al. Diazepam versus alprazolam for the treatment of panic disorder. Journal of Clinical Psychiatry1996;57(8):349‐55. NoyesRJr , GarveyMJ , CookB , SuelzerM . Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. American Journal of Psychiatry1991;148(4):517‐23. ">Noyes 1996</a>) and one comparing alprazolam with clonazepam (<a href="./references#CD011567-bbs2-0029" title="FavaM , RosenbaumJF , MacLaughlinRA , TesarGE , PollackMH , CohenLS , et al. Dehydroepiandrosterone‐sulfate/cortisol ratio in panic disorder. Psychiatry Research1989;28(3):345‐50. LabbateLA , PollackMH , OttoMW , TesarGM , RosenbaumJF . The relationship of alprazolam and clonazepam dose to steady‐state concentration in plasma. Journal of Clinical Psychopharmacology1994;14(4):274‐6. PollackMH , OttoMW , TesarGE , CohenLS , Meltzer‐BrodyS , RosenbaumJF . Long‐term outcome after acute treatment with alprazolam or clonazepam for panic disorder. Journal of Clinical Psychopharmacology1993;13(4):257‐63. TesarGE , RosenbaumJF , PollackMH , HermanJB , SachsGS , MahoneyEM , et al. Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry1987;48(Suppl 10):16‐21. TesarGE , RosenbaumJF , PollackMH , OttoMW , SachsGS , HermanJB , et al. Double‐blind, placebo‐controlled comparison of clonazepam and alprazolam for panic disorder. Journal of Clinical Psychiatry1991;52(2):69‐76. ">Tesar 1991</a>). </p> <section id="CD011567-sec-0277"> <h5 class="title">Primary outcomes</h5> <section id="CD011567-sec-0278"> <h6 class="title">11.1 Failure to respond</h6> <p>The comparison between alprazolam and diazepam did not show any difference in terms of response rate (RR 0.94, 95% CI 0.63 to 1.40; participants = 159; studies = 1) (<a href="./references#CD011567-fig-0098" title="">Analysis 11.1</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0279"> <h6 class="title">11.2 Total number of dropouts</h6> <p>We found no difference between alprazolam and diazepam (RR 0.84, 95% CI 0.44 to 1.64; participants = 159; studies = 1), alprazolam and clonazepam (RR 2.17, 95% CI 0.44 to 10.78; participants = 50; studies = 1). The comparison between alprazolam and other benzodiazepines together did not show a difference (RR 1.01, 95% CI 0.49 to 2.08; participants = 209; studies = 2; I² = 12%) (<a href="./references#CD011567-fig-0099" title="">Analysis 11.2</a>). Risk of bias was considered unclear for this outcome, but both studies were rated as high risk for "other bias" because they were funded by a pharmaceutical company. </p> </section> </section> <section id="CD011567-sec-0280"> <h5 class="title">Secondary outcome</h5> <section id="CD011567-sec-0281"> <h6 class="title">11.3 Failure to remit</h6> <p>We found no difference between alprazolam and diazepam (RR 0.76, 95% CI 0.48 to 1.20; participants = 159; studies = 1), alprazolam and clonazepam (RR 1.26, 95% CI 0.73 to 2.17; participants = 50; studies = 1). The comparison between alprazolam and other benzodiazepines together did not show a difference (RR 0.96, 95% CI 0.58 to 1.57; participants = 209; studies = 2; I<sup>2</sup> = 49%) (<a href="./references#CD011567-fig-0100" title="">Analysis 11.3</a>). Risk of bias was considered unclear for this outcome, but both studies were rated as high risk for "other bias" because they were funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0282"> <h6 class="title">11.4 Panic symptoms</h6> <p>No difference was found between alprazolam and diazepam (MD ‐0.20, 95% CI ‐0.70 to 0.30; participants = 159; studies = 1), and alprazolam and clonazepam (MD 0.60, 95% CI ‐0.12 to 1.32; participants = 50; studies = 1). The comparison between alprazolam and other benzodiazepines together did not show a difference (MD 0.16, 95% CI ‐0.62 to 0.93; participants = 209; studies = 2; I<sup>2</sup> = 69%) (<a href="./references#CD011567-fig-0101" title="">Analysis 11.4</a>). Risk of bias was considered unclear for this outcome, but both studies were rated as high risk for "other bias" because they were funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0283"> <h6 class="title">11.5 Frequency of panic attacks</h6> <p>We found no difference in terms of frequency of panic attacks between alprazolam and diazepam (MD 0.40, 95% CI ‐1.34 to 2.14; participants = 159; studies = 1), alprazolam and clonazepam (MD 0.30, 95% CI ‐6.75 to 7.35; participants = 50; studies = 1) and between alprazolam and other benzodiazepines (MD 0.39, 95% CI ‐1.29 to 2.08; participants = 209; studies = 2; I² = 0%) (<a href="./references#CD011567-fig-0102" title="">Analysis 11.5</a>). Risk of bias was considered unclear for this outcome, but both studies were rated as high risk for "other bias" because they were funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0284"> <h6 class="title">11.6 Agoraphobia</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0285"> <h6 class="title">11.7 General anxiety</h6> <p>We found no difference between alprazolam and diazepam for this outcome (MD 0.20, 95% CI ‐2.28 to 2.68; participants = 159; studies = 1) (<a href="./references#CD011567-fig-0103" title="">Analysis 11.7</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0286"> <h6 class="title">11.8 Depression</h6> <p>We found no difference between alprazolam and clonazepam for this outcome (MD 2.30, 95% CI ‐2.83 to 7.43; participants = 44; studies = 1) (<a href="./references#CD011567-fig-0104" title="">Analysis 11.8</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0287"> <h6 class="title">11.9 Social functioning</h6> <p>There was no difference between alprazolam and diazepam in terms of social functioning (MD ‐0.10, 95% CI ‐0.47 to 0.27; participants = 159; studies = 1) (<a href="./references#CD011567-fig-0105" title="">Analysis 11.9</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0288"> <h6 class="title">11.10 Quality of life</h6> <p>We found no difference between alprazolam and clonazepam for this outcome (MD ‐0.30, 95% CI ‐1.07 to 0.47; participants = 44; studies = 1) (<a href="./references#CD011567-fig-0106" title="">Analysis 11.10</a>). Risk of bias was considered unclear for this outcome, but the study was rated as high risk for "other bias" because it was funded by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0289"> <h6 class="title">11.11 Patient satisfaction</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0290"> <h6 class="title">11.12 Economic costs</h6> <p>Neither study provided data for this outcome.</p> </section> <section id="CD011567-sec-0291"> <h6 class="title">11.13 Number of dropouts due to adverse effects</h6> <p>There was no difference between alprazolam and diazepam (RR 1.04, 95% CI 0.15 to 7.19; participants = 159; studies = 1), alprazolam and clonazepam (RR 5.40, 95% CI 0.27 to 107.09; participants = 50; studies = 1) and alprazolam versus benzodiazepines as a group (RR 1.69, 95% CI 0.33 to 8.58; participants = 209; studies = 2; I² = 0%) (<a href="./references#CD011567-fig-0107" title="">Analysis 11.13</a>). Risk of bias was considered unclear for this outcome, but the studies were rated as high risk for "other bias" because of funding by a pharmaceutical company. </p> </section> <section id="CD011567-sec-0292"> <h6 class="title">11.14 Number of patients experiencing at least one adverse effect</h6> <p>Neither study provided data for this outcome.</p> </section> </section> </section> <section id="CD011567-sec-0293"> <h4 class="title">Subgroup analyses</h4> <p>We could not conduct any of the preplanned subgroup analyses, as no relevant data were available: all studies included both participants with and without agoraphobia, so it was not possible to conduct subgroup analysis 1; no study reported acute data at more than four months, so it was not possible to perform subgroup analysis 2. </p> </section> <section id="CD011567-sec-0294"> <h4 class="title">Sensitivity analyses</h4> <section id="CD011567-sec-0295"> <h5 class="title">Excluding trials with high risk of bias (comparisons 12‐16)</h5> <section id="CD011567-sec-0296"> <h6 class="title">Antidepressants versus benzodiazepines</h6> <section id="CD011567-sec-0297"> <p><b>Failure to respond</b></p> <p>No studies were excluded, so the results did not change.</p> </section> <section id="CD011567-sec-0298"> <p><b>Total number of dropouts</b></p> <p>Excluding two studies at high risk of bias (<a href="./references#CD011567-bbs2-0006" title="AlbusM , LecrubierY , MaierW , BullerR , RosenbergR , HippiusH . Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatrica Scandinavica1990;82(5):359‐65. AlbusM , MaierW , SheraD , BechP . Consistencies and discrepancies in self‐ and observer‐rated anxiety scales. A comparison between the self‐ and observer‐rated Marks‐Sheehan scales. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):96‐102. AnderschS , HansonL , HallstromT . Panic disorder: a five‐year follow‐up study in 52 patients. European Journal of Psychiatry1997;11(3):145‐55. AnderschS , HettaJ . A 15‐year follow‐up study of patients with panic disorder. European Psychiatry2003;18(8):401‐08. AnderschS , RosenbergNK , KullingsjöH , OttossonJO , BechP , Bruun‐HansenJ , et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatrica Scandinavica. Supplementum1991;365:18‐27. BerlangaC , CanettiA , ChavezE , De LaFuenteR , delCarmen LaraM , LeonC , et al. Pharmacologic treatment of panic disorders: Comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study [Tratamiento farmacologico de las crisis de angustia Reporte comparativo de la eficacia y seguridad del alprazolam y la imipramina en un estudio controlado]. Salud Mental1991;14(1):1‐5. BullerR , MaierW , GoldenbergIM , LavoriPW , BenkertO . Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross‐National Collaborative Panic Study. European Archives of Psychiatry and Clinical Neuroscience1991;240(3):163‐8. CassanoGB , ToniC , PetraccaA , DeltitoJ , BenkertO , CurtisG , et al. Adverse effects associated with the short‐term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology1994;4(1):47‐53. Cross National Collaborative Panic Study Second Phase Investigators. Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. British Journal of Psychiatry1992;160:191‐202. CurtisGC , MassanaJ , UdinaC , AyusoJL , CassanoGB , PerugiG . Maintenance drug therapy of panic disorder. Journal of Psychiatry Research1993;27(Suppl 1):127‐42. DeltitoJA , ArgyleN , BullerR , NutzingerD , OttossonJO , BrandonS , et al. The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(2):120‐9. DeltitoJA , ArgyleN , KlermanGL . Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Journal of Clinical Psychiatry1991;52(3):121‐7. GreenMA , CurtisGC . Personality disorders in panic patients: Response to termination of antipanic medication. Journal of Personality Disorders1988;2(4):303‐14. KatschnigH , AmeringM , StolkJM , KlermanGL , BallengerJC , BriggsA , et al. Long‐term follow‐up after a drug trial for panic disorder. British Journal of Psychiatry1995;167(4):487‐94. KlermanGL . Depression and panic anxiety: the effect of depressive co‐morbidity on response to drug treatment of patients with panic disorder and agoraphobia. Journal of Psychiatric Research1990;24(Suppl 2):27‐41. KlermanGL , ColemanJH , PurpuraRP . The design and conduct of the Upjohn Cross‐National Collaborative Panic Study. Psychopharmacology Bulletin1986;22(1):59‐64. LavoriPW , DawsonR , SheraD . A multiple imputation strategy for clinical trials with truncation of patient data. Statistics in Medicine1995;14(17):1913‐25. LeónCA , DeArangoMV , ArevaloW , CalvoA , MontoyaA , LeónA . Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia [Comparacion del efecto del alprazolam, la imipramina y placebo en el tratamiento del trastorno de panico en Cali, Colombia]. Acta Psiquiatrica y Psicologica de America Latina1990;36(1‐2):59‐72. MaierW , AlbusM , BullerR , NutzingerD , SheraD , BechP . Self‐ and observer assessment in anxiolytic drug trials: a comparison of their validity. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):103‐8. MaierW , RothSM , ArgyleN , BullerR , LavoriP , BrandonS , et al. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?. European Archives of Psychiatry and Clinical Neuroscience1991;241(3):151‐8. MaierWA , RothM , BullerR , ArgyleN , RosenbergR , SydneyB , et al. Agoraphobia in panic disorder: An indicator of the severity of panic disorder or a distinct diagnostic entity?. Psychiatric Annals1991;21(6):374‐81. RifkinA . The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(6):559‐60. RosenbergNK , MellergårdM , RosenbergR , BeckP , OttossonJO . Characteristics of panic disorder patients responding to placebo. Acta Psychiatrica Scandinavica Supplementum1991;365:33‐8. RosenbergR , BechP , MellergårdM , OttossonJO . Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response. Acta Psychiatrica Scandinavica. Supplementum1991;365:46‐52. SwobodaH , AmeringM , WindhaberJ , KatschnigH . The long‐term course of panic disorder‐‐an 11 year follow‐up. Journal of Anxiety Disorders2003;17(2):223‐32. ">CNCPS 1992</a>; <a href="./references#CD011567-bbs2-0028" title='ClarkDB , TaylorCB , RothWT , HaywardC , EhlersA , MargrafJ , et al. Surreptitious drug use by patients in a panic disorder study. American Journal of Psychiatry1990;147(4):507‐9. MargrafJ , EhlersA , RothWT , ClarkDB , SheikhJ , AgrasWS , et al. How "blind" are double‐blind studies?. Journal of Consulting and Clinical Psychology1991;59(1):184‐7. TaylorCB , HaywardC , KingR , EhlersA , MargrafJ , MaddockR , et al. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double‐blind, placebo‐controlled trial. Journal of Clinical Psychopharmacology1990;10(2):112‐8. '>Taylor 1990</a>) did not substantially change the results (RR 1.63, 95% CI 0.82 to 3.23; participants = 619; studies = 5); heterogeneity was substantial (I² = 79%) (<a href="./references#CD011567-fig-0108" title="">Analysis 12.1</a>). </p> </section> </section> <section id="CD011567-sec-0299"> <h6 class="title">TCAs versus benzodiazepines</h6> <section id="CD011567-sec-0300"> <p><b>Failure to respond</b></p> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0018" title="">Analysis 2.1</a>). </p> </section> <section id="CD011567-sec-0301"> <p><b>Total number of dropouts</b></p> <p>Excluding two studies at high risk of bias (<a href="./references#CD011567-bbs2-0006" title="AlbusM , LecrubierY , MaierW , BullerR , RosenbergR , HippiusH . Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatrica Scandinavica1990;82(5):359‐65. AlbusM , MaierW , SheraD , BechP . Consistencies and discrepancies in self‐ and observer‐rated anxiety scales. A comparison between the self‐ and observer‐rated Marks‐Sheehan scales. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):96‐102. AnderschS , HansonL , HallstromT . Panic disorder: a five‐year follow‐up study in 52 patients. European Journal of Psychiatry1997;11(3):145‐55. AnderschS , HettaJ . A 15‐year follow‐up study of patients with panic disorder. European Psychiatry2003;18(8):401‐08. AnderschS , RosenbergNK , KullingsjöH , OttossonJO , BechP , Bruun‐HansenJ , et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatrica Scandinavica. Supplementum1991;365:18‐27. BerlangaC , CanettiA , ChavezE , De LaFuenteR , delCarmen LaraM , LeonC , et al. Pharmacologic treatment of panic disorders: Comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study [Tratamiento farmacologico de las crisis de angustia Reporte comparativo de la eficacia y seguridad del alprazolam y la imipramina en un estudio controlado]. Salud Mental1991;14(1):1‐5. BullerR , MaierW , GoldenbergIM , LavoriPW , BenkertO . Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross‐National Collaborative Panic Study. European Archives of Psychiatry and Clinical Neuroscience1991;240(3):163‐8. CassanoGB , ToniC , PetraccaA , DeltitoJ , BenkertO , CurtisG , et al. Adverse effects associated with the short‐term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology1994;4(1):47‐53. Cross National Collaborative Panic Study Second Phase Investigators. Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. British Journal of Psychiatry1992;160:191‐202. CurtisGC , MassanaJ , UdinaC , AyusoJL , CassanoGB , PerugiG . Maintenance drug therapy of panic disorder. Journal of Psychiatry Research1993;27(Suppl 1):127‐42. DeltitoJA , ArgyleN , BullerR , NutzingerD , OttossonJO , BrandonS , et al. The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(2):120‐9. DeltitoJA , ArgyleN , KlermanGL . Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Journal of Clinical Psychiatry1991;52(3):121‐7. GreenMA , CurtisGC . Personality disorders in panic patients: Response to termination of antipanic medication. Journal of Personality Disorders1988;2(4):303‐14. KatschnigH , AmeringM , StolkJM , KlermanGL , BallengerJC , BriggsA , et al. Long‐term follow‐up after a drug trial for panic disorder. British Journal of Psychiatry1995;167(4):487‐94. KlermanGL . Depression and panic anxiety: the effect of depressive co‐morbidity on response to drug treatment of patients with panic disorder and agoraphobia. Journal of Psychiatric Research1990;24(Suppl 2):27‐41. KlermanGL , ColemanJH , PurpuraRP . The design and conduct of the Upjohn Cross‐National Collaborative Panic Study. Psychopharmacology Bulletin1986;22(1):59‐64. LavoriPW , DawsonR , SheraD . A multiple imputation strategy for clinical trials with truncation of patient data. Statistics in Medicine1995;14(17):1913‐25. LeónCA , DeArangoMV , ArevaloW , CalvoA , MontoyaA , LeónA . Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia [Comparacion del efecto del alprazolam, la imipramina y placebo en el tratamiento del trastorno de panico en Cali, Colombia]. Acta Psiquiatrica y Psicologica de America Latina1990;36(1‐2):59‐72. MaierW , AlbusM , BullerR , NutzingerD , SheraD , BechP . Self‐ and observer assessment in anxiolytic drug trials: a comparison of their validity. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):103‐8. MaierW , RothSM , ArgyleN , BullerR , LavoriP , BrandonS , et al. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?. European Archives of Psychiatry and Clinical Neuroscience1991;241(3):151‐8. MaierWA , RothM , BullerR , ArgyleN , RosenbergR , SydneyB , et al. Agoraphobia in panic disorder: An indicator of the severity of panic disorder or a distinct diagnostic entity?. Psychiatric Annals1991;21(6):374‐81. RifkinA . The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(6):559‐60. RosenbergNK , MellergårdM , RosenbergR , BeckP , OttossonJO . Characteristics of panic disorder patients responding to placebo. Acta Psychiatrica Scandinavica Supplementum1991;365:33‐8. RosenbergR , BechP , MellergårdM , OttossonJO . Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response. Acta Psychiatrica Scandinavica. Supplementum1991;365:46‐52. SwobodaH , AmeringM , WindhaberJ , KatschnigH . The long‐term course of panic disorder‐‐an 11 year follow‐up. Journal of Anxiety Disorders2003;17(2):223‐32. ">CNCPS 1992</a>; <a href="./references#CD011567-bbs2-0028" title='ClarkDB , TaylorCB , RothWT , HaywardC , EhlersA , MargrafJ , et al. Surreptitious drug use by patients in a panic disorder study. American Journal of Psychiatry1990;147(4):507‐9. MargrafJ , EhlersA , RothWT , ClarkDB , SheikhJ , AgrasWS , et al. How "blind" are double‐blind studies?. Journal of Consulting and Clinical Psychology1991;59(1):184‐7. TaylorCB , HaywardC , KingR , EhlersA , MargrafJ , MaddockR , et al. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double‐blind, placebo‐controlled trial. Journal of Clinical Psychopharmacology1990;10(2):112‐8. '>Taylor 1990</a>) did not substantially change the results from the original analysis (RR 1.67, 95% CI 0.64 to 4.36; participants = 465; studies = 4); heterogeneity was substantial (I² = 81%) (<a href="./references#CD011567-fig-0109" title="">Analysis 13.1</a>). </p> </section> </section> <section id="CD011567-sec-0302"> <h6 class="title">SSRIs versus benzodiazepines</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0029" title="">Analysis 3.1</a>; <a href="./references#CD011567-fig-0030" title="">Analysis 3.2</a>). </p> </section> <section id="CD011567-sec-0303"> <h6 class="title">TCAs versus SSRIs</h6> <section id="CD011567-sec-0304"> <p><b>Failure to respond</b></p> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0040" title="">Analysis 4.1</a>). </p> </section> <section id="CD011567-sec-0305"> <p><b>Total number of dropouts</b></p> <p>Excluding one study at high risk of bias (<a href="./references#CD011567-bbs2-0001" title="AmoreM , MagnaniK , CerisoliM , CasagrandeC , FerrariG . Panic disorder. A long‐term treatment study: fluoxetine vs imipramine. Human Psychopharmacology: Clinical and Experimental1999;14(6):429‐34. ">Amore 1999</a>) the results did not substantially change from the original analysis, with a moderate heterogeneity (I² = 54%) (RR 0.97, 95% CI 0.62 to 1.50; participants = 890; studies = 6) (<a href="./references#CD011567-fig-0110" title="">Analysis 14.1</a>). </p> </section> </section> <section id="CD011567-sec-0306"> <h6 class="title">TCAs versus MAOIs</h6> <section id="CD011567-sec-0307"> <p><b>Failure to respond</b></p> <p>No studies were excluded from this outcome for high risk of bias, so the results did not change (<a href="./references#CD011567-fig-0052" title="">Analysis 5.1</a>). </p> </section> <section id="CD011567-sec-0308"> <p><b>Total number of dropouts</b></p> <p>Excluding one study at high risk of bias (<a href="./references#CD011567-bbs2-0003" title="BakishD , SaxenaBM , BowenR , D'SouzaJ . Reversible monoamine oxidase‐A inhibitors in panic disorder. Clinical Neuropharmacology1993;16(Suppl 2):S77‐S82. SaxenaB , BakishD , BowenR , D'SouzaJ . Brofaromine and clomipramine in panic disorder: a double‐blind study. Clinical Neuropharmacology1992;15(1 Pt B):60. ">Bakish 1993</a>) did not substantially change the results from the original analysis (RR 0.87, 95% CI 0.47 to 1.59; participants = 135; studies = 1) (<a href="./references#CD011567-fig-0111" title="">Analysis 15.1</a>). </p> </section> </section> <section id="CD011567-sec-0309"> <h6 class="title">SSRIs versus MAOIs</h6> <section id="CD011567-sec-0310"> <p><b>Failure to respond</b></p> <p>Excluding one study at high risk of bias (<a href="./references#CD011567-bbs2-0032" title="SlaapBR , vanVlietIM , WestenbergHGM , denBoerJA . Phobic symptoms as predictors of nonresponse to drug therapy in panic disorder patients (a preliminary report). Journal of Affective Disorders1995;33(1):31‐8. vanVlietIM , denBoerJA , WestenbergHGM , SlaapBR . A double‐blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. Journal of Clinical Psychopharmacology1996;16(4):299‐306. ">Van Vliet 1996</a>) did not substantially change the results from the original analysis (RR 1.08, 95% CI 0.76 to 1.54; participants = 366; studies = 1) (<a href="./references#CD011567-fig-0112" title="">Analysis 16.1</a>). </p> </section> <section id="CD011567-sec-0311"> <p><b>Total number of dropouts</b></p> <p>Excluding studies at high risk of bias, no trials provided data for this analysis.</p> </section> </section> <section id="CD011567-sec-0312"> <h6 class="title">SSRIs versus SNRIs</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0067" title="">Analysis 7.1</a>; <a href="./references#CD011567-fig-0068" title="">Analysis 7.2</a>). </p> </section> <section id="CD011567-sec-0313"> <h6 class="title">SSRIs versus NaSSAs</h6> <section id="CD011567-sec-0314"> <p><b>Failure to respond</b></p> <p>No data were available for this outcome.</p> </section> <section id="CD011567-sec-0315"> <p><b>Total number of dropouts</b></p> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0077" title="">Analysis 8.2</a>). </p> </section> </section> <section id="CD011567-sec-0316"> <h6 class="title">Individual antidepressants versus individual antidepressants</h6> <section id="CD011567-sec-0317"> <p><b>Failure to respond</b></p> <p>Excluding one study at high risk of bias (<a href="./references#CD011567-bbs2-0002" title="AmoreM , MagnaniK , CerisoliM , FerrariG . Short‐term and long‐term evaluation of selective serotonin reuptake inhibitors in the treatment of panic disorder: fluoxetine vs citalopram. Human Psychopharmacology: Clinical and Experimental1999;14(6):435‐40. ">Amore 1999 bis</a>) there were no data for fluoxetine versus citalopram (Analysis 17.1). No studies were excluded for the comparisons between escitalopram versus citalopram and sertraline versus paroxetine, thus the results remained unchanged (<a href="./references#CD011567-fig-0087" title="">Analysis 10.1</a>). </p> </section> <section id="CD011567-sec-0318"> <p><b>Total number of dropouts</b></p> <p>Excluding one study at high risk of bias (<a href="./references#CD011567-bbs2-0002" title="AmoreM , MagnaniK , CerisoliM , FerrariG . Short‐term and long‐term evaluation of selective serotonin reuptake inhibitors in the treatment of panic disorder: fluoxetine vs citalopram. Human Psychopharmacology: Clinical and Experimental1999;14(6):435‐40. ">Amore 1999 bis</a>) no trials provided data for fluoxetine versus citalopram . No studies were excluded for the comparisons between escitalopram versus citalopram and sertraline versus paroxetine, thus the results remained unchanged (<a href="./references#CD011567-fig-0088" title="">Analysis 10.2</a>). </p> </section> </section> <section id="CD011567-sec-0319"> <h6 class="title">Individual benzodiazepines versus individual benzodiazepines</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0098" title="">Analysis 11.1</a>; <a href="./references#CD011567-fig-0099" title="">Analysis 11.2</a>). </p> </section> </section> <section id="CD011567-sec-0320"> <h5 class="title">Excluding trials with dropout rates greater than 20% (comparisons 17‐19)</h5> <section id="CD011567-sec-0321"> <h6 class="title">Antidepressants versus benzodiazepines</h6> <section id="CD011567-sec-0322"> <p><b>Failure to respond</b></p> <p>Excluding studies for high dropout rates, no trials provided data for this outcome.</p> </section> <section id="CD011567-sec-0323"> <p><b>Total number of dropouts</b></p> <p>Excluding five studies for high dropout rates (<a href="./references#CD011567-bbs2-0006" title="AlbusM , LecrubierY , MaierW , BullerR , RosenbergR , HippiusH . Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatrica Scandinavica1990;82(5):359‐65. AlbusM , MaierW , SheraD , BechP . Consistencies and discrepancies in self‐ and observer‐rated anxiety scales. A comparison between the self‐ and observer‐rated Marks‐Sheehan scales. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):96‐102. AnderschS , HansonL , HallstromT . Panic disorder: a five‐year follow‐up study in 52 patients. European Journal of Psychiatry1997;11(3):145‐55. AnderschS , HettaJ . A 15‐year follow‐up study of patients with panic disorder. European Psychiatry2003;18(8):401‐08. AnderschS , RosenbergNK , KullingsjöH , OttossonJO , BechP , Bruun‐HansenJ , et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatrica Scandinavica. Supplementum1991;365:18‐27. BerlangaC , CanettiA , ChavezE , De LaFuenteR , delCarmen LaraM , LeonC , et al. Pharmacologic treatment of panic disorders: Comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study [Tratamiento farmacologico de las crisis de angustia Reporte comparativo de la eficacia y seguridad del alprazolam y la imipramina en un estudio controlado]. Salud Mental1991;14(1):1‐5. BullerR , MaierW , GoldenbergIM , LavoriPW , BenkertO . Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross‐National Collaborative Panic Study. European Archives of Psychiatry and Clinical Neuroscience1991;240(3):163‐8. CassanoGB , ToniC , PetraccaA , DeltitoJ , BenkertO , CurtisG , et al. Adverse effects associated with the short‐term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology1994;4(1):47‐53. Cross National Collaborative Panic Study Second Phase Investigators. Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. British Journal of Psychiatry1992;160:191‐202. CurtisGC , MassanaJ , UdinaC , AyusoJL , CassanoGB , PerugiG . Maintenance drug therapy of panic disorder. Journal of Psychiatry Research1993;27(Suppl 1):127‐42. DeltitoJA , ArgyleN , BullerR , NutzingerD , OttossonJO , BrandonS , et al. The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(2):120‐9. DeltitoJA , ArgyleN , KlermanGL . Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Journal of Clinical Psychiatry1991;52(3):121‐7. GreenMA , CurtisGC . Personality disorders in panic patients: Response to termination of antipanic medication. Journal of Personality Disorders1988;2(4):303‐14. KatschnigH , AmeringM , StolkJM , KlermanGL , BallengerJC , BriggsA , et al. Long‐term follow‐up after a drug trial for panic disorder. British Journal of Psychiatry1995;167(4):487‐94. KlermanGL . Depression and panic anxiety: the effect of depressive co‐morbidity on response to drug treatment of patients with panic disorder and agoraphobia. Journal of Psychiatric Research1990;24(Suppl 2):27‐41. KlermanGL , ColemanJH , PurpuraRP . The design and conduct of the Upjohn Cross‐National Collaborative Panic Study. Psychopharmacology Bulletin1986;22(1):59‐64. LavoriPW , DawsonR , SheraD . A multiple imputation strategy for clinical trials with truncation of patient data. Statistics in Medicine1995;14(17):1913‐25. LeónCA , DeArangoMV , ArevaloW , CalvoA , MontoyaA , LeónA . Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia [Comparacion del efecto del alprazolam, la imipramina y placebo en el tratamiento del trastorno de panico en Cali, Colombia]. Acta Psiquiatrica y Psicologica de America Latina1990;36(1‐2):59‐72. MaierW , AlbusM , BullerR , NutzingerD , SheraD , BechP . Self‐ and observer assessment in anxiolytic drug trials: a comparison of their validity. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):103‐8. MaierW , RothSM , ArgyleN , BullerR , LavoriP , BrandonS , et al. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?. European Archives of Psychiatry and Clinical Neuroscience1991;241(3):151‐8. MaierWA , RothM , BullerR , ArgyleN , RosenbergR , SydneyB , et al. Agoraphobia in panic disorder: An indicator of the severity of panic disorder or a distinct diagnostic entity?. Psychiatric Annals1991;21(6):374‐81. RifkinA . The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(6):559‐60. RosenbergNK , MellergårdM , RosenbergR , BeckP , OttossonJO . Characteristics of panic disorder patients responding to placebo. Acta Psychiatrica Scandinavica Supplementum1991;365:33‐8. RosenbergR , BechP , MellergårdM , OttossonJO . Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response. Acta Psychiatrica Scandinavica. Supplementum1991;365:46‐52. SwobodaH , AmeringM , WindhaberJ , KatschnigH . The long‐term course of panic disorder‐‐an 11 year follow‐up. Journal of Anxiety Disorders2003;17(2):223‐32. ">CNCPS 1992</a>; <a href="./references#CD011567-bbs2-0011" title="GSK . A double‐blind, multicenter, flexible‐dose study of paroxetine, alprazolam and placebo in the treatment of panic disorder. GSK Clinical Studies Register [http://www.gsk‐clinicalstudyregister.com/]. ">GSK‐29060/1</a>; <a href="./references#CD011567-bbs2-0013" title="HollandR , MuschB , HindmarchI . Specific effects of benzodiazepines and tricyclic antidepressants in panic disorder: comparisons of clomipramine with alprazolam SR and adinazolam SR. Human Psychopharmacology Clinical Experimental1999;14:119‐24. ">Holland 1999</a>; <a href="./references#CD011567-bbs2-0025" title="RickelsK , SchweizerE . Panic disorder: Long‐term pharmacotherapy and discontinuation. Journal of Clinical Psychopharmacology1998;18(6 Suppl 2):12‐8. RickelsK , SchweizerE , WeissS , ZavodnickS . Maintenance drug treatment for panic disorder. II. Short‐ and long‐term outcome after drug taper. Archives of General Psychiatry1993;50:61‐8. SchweizerE , RickelsK , WeissS , ZavodnickS . Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo‐controlled comparison of alprazolam and imipramine. Archives of General Psychiatry1993;50:51‐60. ">Schweizer 1993</a>; <a href="./references#CD011567-bbs2-0031" title="UhlenhuthEH , MatuzasW , GlassRM , EastonC . Response of panic disorder to fixed doses of alprazolam or imipramine. Journal of Affective Disorders1989;17(3):261‐70. ">Uhlenhuth 1989</a>), no difference was found between antidepressants and benzodiazepines (RR 2.42, 95% CI 0.61 to 9.64; participants = 71; studies = 2; I<sup>2</sup> = 0%) (<a href="./references#CD011567-fig-0113" title="">Analysis 17.1</a>). </p> </section> </section> <section id="CD011567-sec-0324"> <h6 class="title">TCAs versus benzodiazepines</h6> <section id="CD011567-sec-0325"> <p><b>Failure to respond</b></p> <p>Excluding studies for high dropout rates, no trials provided data for this analysis.</p> </section> <section id="CD011567-sec-0326"> <p><b>Total number of dropouts</b></p> <p>Excluding four studies for high dropout rates (<a href="./references#CD011567-bbs2-0006" title="AlbusM , LecrubierY , MaierW , BullerR , RosenbergR , HippiusH . Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatrica Scandinavica1990;82(5):359‐65. AlbusM , MaierW , SheraD , BechP . Consistencies and discrepancies in self‐ and observer‐rated anxiety scales. A comparison between the self‐ and observer‐rated Marks‐Sheehan scales. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):96‐102. AnderschS , HansonL , HallstromT . Panic disorder: a five‐year follow‐up study in 52 patients. European Journal of Psychiatry1997;11(3):145‐55. AnderschS , HettaJ . A 15‐year follow‐up study of patients with panic disorder. European Psychiatry2003;18(8):401‐08. AnderschS , RosenbergNK , KullingsjöH , OttossonJO , BechP , Bruun‐HansenJ , et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatrica Scandinavica. Supplementum1991;365:18‐27. BerlangaC , CanettiA , ChavezE , De LaFuenteR , delCarmen LaraM , LeonC , et al. Pharmacologic treatment of panic disorders: Comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study [Tratamiento farmacologico de las crisis de angustia Reporte comparativo de la eficacia y seguridad del alprazolam y la imipramina en un estudio controlado]. Salud Mental1991;14(1):1‐5. BullerR , MaierW , GoldenbergIM , LavoriPW , BenkertO . Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross‐National Collaborative Panic Study. European Archives of Psychiatry and Clinical Neuroscience1991;240(3):163‐8. CassanoGB , ToniC , PetraccaA , DeltitoJ , BenkertO , CurtisG , et al. Adverse effects associated with the short‐term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology1994;4(1):47‐53. Cross National Collaborative Panic Study Second Phase Investigators. Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. British Journal of Psychiatry1992;160:191‐202. CurtisGC , MassanaJ , UdinaC , AyusoJL , CassanoGB , PerugiG . Maintenance drug therapy of panic disorder. Journal of Psychiatry Research1993;27(Suppl 1):127‐42. DeltitoJA , ArgyleN , BullerR , NutzingerD , OttossonJO , BrandonS , et al. The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(2):120‐9. DeltitoJA , ArgyleN , KlermanGL . Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Journal of Clinical Psychiatry1991;52(3):121‐7. GreenMA , CurtisGC . Personality disorders in panic patients: Response to termination of antipanic medication. Journal of Personality Disorders1988;2(4):303‐14. KatschnigH , AmeringM , StolkJM , KlermanGL , BallengerJC , BriggsA , et al. Long‐term follow‐up after a drug trial for panic disorder. British Journal of Psychiatry1995;167(4):487‐94. KlermanGL . Depression and panic anxiety: the effect of depressive co‐morbidity on response to drug treatment of patients with panic disorder and agoraphobia. Journal of Psychiatric Research1990;24(Suppl 2):27‐41. KlermanGL , ColemanJH , PurpuraRP . The design and conduct of the Upjohn Cross‐National Collaborative Panic Study. Psychopharmacology Bulletin1986;22(1):59‐64. LavoriPW , DawsonR , SheraD . A multiple imputation strategy for clinical trials with truncation of patient data. Statistics in Medicine1995;14(17):1913‐25. LeónCA , DeArangoMV , ArevaloW , CalvoA , MontoyaA , LeónA . Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia [Comparacion del efecto del alprazolam, la imipramina y placebo en el tratamiento del trastorno de panico en Cali, Colombia]. Acta Psiquiatrica y Psicologica de America Latina1990;36(1‐2):59‐72. MaierW , AlbusM , BullerR , NutzingerD , SheraD , BechP . Self‐ and observer assessment in anxiolytic drug trials: a comparison of their validity. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):103‐8. MaierW , RothSM , ArgyleN , BullerR , LavoriP , BrandonS , et al. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?. European Archives of Psychiatry and Clinical Neuroscience1991;241(3):151‐8. MaierWA , RothM , BullerR , ArgyleN , RosenbergR , SydneyB , et al. Agoraphobia in panic disorder: An indicator of the severity of panic disorder or a distinct diagnostic entity?. Psychiatric Annals1991;21(6):374‐81. RifkinA . The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(6):559‐60. RosenbergNK , MellergårdM , RosenbergR , BeckP , OttossonJO . Characteristics of panic disorder patients responding to placebo. Acta Psychiatrica Scandinavica Supplementum1991;365:33‐8. RosenbergR , BechP , MellergårdM , OttossonJO . Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response. Acta Psychiatrica Scandinavica. Supplementum1991;365:46‐52. SwobodaH , AmeringM , WindhaberJ , KatschnigH . The long‐term course of panic disorder‐‐an 11 year follow‐up. Journal of Anxiety Disorders2003;17(2):223‐32. ">CNCPS 1992</a>; <a href="./references#CD011567-bbs2-0013" title="HollandR , MuschB , HindmarchI . Specific effects of benzodiazepines and tricyclic antidepressants in panic disorder: comparisons of clomipramine with alprazolam SR and adinazolam SR. Human Psychopharmacology Clinical Experimental1999;14:119‐24. ">Holland 1999</a>; <a href="./references#CD011567-bbs2-0025" title="RickelsK , SchweizerE . Panic disorder: Long‐term pharmacotherapy and discontinuation. Journal of Clinical Psychopharmacology1998;18(6 Suppl 2):12‐8. RickelsK , SchweizerE , WeissS , ZavodnickS . Maintenance drug treatment for panic disorder. II. Short‐ and long‐term outcome after drug taper. Archives of General Psychiatry1993;50:61‐8. SchweizerE , RickelsK , WeissS , ZavodnickS . Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo‐controlled comparison of alprazolam and imipramine. Archives of General Psychiatry1993;50:51‐60. ">Schweizer 1993</a>; <a href="./references#CD011567-bbs2-0031" title="UhlenhuthEH , MatuzasW , GlassRM , EastonC . Response of panic disorder to fixed doses of alprazolam or imipramine. Journal of Affective Disorders1989;17(3):261‐70. ">Uhlenhuth 1989</a>), the results did not substantially change from the original analysis (RR 2.42, 95% CI 0.61 to 9.64; participants = 71; studies = 2; I<sup>2</sup> = 0%) (<a href="./references#CD011567-fig-0114" title="">Analysis 18.1</a>). </p> </section> </section> <section id="CD011567-sec-0327"> <h6 class="title">SSRIs versus benzodiazepines</h6> <p>Excluding studies for high dropout rates, no trials provided data for this analysis.</p> </section> <section id="CD011567-sec-0328"> <h6 class="title">TCAs versus SSRIs</h6> <section id="CD011567-sec-0329"> <p><b>Failure to respond</b></p> <p>Excluding two studies for high dropout rates (<a href="./references#CD011567-bbs2-0015" title="GlaxoSmithKline . A double‐blind placebo controlled comparative study of paroxetine and clomipramine in the treatment of panic disorder. GSK‐ClinicalStudy Register (www.gsk‐clinicalstudyregister.com) 1993/11/12. LecrubierY , BakkerA , DunbarG , Judge R and the Collaborative Panic Study Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatrica Scandinavica1997;95:145‐52. LecrubierY , Judge R and the Collaborative Paroxetine Panic Study Investigators. Long‐term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatrica Scandinavica1997;95:153‐60. ">Lecrubier 1997</a>; <a href="./references#CD011567-bbs2-0018" title="BakishD , HooperCL , FilteauMJ , CharbonneauY , FraserG , WestDL , et al. A double‐blind placebo‐controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacology Bulletin1996;32(1):135‐41. NairNP , BakishD , SaxenaB , AminM , SchwartzG , WestTE . Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety1996;2(4):192‐8. ">Nair 1996</a>), the results did not substantially change from the original analysis (RR 1.22, 95% CI 0.47 to 3.15; participants = 95; studies = 2; I² = 0%) (<a href="./references#CD011567-fig-0115" title="">Analysis 19.1</a>). </p> </section> <section id="CD011567-sec-0330"> <p><b>Total number of dropouts</b></p> <p>Excluding three studies for high dropout rates (<a href="./references#CD011567-bbs2-0015" title="GlaxoSmithKline . A double‐blind placebo controlled comparative study of paroxetine and clomipramine in the treatment of panic disorder. GSK‐ClinicalStudy Register (www.gsk‐clinicalstudyregister.com) 1993/11/12. LecrubierY , BakkerA , DunbarG , Judge R and the Collaborative Panic Study Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatrica Scandinavica1997;95:145‐52. LecrubierY , Judge R and the Collaborative Paroxetine Panic Study Investigators. Long‐term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatrica Scandinavica1997;95:153‐60. ">Lecrubier 1997</a>; <a href="./references#CD011567-bbs2-0018" title="BakishD , HooperCL , FilteauMJ , CharbonneauY , FraserG , WestDL , et al. A double‐blind placebo‐controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacology Bulletin1996;32(1):135‐41. NairNP , BakishD , SaxenaB , AminM , SchwartzG , WestTE . Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety1996;2(4):192‐8. ">Nair 1996</a>; <a href="./references#CD011567-bbs2-0033" title="LeinonenE , LepolaU , KoponenH , TurtonenJ , WadeA , LehtoH . Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. Journal of Psychiatry and Neuroscience2000;25(1):24‐32. LepolaU , WadeAG , LeinonenEV , KoponenHJ , FrazerJ , SjoedinI , et al. A controlled, prospective, 1‐year trial of citalopram in the treatment of panic disorder. Journal of Clinical Psychiatry1998;59:528‐34. WadeA , OvereKF , LemmingO . Weight monitoring during two long‐term trials of citalopram. European Neuropsychopharmacology1999;9 Suppl 5:S221. WadeAG , LepolaU , KoponenHJ , PedersenV , PedersenT . The effect of citalopram in panic disorder. British Journal of Psychiatry1997;170:549‐53. ">Wade 1997</a>), the results did not substantially change (RR 3.02, 95% CI 1.00 to 9.11; participants = 206; studies = 4; I² = 0%) (<a href="./references#CD011567-fig-0116" title="">Analysis 19.2</a>). </p> </section> </section> <section id="CD011567-sec-0331"> <h6 class="title">TCAs versus MAOIs</h6> <p>Excluding studies for high dropout rates, no trials provided data for this comparison.</p> </section> <section id="CD011567-sec-0332"> <h6 class="title">SSRIs versus MAOIs</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0060" title="">Analysis 6.1</a>; <a href="./references#CD011567-fig-0061" title="">Analysis 6.2</a>). </p> </section> <section id="CD011567-sec-0333"> <h6 class="title">SSRIs versus SNRIs</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0067" title="">Analysis 7.1</a>; <a href="./references#CD011567-fig-0068" title="">Analysis 7.2</a>). </p> </section> <section id="CD011567-sec-0334"> <h6 class="title">SSRIs versus NaSSAs</h6> <section id="CD011567-sec-0335"> <p><b>Failure to respond</b></p> <p>No data were available for this outcome.</p> </section> <section id="CD011567-sec-0336"> <p><b>Total number of dropouts</b></p> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0077" title="">Analysis 8.2</a>). </p> </section> </section> <section id="CD011567-sec-0337"> <h6 class="title">Individual antidepressants versus individual antidepressants</h6> <section id="CD011567-sec-0338"> <p><b>Failure to respond</b></p> <p>Excluding three studies for high dropout rates (<a href="./references#CD011567-bbs2-0004" title="BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , DombrowskiA , et al. Sertraline versus paroxetine in the treatment of panic disorder: a multinational randomized double‐blind 15 week study. European Neuropsychopharmacology2002;12(Suppl 3):S363. BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , GoebelC , et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double‐blind noninferiority comparison. Journal of Clinical Psychiatry2004;65(3):405‐13. ">Bandelow 2004</a>; <a href="./references#CD011567-bbs2-0020" title="Pfizer . A randomized, double‐blind, multicenter study of sertraline compared with paroxetine In the treatment of panic disorder. http://clinicaltrials.gov/show/NCT006773522008. ">Pfizer 2008</a>; <a href="./references#CD011567-bbs2-0027" title="BandelowB , SteinDJ , DolbergOT , AndersenHF , BaldwinDS . Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry2007;40:152‐6. ForestLaboratories . Flexible‐dose comparison of the safety and efficacy of Lu 26‐054 (escitalopram), citalopram and placebo in the treatment of panic disorder. Forest Laboratories Clinical Study Register [www.forestclinicaltrials.com]. StahlS , GergelI , LiD . Escitalopram in the treatment of panic disorder: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2003;64:1322‐7. ">Stahl 2003</a>), the only data available were for fluoxetine versus citalopram. The results of this sensitivity analysis did not change when compared with the primary analysis (<a href="./references#CD011567-fig-0087" title="">Analysis 10.1</a>). </p> </section> <section id="CD011567-sec-0339"> <p><b>Total number of dropouts</b></p> <p>Excluding four studies for high dropout rates (<a href="./references#CD011567-bbs2-0004" title="BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , DombrowskiA , et al. Sertraline versus paroxetine in the treatment of panic disorder: a multinational randomized double‐blind 15 week study. European Neuropsychopharmacology2002;12(Suppl 3):S363. BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , GoebelC , et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double‐blind noninferiority comparison. Journal of Clinical Psychiatry2004;65(3):405‐13. ">Bandelow 2004</a>; <a href="./references#CD011567-bbs2-0010" title="GentilV , Lotufo‐NetoF , AndradeL , CordásT , BernikM , RamosR , et al. Clomipramine, a better reference drug for panic/agoraphobia. I. Effectiveness comparison with imipramine. Journal of Psychopharmacology1993;7(4):316‐24. MarcourakisT , GorensteinC , GentilV . Clomipramine, a better reference drug for panic/agoraphobia. II. Psychomotor and cognitive effects. Journal of Psychopharmacology1993;7(4):325‐30. ">Gentil 1993</a>; <a href="./references#CD011567-bbs2-0020" title="Pfizer . A randomized, double‐blind, multicenter study of sertraline compared with paroxetine In the treatment of panic disorder. http://clinicaltrials.gov/show/NCT006773522008. ">Pfizer 2008</a>; <a href="./references#CD011567-bbs2-0027" title="BandelowB , SteinDJ , DolbergOT , AndersenHF , BaldwinDS . Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry2007;40:152‐6. ForestLaboratories . Flexible‐dose comparison of the safety and efficacy of Lu 26‐054 (escitalopram), citalopram and placebo in the treatment of panic disorder. Forest Laboratories Clinical Study Register [www.forestclinicaltrials.com]. StahlS , GergelI , LiD . Escitalopram in the treatment of panic disorder: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2003;64:1322‐7. ">Stahl 2003</a>), the only data available were for fluoxetine versus citalopram. The results of this sensitivity analysis did not change when compared with the primary analysis (<a href="./references#CD011567-fig-0088" title="">Analysis 10.2</a>). </p> </section> </section> <section id="CD011567-sec-0340"> <h6 class="title">Individual benzodiazepines versus individual benzodiazepines</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0098" title="">Analysis 11.1</a>; <a href="./references#CD011567-fig-0099" title="">Analysis 11.2</a>). </p> </section> </section> <section id="CD011567-sec-0341"> <h5 class="title">Excluding studies funded by the pharmaceutical company marketing each antidepressant or benzodiazepine (comparisons 20‐23) </h5> <section id="CD011567-sec-0342"> <h6 class="title">Antidepressants versus benzodiazepines</h6> <section id="CD011567-sec-0343"> <p><b>Failure to respond</b></p> <p>Excluding studies funded by the pharmaceutical company, no trials provided data for this analysis. </p> </section> <section id="CD011567-sec-0344"> <p><b>Total number of dropouts</b></p> <p>Excluding five studies funded by the pharmaceutical company marketing the drug (<a href="./references#CD011567-bbs2-0006" title="AlbusM , LecrubierY , MaierW , BullerR , RosenbergR , HippiusH . Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatrica Scandinavica1990;82(5):359‐65. AlbusM , MaierW , SheraD , BechP . Consistencies and discrepancies in self‐ and observer‐rated anxiety scales. A comparison between the self‐ and observer‐rated Marks‐Sheehan scales. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):96‐102. AnderschS , HansonL , HallstromT . Panic disorder: a five‐year follow‐up study in 52 patients. European Journal of Psychiatry1997;11(3):145‐55. AnderschS , HettaJ . A 15‐year follow‐up study of patients with panic disorder. European Psychiatry2003;18(8):401‐08. AnderschS , RosenbergNK , KullingsjöH , OttossonJO , BechP , Bruun‐HansenJ , et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatrica Scandinavica. Supplementum1991;365:18‐27. BerlangaC , CanettiA , ChavezE , De LaFuenteR , delCarmen LaraM , LeonC , et al. Pharmacologic treatment of panic disorders: Comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study [Tratamiento farmacologico de las crisis de angustia Reporte comparativo de la eficacia y seguridad del alprazolam y la imipramina en un estudio controlado]. Salud Mental1991;14(1):1‐5. BullerR , MaierW , GoldenbergIM , LavoriPW , BenkertO . Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross‐National Collaborative Panic Study. European Archives of Psychiatry and Clinical Neuroscience1991;240(3):163‐8. CassanoGB , ToniC , PetraccaA , DeltitoJ , BenkertO , CurtisG , et al. Adverse effects associated with the short‐term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology1994;4(1):47‐53. Cross National Collaborative Panic Study Second Phase Investigators. Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. British Journal of Psychiatry1992;160:191‐202. CurtisGC , MassanaJ , UdinaC , AyusoJL , CassanoGB , PerugiG . Maintenance drug therapy of panic disorder. Journal of Psychiatry Research1993;27(Suppl 1):127‐42. DeltitoJA , ArgyleN , BullerR , NutzingerD , OttossonJO , BrandonS , et al. The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(2):120‐9. DeltitoJA , ArgyleN , KlermanGL . Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Journal of Clinical Psychiatry1991;52(3):121‐7. GreenMA , CurtisGC . Personality disorders in panic patients: Response to termination of antipanic medication. Journal of Personality Disorders1988;2(4):303‐14. KatschnigH , AmeringM , StolkJM , KlermanGL , BallengerJC , BriggsA , et al. Long‐term follow‐up after a drug trial for panic disorder. British Journal of Psychiatry1995;167(4):487‐94. KlermanGL . Depression and panic anxiety: the effect of depressive co‐morbidity on response to drug treatment of patients with panic disorder and agoraphobia. Journal of Psychiatric Research1990;24(Suppl 2):27‐41. KlermanGL , ColemanJH , PurpuraRP . The design and conduct of the Upjohn Cross‐National Collaborative Panic Study. Psychopharmacology Bulletin1986;22(1):59‐64. LavoriPW , DawsonR , SheraD . A multiple imputation strategy for clinical trials with truncation of patient data. Statistics in Medicine1995;14(17):1913‐25. LeónCA , DeArangoMV , ArevaloW , CalvoA , MontoyaA , LeónA . Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia [Comparacion del efecto del alprazolam, la imipramina y placebo en el tratamiento del trastorno de panico en Cali, Colombia]. Acta Psiquiatrica y Psicologica de America Latina1990;36(1‐2):59‐72. MaierW , AlbusM , BullerR , NutzingerD , SheraD , BechP . Self‐ and observer assessment in anxiolytic drug trials: a comparison of their validity. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):103‐8. MaierW , RothSM , ArgyleN , BullerR , LavoriP , BrandonS , et al. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?. European Archives of Psychiatry and Clinical Neuroscience1991;241(3):151‐8. MaierWA , RothM , BullerR , ArgyleN , RosenbergR , SydneyB , et al. Agoraphobia in panic disorder: An indicator of the severity of panic disorder or a distinct diagnostic entity?. Psychiatric Annals1991;21(6):374‐81. RifkinA . The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(6):559‐60. RosenbergNK , MellergårdM , RosenbergR , BeckP , OttossonJO . Characteristics of panic disorder patients responding to placebo. Acta Psychiatrica Scandinavica Supplementum1991;365:33‐8. RosenbergR , BechP , MellergårdM , OttossonJO . Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response. Acta Psychiatrica Scandinavica. Supplementum1991;365:46‐52. SwobodaH , AmeringM , WindhaberJ , KatschnigH . The long‐term course of panic disorder‐‐an 11 year follow‐up. Journal of Anxiety Disorders2003;17(2):223‐32. ">CNCPS 1992</a>; <a href="./references#CD011567-bbs2-0025" title="RickelsK , SchweizerE . Panic disorder: Long‐term pharmacotherapy and discontinuation. Journal of Clinical Psychopharmacology1998;18(6 Suppl 2):12‐8. RickelsK , SchweizerE , WeissS , ZavodnickS . Maintenance drug treatment for panic disorder. II. Short‐ and long‐term outcome after drug taper. Archives of General Psychiatry1993;50:61‐8. SchweizerE , RickelsK , WeissS , ZavodnickS . Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo‐controlled comparison of alprazolam and imipramine. Archives of General Psychiatry1993;50:51‐60. ">Schweizer 1993</a>; <a href="./references#CD011567-bbs2-0026" title="SheikhJI , SwalesPJ . Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo. International Journal of Psychiatry in Medicine1999;29(1):107‐17. ">Sheikh 1999</a>; <a href="./references#CD011567-bbs2-0028" title='ClarkDB , TaylorCB , RothWT , HaywardC , EhlersA , MargrafJ , et al. Surreptitious drug use by patients in a panic disorder study. American Journal of Psychiatry1990;147(4):507‐9. MargrafJ , EhlersA , RothWT , ClarkDB , SheikhJ , AgrasWS , et al. How "blind" are double‐blind studies?. Journal of Consulting and Clinical Psychology1991;59(1):184‐7. TaylorCB , HaywardC , KingR , EhlersA , MargrafJ , MaddockR , et al. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double‐blind, placebo‐controlled trial. Journal of Clinical Psychopharmacology1990;10(2):112‐8. '>Taylor 1990</a>; <a href="./references#CD011567-bbs2-0031" title="UhlenhuthEH , MatuzasW , GlassRM , EastonC . Response of panic disorder to fixed doses of alprazolam or imipramine. Journal of Affective Disorders1989;17(3):261‐70. ">Uhlenhuth 1989</a>), no difference between antidepressants and benzodiazepines was found (RR 1.07, 95% CI 0.44 to 2.58; participants = 469; studies = 2), but with considerable heterogeneity (I² = 88%) (<a href="./references#CD011567-fig-0117" title="">Analysis 20.1</a>). </p> </section> </section> <section id="CD011567-sec-0345"> <h6 class="title">TCAs versus benzodiazepines</h6> <section id="CD011567-sec-0346"> <p><b>Failure to respond</b></p> <p>Excluding studies funded by the pharmaceutical company, no trials provided data for this analysis. </p> </section> <section id="CD011567-sec-0347"> <p><b>Total number of dropouts</b></p> <p>Excluding five studies funded by the pharmaceutical company marketing the drug, comparing imipramine with benzodiazepines (<a href="./references#CD011567-bbs2-0006" title="AlbusM , LecrubierY , MaierW , BullerR , RosenbergR , HippiusH . Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatrica Scandinavica1990;82(5):359‐65. AlbusM , MaierW , SheraD , BechP . Consistencies and discrepancies in self‐ and observer‐rated anxiety scales. A comparison between the self‐ and observer‐rated Marks‐Sheehan scales. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):96‐102. AnderschS , HansonL , HallstromT . Panic disorder: a five‐year follow‐up study in 52 patients. European Journal of Psychiatry1997;11(3):145‐55. AnderschS , HettaJ . A 15‐year follow‐up study of patients with panic disorder. European Psychiatry2003;18(8):401‐08. AnderschS , RosenbergNK , KullingsjöH , OttossonJO , BechP , Bruun‐HansenJ , et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatrica Scandinavica. Supplementum1991;365:18‐27. BerlangaC , CanettiA , ChavezE , De LaFuenteR , delCarmen LaraM , LeonC , et al. Pharmacologic treatment of panic disorders: Comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study [Tratamiento farmacologico de las crisis de angustia Reporte comparativo de la eficacia y seguridad del alprazolam y la imipramina en un estudio controlado]. Salud Mental1991;14(1):1‐5. BullerR , MaierW , GoldenbergIM , LavoriPW , BenkertO . Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross‐National Collaborative Panic Study. European Archives of Psychiatry and Clinical Neuroscience1991;240(3):163‐8. CassanoGB , ToniC , PetraccaA , DeltitoJ , BenkertO , CurtisG , et al. Adverse effects associated with the short‐term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology1994;4(1):47‐53. Cross National Collaborative Panic Study Second Phase Investigators. Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. British Journal of Psychiatry1992;160:191‐202. CurtisGC , MassanaJ , UdinaC , AyusoJL , CassanoGB , PerugiG . Maintenance drug therapy of panic disorder. Journal of Psychiatry Research1993;27(Suppl 1):127‐42. DeltitoJA , ArgyleN , BullerR , NutzingerD , OttossonJO , BrandonS , et al. The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(2):120‐9. DeltitoJA , ArgyleN , KlermanGL . Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Journal of Clinical Psychiatry1991;52(3):121‐7. GreenMA , CurtisGC . Personality disorders in panic patients: Response to termination of antipanic medication. Journal of Personality Disorders1988;2(4):303‐14. KatschnigH , AmeringM , StolkJM , KlermanGL , BallengerJC , BriggsA , et al. Long‐term follow‐up after a drug trial for panic disorder. British Journal of Psychiatry1995;167(4):487‐94. KlermanGL . Depression and panic anxiety: the effect of depressive co‐morbidity on response to drug treatment of patients with panic disorder and agoraphobia. Journal of Psychiatric Research1990;24(Suppl 2):27‐41. KlermanGL , ColemanJH , PurpuraRP . The design and conduct of the Upjohn Cross‐National Collaborative Panic Study. Psychopharmacology Bulletin1986;22(1):59‐64. LavoriPW , DawsonR , SheraD . A multiple imputation strategy for clinical trials with truncation of patient data. Statistics in Medicine1995;14(17):1913‐25. LeónCA , DeArangoMV , ArevaloW , CalvoA , MontoyaA , LeónA . Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia [Comparacion del efecto del alprazolam, la imipramina y placebo en el tratamiento del trastorno de panico en Cali, Colombia]. Acta Psiquiatrica y Psicologica de America Latina1990;36(1‐2):59‐72. MaierW , AlbusM , BullerR , NutzingerD , SheraD , BechP . Self‐ and observer assessment in anxiolytic drug trials: a comparison of their validity. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):103‐8. MaierW , RothSM , ArgyleN , BullerR , LavoriP , BrandonS , et al. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?. European Archives of Psychiatry and Clinical Neuroscience1991;241(3):151‐8. MaierWA , RothM , BullerR , ArgyleN , RosenbergR , SydneyB , et al. Agoraphobia in panic disorder: An indicator of the severity of panic disorder or a distinct diagnostic entity?. Psychiatric Annals1991;21(6):374‐81. RifkinA . The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(6):559‐60. RosenbergNK , MellergårdM , RosenbergR , BeckP , OttossonJO . Characteristics of panic disorder patients responding to placebo. Acta Psychiatrica Scandinavica Supplementum1991;365:33‐8. RosenbergR , BechP , MellergårdM , OttossonJO . Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response. Acta Psychiatrica Scandinavica. Supplementum1991;365:46‐52. SwobodaH , AmeringM , WindhaberJ , KatschnigH . The long‐term course of panic disorder‐‐an 11 year follow‐up. Journal of Anxiety Disorders2003;17(2):223‐32. ">CNCPS 1992</a>; <a href="./references#CD011567-bbs2-0025" title="RickelsK , SchweizerE . Panic disorder: Long‐term pharmacotherapy and discontinuation. Journal of Clinical Psychopharmacology1998;18(6 Suppl 2):12‐8. RickelsK , SchweizerE , WeissS , ZavodnickS . Maintenance drug treatment for panic disorder. II. Short‐ and long‐term outcome after drug taper. Archives of General Psychiatry1993;50:61‐8. SchweizerE , RickelsK , WeissS , ZavodnickS . Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo‐controlled comparison of alprazolam and imipramine. Archives of General Psychiatry1993;50:51‐60. ">Schweizer 1993</a>; <a href="./references#CD011567-bbs2-0026" title="SheikhJI , SwalesPJ . Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo. International Journal of Psychiatry in Medicine1999;29(1):107‐17. ">Sheikh 1999</a>; <a href="./references#CD011567-bbs2-0028" title='ClarkDB , TaylorCB , RothWT , HaywardC , EhlersA , MargrafJ , et al. Surreptitious drug use by patients in a panic disorder study. American Journal of Psychiatry1990;147(4):507‐9. MargrafJ , EhlersA , RothWT , ClarkDB , SheikhJ , AgrasWS , et al. How "blind" are double‐blind studies?. Journal of Consulting and Clinical Psychology1991;59(1):184‐7. TaylorCB , HaywardC , KingR , EhlersA , MargrafJ , MaddockR , et al. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double‐blind, placebo‐controlled trial. Journal of Clinical Psychopharmacology1990;10(2):112‐8. '>Taylor 1990</a>, <a href="./references#CD011567-bbs2-0031" title="UhlenhuthEH , MatuzasW , GlassRM , EastonC . Response of panic disorder to fixed doses of alprazolam or imipramine. Journal of Affective Disorders1989;17(3):261‐70. ">Uhlenhuth 1989</a>), only one study on clomipramine provided data for this comparison, showing a more favourable profile of TCAs over benzodiazepines (RR 0.69, 95% CI 0.49 to 0.98; participants = 315; studies = 1; I² = 0%) (<a href="./references#CD011567-fig-0118" title="">Analysis 21.1</a>). </p> </section> </section> <section id="CD011567-sec-0348"> <h6 class="title">SSRIs versus benzodiazepines</h6> <p>Excluding studies funded by the pharmaceutical company, no trials provided data for this analysis. </p> </section> <section id="CD011567-sec-0349"> <h6 class="title">TCAs versus SSRIs</h6> <section id="CD011567-sec-0350"> <p><b>Failure to respond</b></p> <p>Excluding three studies funded by the pharmaceutical company marketing the drug (<a href="./references#CD011567-bbs2-0015" title="GlaxoSmithKline . A double‐blind placebo controlled comparative study of paroxetine and clomipramine in the treatment of panic disorder. GSK‐ClinicalStudy Register (www.gsk‐clinicalstudyregister.com) 1993/11/12. LecrubierY , BakkerA , DunbarG , Judge R and the Collaborative Panic Study Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatrica Scandinavica1997;95:145‐52. LecrubierY , Judge R and the Collaborative Paroxetine Panic Study Investigators. Long‐term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatrica Scandinavica1997;95:153‐60. ">Lecrubier 1997</a>; <a href="./references#CD011567-bbs2-0018" title="BakishD , HooperCL , FilteauMJ , CharbonneauY , FraserG , WestDL , et al. A double‐blind placebo‐controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacology Bulletin1996;32(1):135‐41. NairNP , BakishD , SaxenaB , AminM , SchwartzG , WestTE . Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety1996;2(4):192‐8. ">Nair 1996</a>; <a href="./references#CD011567-bbs2-0035" title="ZhangHY , ZhaoQP , MaC . Paroxetine versus clomipramine for the treatment of panic disorders: a double‐blind randomised study. Chinese Mental Health Journal2000;14(6):410‐3. ">Zhang 2000</a>), did not substantially change the results (RR 2.00, 95% CI 0.46 to 8.76; participants = 22; studies = 1) (<a href="./references#CD011567-fig-0119" title="">Analysis 22.1</a>). </p> </section> <section id="CD011567-sec-0351"> <p><b>Total number of dropouts</b></p> <p>Excluding four studies funded by the pharmaceutical company marketing the drug (<a href="./references#CD011567-bbs2-0012" title="GSK . A double blind, multicenter randomized drug‐controlled study to assess the efficacy and tolerance of paroxetine compared with clomipramine in treatment of panic disorder. GSK Clinical Studies Register [http://www.gsk‐clinicalstudyregister.com/]. ">GSK‐29060/525</a>; <a href="./references#CD011567-bbs2-0015" title="GlaxoSmithKline . A double‐blind placebo controlled comparative study of paroxetine and clomipramine in the treatment of panic disorder. GSK‐ClinicalStudy Register (www.gsk‐clinicalstudyregister.com) 1993/11/12. LecrubierY , BakkerA , DunbarG , Judge R and the Collaborative Panic Study Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatrica Scandinavica1997;95:145‐52. LecrubierY , Judge R and the Collaborative Paroxetine Panic Study Investigators. Long‐term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatrica Scandinavica1997;95:153‐60. ">Lecrubier 1997</a>; <a href="./references#CD011567-bbs2-0018" title="BakishD , HooperCL , FilteauMJ , CharbonneauY , FraserG , WestDL , et al. A double‐blind placebo‐controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacology Bulletin1996;32(1):135‐41. NairNP , BakishD , SaxenaB , AminM , SchwartzG , WestTE . Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety1996;2(4):192‐8. ">Nair 1996</a>; <a href="./references#CD011567-bbs2-0035" title="ZhangHY , ZhaoQP , MaC . Paroxetine versus clomipramine for the treatment of panic disorders: a double‐blind randomised study. Chinese Mental Health Journal2000;14(6):410‐3. ">Zhang 2000</a>), the results did not substantially change (RR 1.14, 95% CI 0.77 to 1.68; participants = 439; studies = 3; I² = 0%) (<a href="./references#CD011567-fig-0120" title="">Analysis 22.2</a>). </p> </section> </section> <section id="CD011567-sec-0352"> <h6 class="title">TCAs versus MAOIs</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0052" title="">Analysis 5.1</a>; <a href="./references#CD011567-fig-0053" title="">Analysis 5.2</a>). </p> </section> <section id="CD011567-sec-0353"> <h6 class="title">SSRIs versus MAOIs</h6> <section id="CD011567-sec-0354"> <p><b>Failure to respond</b></p> <p>Excluding one study funded by the pharmaceutical company marketing the drug (<a href="./references#CD011567-bbs2-0030" title="TillerJWG , BouwerC , BehnkeK . Moclobemide and fluoxetine for panic disorder. European Archives of Psychiatry and Clinical Neuroscience1999;249(Suppl1):S7‐S10. ">Tiller 1999</a>), the results did not substantially change (RR 1.25, 95% CI 0.69 to 2.26; participants = 30; studies = 1) (<a href="./references#CD011567-fig-0121" title="">Analysis 23.1</a>). </p> </section> <section id="CD011567-sec-0355"> <p><b>Total number of dropouts</b></p> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0060" title="">Analysis 6.1</a>; <a href="./references#CD011567-fig-0061" title="">Analysis 6.2</a>). </p> </section> </section> <section id="CD011567-sec-0356"> <h6 class="title">SSRIs versus SNRIs</h6> <p>Excluding studies funded by the pharmaceutical company, no trials provided data for this analysis. </p> </section> <section id="CD011567-sec-0357"> <h6 class="title">SSRIs versus NaSSAs</h6> <section id="CD011567-sec-0358"> <p><b>Failure to respond</b></p> <p>No data were available for this analysis.</p> </section> <section id="CD011567-sec-0359"> <p><b>Total number of dropouts</b></p> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0077" title="">Analysis 8.2</a>). </p> </section> </section> <section id="CD011567-sec-0360"> <h6 class="title">Individual antidepressants versus individual antidepressants</h6> <section id="CD011567-sec-0361"> <p><b>Failure to respond</b></p> <p>Excluding three studies funded by the pharmaceutical company marketing the drug (<a href="./references#CD011567-bbs2-0004" title="BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , DombrowskiA , et al. Sertraline versus paroxetine in the treatment of panic disorder: a multinational randomized double‐blind 15 week study. European Neuropsychopharmacology2002;12(Suppl 3):S363. BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , GoebelC , et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double‐blind noninferiority comparison. Journal of Clinical Psychiatry2004;65(3):405‐13. ">Bandelow 2004</a>; <a href="./references#CD011567-bbs2-0020" title="Pfizer . A randomized, double‐blind, multicenter study of sertraline compared with paroxetine In the treatment of panic disorder. http://clinicaltrials.gov/show/NCT006773522008. ">Pfizer 2008</a>; <a href="./references#CD011567-bbs2-0027" title="BandelowB , SteinDJ , DolbergOT , AndersenHF , BaldwinDS . Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry2007;40:152‐6. ForestLaboratories . Flexible‐dose comparison of the safety and efficacy of Lu 26‐054 (escitalopram), citalopram and placebo in the treatment of panic disorder. Forest Laboratories Clinical Study Register [www.forestclinicaltrials.com]. StahlS , GergelI , LiD . Escitalopram in the treatment of panic disorder: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2003;64:1322‐7. ">Stahl 2003</a>), the only data available were for fluoxetine versus citalopram. The results of this sensitivity analysis did not change when compared with the primary analysis (<a href="./references#CD011567-fig-0087" title="">Analysis 10.1</a>). </p> </section> <section id="CD011567-sec-0362"> <p><b>Total number of dropouts</b></p> <p>Excluding three studies funded by the pharmaceutical company marketing the drug (<a href="./references#CD011567-bbs2-0004" title="BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , DombrowskiA , et al. Sertraline versus paroxetine in the treatment of panic disorder: a multinational randomized double‐blind 15 week study. European Neuropsychopharmacology2002;12(Suppl 3):S363. BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , GoebelC , et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double‐blind noninferiority comparison. Journal of Clinical Psychiatry2004;65(3):405‐13. ">Bandelow 2004</a>; <a href="./references#CD011567-bbs2-0020" title="Pfizer . A randomized, double‐blind, multicenter study of sertraline compared with paroxetine In the treatment of panic disorder. http://clinicaltrials.gov/show/NCT006773522008. ">Pfizer 2008</a>; <a href="./references#CD011567-bbs2-0027" title="BandelowB , SteinDJ , DolbergOT , AndersenHF , BaldwinDS . Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry2007;40:152‐6. ForestLaboratories . Flexible‐dose comparison of the safety and efficacy of Lu 26‐054 (escitalopram), citalopram and placebo in the treatment of panic disorder. Forest Laboratories Clinical Study Register [www.forestclinicaltrials.com]. StahlS , GergelI , LiD . Escitalopram in the treatment of panic disorder: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2003;64:1322‐7. ">Stahl 2003</a>), the only data available were for fluoxetine versus citalopram and imipramine versus clomipramine. The results of these sensitivity analyses did not change when compared with the primary analyses (<a href="./references#CD011567-fig-0088" title="">Analysis 10.2</a>). </p> </section> </section> <section id="CD011567-sec-0363"> <h6 class="title">Individual benzodiazepines versus individual benzodiazepines</h6> <p>Excluding studies funded by the pharmaceutical company, no trials provided data for this analysis. </p> </section> </section> <section id="CD011567-sec-0364"> <h5 class="title">Excluding studies whose participants clearly have significant psychiatric co‐morbidities including primary or secondary depressive disorders (comparisons 24‐28) </h5> <section id="CD011567-sec-0365"> <h6 class="title">Antidepressants versus benzodiazepines</h6> <section id="CD011567-sec-0366"> <p><b>Failure to respond</b></p> <p>Excluding one study that included participants with psychiatric co‐morbidities (<a href="./references#CD011567-bbs2-0011" title="GSK . A double‐blind, multicenter, flexible‐dose study of paroxetine, alprazolam and placebo in the treatment of panic disorder. GSK Clinical Studies Register [http://www.gsk‐clinicalstudyregister.com/]. ">GSK‐29060/1</a>) did not substantially change the results (RR 1.02, 95% CI 0.63 to 1.67; participants = 61; studies = 1) (<a href="./references#CD011567-fig-0122" title="">Analysis 24.1</a>). </p> </section> <section id="CD011567-sec-0367"> <p><b>Total number of dropouts</b></p> <p>Excluding three studies that included participants with psychiatric co‐morbidities (<a href="./references#CD011567-bbs2-0006" title="AlbusM , LecrubierY , MaierW , BullerR , RosenbergR , HippiusH . Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatrica Scandinavica1990;82(5):359‐65. AlbusM , MaierW , SheraD , BechP . Consistencies and discrepancies in self‐ and observer‐rated anxiety scales. A comparison between the self‐ and observer‐rated Marks‐Sheehan scales. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):96‐102. AnderschS , HansonL , HallstromT . Panic disorder: a five‐year follow‐up study in 52 patients. European Journal of Psychiatry1997;11(3):145‐55. AnderschS , HettaJ . A 15‐year follow‐up study of patients with panic disorder. European Psychiatry2003;18(8):401‐08. AnderschS , RosenbergNK , KullingsjöH , OttossonJO , BechP , Bruun‐HansenJ , et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatrica Scandinavica. Supplementum1991;365:18‐27. BerlangaC , CanettiA , ChavezE , De LaFuenteR , delCarmen LaraM , LeonC , et al. Pharmacologic treatment of panic disorders: Comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study [Tratamiento farmacologico de las crisis de angustia Reporte comparativo de la eficacia y seguridad del alprazolam y la imipramina en un estudio controlado]. Salud Mental1991;14(1):1‐5. BullerR , MaierW , GoldenbergIM , LavoriPW , BenkertO . Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross‐National Collaborative Panic Study. European Archives of Psychiatry and Clinical Neuroscience1991;240(3):163‐8. CassanoGB , ToniC , PetraccaA , DeltitoJ , BenkertO , CurtisG , et al. Adverse effects associated with the short‐term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology1994;4(1):47‐53. Cross National Collaborative Panic Study Second Phase Investigators. Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. British Journal of Psychiatry1992;160:191‐202. CurtisGC , MassanaJ , UdinaC , AyusoJL , CassanoGB , PerugiG . Maintenance drug therapy of panic disorder. Journal of Psychiatry Research1993;27(Suppl 1):127‐42. DeltitoJA , ArgyleN , BullerR , NutzingerD , OttossonJO , BrandonS , et al. The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(2):120‐9. DeltitoJA , ArgyleN , KlermanGL . Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Journal of Clinical Psychiatry1991;52(3):121‐7. GreenMA , CurtisGC . Personality disorders in panic patients: Response to termination of antipanic medication. Journal of Personality Disorders1988;2(4):303‐14. KatschnigH , AmeringM , StolkJM , KlermanGL , BallengerJC , BriggsA , et al. Long‐term follow‐up after a drug trial for panic disorder. British Journal of Psychiatry1995;167(4):487‐94. KlermanGL . Depression and panic anxiety: the effect of depressive co‐morbidity on response to drug treatment of patients with panic disorder and agoraphobia. Journal of Psychiatric Research1990;24(Suppl 2):27‐41. KlermanGL , ColemanJH , PurpuraRP . The design and conduct of the Upjohn Cross‐National Collaborative Panic Study. Psychopharmacology Bulletin1986;22(1):59‐64. LavoriPW , DawsonR , SheraD . A multiple imputation strategy for clinical trials with truncation of patient data. Statistics in Medicine1995;14(17):1913‐25. LeónCA , DeArangoMV , ArevaloW , CalvoA , MontoyaA , LeónA . Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia [Comparacion del efecto del alprazolam, la imipramina y placebo en el tratamiento del trastorno de panico en Cali, Colombia]. Acta Psiquiatrica y Psicologica de America Latina1990;36(1‐2):59‐72. MaierW , AlbusM , BullerR , NutzingerD , SheraD , BechP . Self‐ and observer assessment in anxiolytic drug trials: a comparison of their validity. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):103‐8. MaierW , RothSM , ArgyleN , BullerR , LavoriP , BrandonS , et al. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?. European Archives of Psychiatry and Clinical Neuroscience1991;241(3):151‐8. MaierWA , RothM , BullerR , ArgyleN , RosenbergR , SydneyB , et al. Agoraphobia in panic disorder: An indicator of the severity of panic disorder or a distinct diagnostic entity?. Psychiatric Annals1991;21(6):374‐81. RifkinA . The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(6):559‐60. RosenbergNK , MellergårdM , RosenbergR , BeckP , OttossonJO . Characteristics of panic disorder patients responding to placebo. Acta Psychiatrica Scandinavica Supplementum1991;365:33‐8. RosenbergR , BechP , MellergårdM , OttossonJO . Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response. Acta Psychiatrica Scandinavica. Supplementum1991;365:46‐52. SwobodaH , AmeringM , WindhaberJ , KatschnigH . The long‐term course of panic disorder‐‐an 11 year follow‐up. Journal of Anxiety Disorders2003;17(2):223‐32. ">CNCPS 1992</a>, <a href="./references#CD011567-bbs2-0011" title="GSK . A double‐blind, multicenter, flexible‐dose study of paroxetine, alprazolam and placebo in the treatment of panic disorder. GSK Clinical Studies Register [http://www.gsk‐clinicalstudyregister.com/]. ">GSK‐29060/1</a>, <a href="./references#CD011567-bbs2-0028" title='ClarkDB , TaylorCB , RothWT , HaywardC , EhlersA , MargrafJ , et al. Surreptitious drug use by patients in a panic disorder study. American Journal of Psychiatry1990;147(4):507‐9. MargrafJ , EhlersA , RothWT , ClarkDB , SheikhJ , AgrasWS , et al. How "blind" are double‐blind studies?. Journal of Consulting and Clinical Psychology1991;59(1):184‐7. TaylorCB , HaywardC , KingR , EhlersA , MargrafJ , MaddockR , et al. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double‐blind, placebo‐controlled trial. Journal of Clinical Psychopharmacology1990;10(2):112‐8. '>Taylor 1990</a>), no difference between antidepressants and benzodiazepines was found (RR 1.67, 95% CI 0.64 to 4.36; participants = 465; studies = 4), with a substantial heterogeneity (I² = 81%) (<a href="./references#CD011567-fig-0123" title="">Analysis 24.2</a>). </p> </section> </section> <section id="CD011567-sec-0368"> <h6 class="title">TCAs versus benzodiazepines</h6> <section id="CD011567-sec-0369"> <p><b>Failure to respond</b></p> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0018" title="">Analysis 2.1</a>). </p> </section> <section id="CD011567-sec-0370"> <p><b>Total number of dropouts</b></p> <p>Excluding two studies that included participants with psychiatric co‐morbidities (<a href="./references#CD011567-bbs2-0006" title="AlbusM , LecrubierY , MaierW , BullerR , RosenbergR , HippiusH . Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatrica Scandinavica1990;82(5):359‐65. AlbusM , MaierW , SheraD , BechP . Consistencies and discrepancies in self‐ and observer‐rated anxiety scales. A comparison between the self‐ and observer‐rated Marks‐Sheehan scales. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):96‐102. AnderschS , HansonL , HallstromT . Panic disorder: a five‐year follow‐up study in 52 patients. European Journal of Psychiatry1997;11(3):145‐55. AnderschS , HettaJ . A 15‐year follow‐up study of patients with panic disorder. European Psychiatry2003;18(8):401‐08. AnderschS , RosenbergNK , KullingsjöH , OttossonJO , BechP , Bruun‐HansenJ , et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatrica Scandinavica. Supplementum1991;365:18‐27. BerlangaC , CanettiA , ChavezE , De LaFuenteR , delCarmen LaraM , LeonC , et al. Pharmacologic treatment of panic disorders: Comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study [Tratamiento farmacologico de las crisis de angustia Reporte comparativo de la eficacia y seguridad del alprazolam y la imipramina en un estudio controlado]. Salud Mental1991;14(1):1‐5. BullerR , MaierW , GoldenbergIM , LavoriPW , BenkertO . Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross‐National Collaborative Panic Study. European Archives of Psychiatry and Clinical Neuroscience1991;240(3):163‐8. CassanoGB , ToniC , PetraccaA , DeltitoJ , BenkertO , CurtisG , et al. Adverse effects associated with the short‐term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology1994;4(1):47‐53. Cross National Collaborative Panic Study Second Phase Investigators. Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. British Journal of Psychiatry1992;160:191‐202. CurtisGC , MassanaJ , UdinaC , AyusoJL , CassanoGB , PerugiG . Maintenance drug therapy of panic disorder. Journal of Psychiatry Research1993;27(Suppl 1):127‐42. DeltitoJA , ArgyleN , BullerR , NutzingerD , OttossonJO , BrandonS , et al. The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(2):120‐9. DeltitoJA , ArgyleN , KlermanGL . Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Journal of Clinical Psychiatry1991;52(3):121‐7. GreenMA , CurtisGC . Personality disorders in panic patients: Response to termination of antipanic medication. Journal of Personality Disorders1988;2(4):303‐14. KatschnigH , AmeringM , StolkJM , KlermanGL , BallengerJC , BriggsA , et al. Long‐term follow‐up after a drug trial for panic disorder. British Journal of Psychiatry1995;167(4):487‐94. KlermanGL . Depression and panic anxiety: the effect of depressive co‐morbidity on response to drug treatment of patients with panic disorder and agoraphobia. Journal of Psychiatric Research1990;24(Suppl 2):27‐41. KlermanGL , ColemanJH , PurpuraRP . The design and conduct of the Upjohn Cross‐National Collaborative Panic Study. Psychopharmacology Bulletin1986;22(1):59‐64. LavoriPW , DawsonR , SheraD . A multiple imputation strategy for clinical trials with truncation of patient data. Statistics in Medicine1995;14(17):1913‐25. LeónCA , DeArangoMV , ArevaloW , CalvoA , MontoyaA , LeónA . Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia [Comparacion del efecto del alprazolam, la imipramina y placebo en el tratamiento del trastorno de panico en Cali, Colombia]. Acta Psiquiatrica y Psicologica de America Latina1990;36(1‐2):59‐72. MaierW , AlbusM , BullerR , NutzingerD , SheraD , BechP . Self‐ and observer assessment in anxiolytic drug trials: a comparison of their validity. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):103‐8. MaierW , RothSM , ArgyleN , BullerR , LavoriP , BrandonS , et al. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?. European Archives of Psychiatry and Clinical Neuroscience1991;241(3):151‐8. MaierWA , RothM , BullerR , ArgyleN , RosenbergR , SydneyB , et al. Agoraphobia in panic disorder: An indicator of the severity of panic disorder or a distinct diagnostic entity?. Psychiatric Annals1991;21(6):374‐81. RifkinA . The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(6):559‐60. RosenbergNK , MellergårdM , RosenbergR , BeckP , OttossonJO . Characteristics of panic disorder patients responding to placebo. Acta Psychiatrica Scandinavica Supplementum1991;365:33‐8. RosenbergR , BechP , MellergårdM , OttossonJO . Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response. Acta Psychiatrica Scandinavica. Supplementum1991;365:46‐52. SwobodaH , AmeringM , WindhaberJ , KatschnigH . The long‐term course of panic disorder‐‐an 11 year follow‐up. Journal of Anxiety Disorders2003;17(2):223‐32. ">CNCPS 1992</a>; <a href="./references#CD011567-bbs2-0028" title='ClarkDB , TaylorCB , RothWT , HaywardC , EhlersA , MargrafJ , et al. Surreptitious drug use by patients in a panic disorder study. American Journal of Psychiatry1990;147(4):507‐9. MargrafJ , EhlersA , RothWT , ClarkDB , SheikhJ , AgrasWS , et al. How "blind" are double‐blind studies?. Journal of Consulting and Clinical Psychology1991;59(1):184‐7. TaylorCB , HaywardC , KingR , EhlersA , MargrafJ , MaddockR , et al. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double‐blind, placebo‐controlled trial. Journal of Clinical Psychopharmacology1990;10(2):112‐8. '>Taylor 1990</a>) did not substantially change the results (RR 1.67, 95% CI 0.64 to 4.36; participants = 465; studies = 4), with a substantial heterogeneity (I² = 81%) (<a href="./references#CD011567-fig-0124" title="">Analysis 25.1</a>). </p> </section> </section> <section id="CD011567-sec-0371"> <h6 class="title">SSRIs versus benzodiazepines</h6> <p>Excluding studies that included participants with psychiatric co‐morbidities, no trials provided data for this analysis. </p> </section> <section id="CD011567-sec-0372"> <h6 class="title">TCAs versus SSRIs</h6> <section id="CD011567-sec-0373"> <p><b>Failure to respond</b></p> <p>Excluding one study that included participants with psychiatric co‐morbidities (<a href="./references#CD011567-bbs2-0005" title="BystritskyA , RosenRM , MurphyKJ , BohnP , KeysSA , VapnikT . Double‐blind pilot trial of desipramine versus fluoxetine in panic patients. Anxiety 1994‐1995;1(6):287‐90. ">Bystritsky 1995</a>) did not change the results (RR 1.03, 95% CI 0.66 to 1.61; participants = 416; studies = 3). The heterogeneity was moderate (I² = 69%) (<a href="./references#CD011567-fig-0125" title="">Analysis 26.1</a>). </p> </section> <section id="CD011567-sec-0374"> <p><b>Total number of dropouts</b></p> <p>Excluding one study that included participants with psychiatric co‐morbidities (<a href="./references#CD011567-bbs2-0005" title="BystritskyA , RosenRM , MurphyKJ , BohnP , KeysSA , VapnikT . Double‐blind pilot trial of desipramine versus fluoxetine in panic patients. Anxiety 1994‐1995;1(6):287‐90. ">Bystritsky 1995</a>) did not change the results (RR 0.96, 95% CI 0.62 to 1.49; participants = 906; studies = 6). The heterogeneity was moderate (I² = 54%) (<a href="./references#CD011567-fig-0126" title="">Analysis 26.2</a>). </p> </section> </section> <section id="CD011567-sec-0375"> <h6 class="title">TCAs versus MAOIs</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0052" title="">Analysis 5.1</a>; <a href="./references#CD011567-fig-0053" title="">Analysis 5.2</a>). </p> </section> <section id="CD011567-sec-0376"> <h6 class="title">SSRIs versus MAOIs</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0060" title="">Analysis 6.1</a>; <a href="./references#CD011567-fig-0061" title="">Analysis 6.2</a>). </p> </section> <section id="CD011567-sec-0377"> <h6 class="title">SSRIs versus SNRIs</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0067" title="">Analysis 7.1</a>; <a href="./references#CD011567-fig-0068" title="">Analysis 7.2</a>). </p> </section> <section id="CD011567-sec-0378"> <h6 class="title">SSRIs versus NaSSAs</h6> <section id="CD011567-sec-0379"> <p><b>Failure to respond</b></p> <p>No data were available for this analysis.</p> </section> <section id="CD011567-sec-0380"> <p><b>Total number of dropouts</b></p> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0077" title="">Analysis 8.2</a>). </p> </section> </section> <section id="CD011567-sec-0381"> <h6 class="title">Individual antidepressants versus individual antidepressants</h6> <section id="CD011567-sec-0382"> <p><b>Failure to respond</b></p> <p>Excluding one study that included participants with psychiatric co‐morbidities (<a href="./references#CD011567-bbs2-0020" title="Pfizer . A randomized, double‐blind, multicenter study of sertraline compared with paroxetine In the treatment of panic disorder. http://clinicaltrials.gov/show/NCT006773522008. ">Pfizer 2008</a>) did not change the results on sertraline versus paroxetine (RR 0.98, 95% CI 0.78 to 1.23; participants = 225; studies = 1) (<a href="./references#CD011567-fig-0127" title="">Analysis 27.1</a>). </p> </section> <section id="CD011567-sec-0383"> <p><b>Total number of dropouts</b></p> <p>Excluding two studies which included participants with psychiatric co‐morbidities (<a href="./references#CD011567-bbs2-0010" title="GentilV , Lotufo‐NetoF , AndradeL , CordásT , BernikM , RamosR , et al. Clomipramine, a better reference drug for panic/agoraphobia. I. Effectiveness comparison with imipramine. Journal of Psychopharmacology1993;7(4):316‐24. MarcourakisT , GorensteinC , GentilV . Clomipramine, a better reference drug for panic/agoraphobia. II. Psychomotor and cognitive effects. Journal of Psychopharmacology1993;7(4):325‐30. ">Gentil 1993</a>; <a href="./references#CD011567-bbs2-0020" title="Pfizer . A randomized, double‐blind, multicenter study of sertraline compared with paroxetine In the treatment of panic disorder. http://clinicaltrials.gov/show/NCT006773522008. ">Pfizer 2008</a>), the conclusion changed from the main analysis, showing no difference between sertraline and paroxetine (RR 0.85, 95% CI 0.57 to 1.26; participants = 225; studies = 1) (<a href="./references#CD011567-fig-0128" title="">Analysis 27.2</a>). </p> </section> </section> <section id="CD011567-sec-0384"> <h6 class="title">Individual benzodiazepines versus individual benzodiazepines</h6> <section id="CD011567-sec-0385"> <p><b>Failure to respond</b></p> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0098" title="">Analysis 11.1</a>). </p> </section> <section id="CD011567-sec-0386"> <p><b>Total number of dropouts</b></p> <p>Excluding one study that included participants with psychiatric co‐morbidities (<a href="./references#CD011567-bbs2-0029" title="FavaM , RosenbaumJF , MacLaughlinRA , TesarGE , PollackMH , CohenLS , et al. Dehydroepiandrosterone‐sulfate/cortisol ratio in panic disorder. Psychiatry Research1989;28(3):345‐50. LabbateLA , PollackMH , OttoMW , TesarGM , RosenbaumJF . The relationship of alprazolam and clonazepam dose to steady‐state concentration in plasma. Journal of Clinical Psychopharmacology1994;14(4):274‐6. PollackMH , OttoMW , TesarGE , CohenLS , Meltzer‐BrodyS , RosenbaumJF . Long‐term outcome after acute treatment with alprazolam or clonazepam for panic disorder. Journal of Clinical Psychopharmacology1993;13(4):257‐63. TesarGE , RosenbaumJF , PollackMH , HermanJB , SachsGS , MahoneyEM , et al. Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry1987;48(Suppl 10):16‐21. TesarGE , RosenbaumJF , PollackMH , OttoMW , SachsGS , HermanJB , et al. Double‐blind, placebo‐controlled comparison of clonazepam and alprazolam for panic disorder. Journal of Clinical Psychiatry1991;52(2):69‐76. ">Tesar 1991</a>) the results did not change (RR 0.84, 95% CI 0.44 to 1.64; participants = 159; studies = 1) (<a href="./references#CD011567-fig-0129" title="">Analysis 28.1</a>). </p> </section> </section> </section> <section id="CD011567-sec-0387"> <h5 class="title">Excluding studies mostly focused on agoraphobia</h5> <p>This sensitivity analysis was not carried out as no studies were "mostly focused on agoraphobia". </p> </section> <section id="CD011567-sec-0388"> <h5 class="title">Applying best and worst case scenarios to studies where participants left the study before the endpoint </h5> <p>The main analyses, according to the study protocol, considered participants who discontinued early as treatment failures (worst‐case scenario) as this approach was considered more conservative. A sensitivity analysis based on a best‐case scenario, which considers all dropouts as responders or remitters, was not feasible as the vast majority of studies carried forward, and included in the analyses, some observations on dropouts. This did not allow us to make the assumptions that all dropouts were responders. </p> </section> <section id="CD011567-sec-0389"> <h5 class="title">Excluding studies where responding participants are calculated according to an imputation method (comparisons 29‐30) </h5> <section id="CD011567-sec-0390"> <h6 class="title">Antidepressants versus benzodiazepines</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0006" title="">Analysis 1.1</a>; <a href="./references#CD011567-fig-0007" title="">Analysis 1.2</a>). </p> </section> <section id="CD011567-sec-0391"> <h6 class="title">TCAs versus benzodiazepines</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0018" title="">Analysis 2.1</a>; <a href="./references#CD011567-fig-0019" title="">Analysis 2.2</a>). </p> </section> <section id="CD011567-sec-0392"> <h6 class="title">SSRIs versus benzodiazepines</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0029" title="">Analysis 3.1</a>; <a href="./references#CD011567-fig-0030" title="">Analysis 3.2</a>). </p> </section> <section id="CD011567-sec-0393"> <h6 class="title">TCAs versus SSRIs</h6> <section id="CD011567-sec-0394"> <p><b>Failure to respond</b></p> <p>Excluding two studies where imputation methods were used (<a href="./references#CD011567-bbs2-0005" title="BystritskyA , RosenRM , MurphyKJ , BohnP , KeysSA , VapnikT . Double‐blind pilot trial of desipramine versus fluoxetine in panic patients. Anxiety 1994‐1995;1(6):287‐90. ">Bystritsky 1995</a>; <a href="./references#CD011567-bbs2-0018" title="BakishD , HooperCL , FilteauMJ , CharbonneauY , FraserG , WestDL , et al. A double‐blind placebo‐controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacology Bulletin1996;32(1):135‐41. NairNP , BakishD , SaxenaB , AminM , SchwartzG , WestTE . Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety1996;2(4):192‐8. ">Nair 1996</a>)did not substantially change the results (RR 1.33, 95% CI 0.95 to 1.86; participants = 318; studies = 2; I² = 0%) (<a href="./references#CD011567-fig-0130" title="">Analysis 29.1</a>). </p> </section> <section id="CD011567-sec-0395"> <p><b>Total number of dropouts</b></p> <p>Excluding two studies where imputation methods were used (<a href="./references#CD011567-bbs2-0005" title="BystritskyA , RosenRM , MurphyKJ , BohnP , KeysSA , VapnikT . Double‐blind pilot trial of desipramine versus fluoxetine in panic patients. Anxiety 1994‐1995;1(6):287‐90. ">Bystritsky 1995</a>; <a href="./references#CD011567-bbs2-0018" title="BakishD , HooperCL , FilteauMJ , CharbonneauY , FraserG , WestDL , et al. A double‐blind placebo‐controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacology Bulletin1996;32(1):135‐41. NairNP , BakishD , SaxenaB , AminM , SchwartzG , WestTE . Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety1996;2(4):192‐8. ">Nair 1996</a>)did not substantially change the results (RR 1.08, 95% CI 0.80 to 1.45; participants = 808; studies = 5; I² = 4%) (<a href="./references#CD011567-fig-0131" title="">Analysis 29.2</a>). </p> </section> </section> <section id="CD011567-sec-0396"> <h6 class="title">TCAs versus MAOIs</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0052" title="">Analysis 5.1</a>; <a href="./references#CD011567-fig-0053" title="">Analysis 5.2</a>). </p> </section> <section id="CD011567-sec-0397"> <h6 class="title">SSRIs versus MAOIs</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0060" title="">Analysis 6.1</a>; <a href="./references#CD011567-fig-0061" title="">Analysis 6.2</a>). </p> </section> <section id="CD011567-sec-0398"> <h6 class="title">SSRIs versus SNRIs</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0067" title="">Analysis 7.1</a>; <a href="./references#CD011567-fig-0068" title="">Analysis 7.2</a>). </p> </section> <section id="CD011567-sec-0399"> <h6 class="title">SSRIs versus NaSSAs</h6> <section id="CD011567-sec-0400"> <p><b>Failure to respond</b></p> <p>No data were available for this analysis.</p> </section> <section id="CD011567-sec-0401"> <p><b>Total number of dropouts</b></p> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0077" title="">Analysis 8.2</a>). </p> </section> </section> <section id="CD011567-sec-0402"> <h6 class="title">Individual antidepressants versus individual antidepressants</h6> <section id="CD011567-sec-0403"> <p><b>Failure to respond</b></p> <p>Excluding two studies where imputation methods were used (<a href="./references#CD011567-bbs2-0004" title="BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , DombrowskiA , et al. Sertraline versus paroxetine in the treatment of panic disorder: a multinational randomized double‐blind 15 week study. European Neuropsychopharmacology2002;12(Suppl 3):S363. BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , GoebelC , et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double‐blind noninferiority comparison. Journal of Clinical Psychiatry2004;65(3):405‐13. ">Bandelow 2004</a>; <a href="./references#CD011567-bbs2-0027" title="BandelowB , SteinDJ , DolbergOT , AndersenHF , BaldwinDS . Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry2007;40:152‐6. ForestLaboratories . Flexible‐dose comparison of the safety and efficacy of Lu 26‐054 (escitalopram), citalopram and placebo in the treatment of panic disorder. Forest Laboratories Clinical Study Register [www.forestclinicaltrials.com]. StahlS , GergelI , LiD . Escitalopram in the treatment of panic disorder: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2003;64:1322‐7. ">Stahl 2003</a>), the results on sertraline versus paroxetine did not change (RR 0.95, 95% CI 0.70 to 1.30; participants = 321; studies = 1) (<a href="./references#CD011567-fig-0132" title="">Analysis 30.1</a>). </p> </section> <section id="CD011567-sec-0404"> <p><b>Total number of dropouts</b></p> <p>Excluding two studies where imputation methods were used (<a href="./references#CD011567-bbs2-0004" title="BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , DombrowskiA , et al. Sertraline versus paroxetine in the treatment of panic disorder: a multinational randomized double‐blind 15 week study. European Neuropsychopharmacology2002;12(Suppl 3):S363. BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , GoebelC , et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double‐blind noninferiority comparison. Journal of Clinical Psychiatry2004;65(3):405‐13. ">Bandelow 2004</a>; <a href="./references#CD011567-bbs2-0027" title="BandelowB , SteinDJ , DolbergOT , AndersenHF , BaldwinDS . Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry2007;40:152‐6. ForestLaboratories . Flexible‐dose comparison of the safety and efficacy of Lu 26‐054 (escitalopram), citalopram and placebo in the treatment of panic disorder. Forest Laboratories Clinical Study Register [www.forestclinicaltrials.com]. StahlS , GergelI , LiD . Escitalopram in the treatment of panic disorder: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2003;64:1322‐7. ">Stahl 2003</a>), the results on sertraline versus paroxetine did not change (RR 0.62, 95% CI 0.40 to 0.97; participants = 321; studies = 1; I² = 0%) (<a href="./references#CD011567-fig-0133" title="">Analysis 30.2</a>). </p> </section> </section> <section id="CD011567-sec-0405"> <h6 class="title">Individual benzodiazepines versus individual benzodiazepines</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0098" title="">Analysis 11.1</a>; <a href="./references#CD011567-fig-0099" title="">Analysis 11.2</a>). </p> </section> </section> <section id="CD011567-sec-0406"> <h5 class="title">Excluding studies where irregular benzodiazepine use was allowed after the first 15 days after random allocation (comparisons 31‐33) </h5> <section id="CD011567-sec-0407"> <h6 class="title">Antidepressants versus benzodiazepines</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0006" title="">Analysis 1.1</a>; <a href="./references#CD011567-fig-0007" title="">Analysis 1.2</a>). </p> </section> <section id="CD011567-sec-0408"> <h6 class="title">TCAs versus benzodiazepines</h6> <p>No studies were excluded from this comparison because of the irregular use of benzodiazepines, so the results did not change (<a href="./references#CD011567-fig-0018" title="">Analysis 2.1</a>; <a href="./references#CD011567-fig-0019" title="">Analysis 2.2</a>). </p> </section> <section id="CD011567-sec-0409"> <h6 class="title">SSRIs versus benzodiazepines</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0029" title="">Analysis 3.1</a>; <a href="./references#CD011567-fig-0030" title="">Analysis 3.2</a>). </p> </section> <section id="CD011567-sec-0410"> <h6 class="title">TCAs versus SSRIs</h6> <section id="CD011567-sec-0411"> <p><b>Failure to respond</b></p> <p>Excluding two studies in which irregular use of benzodiazepines was allowed (<a href="./references#CD011567-bbs2-0015" title="GlaxoSmithKline . A double‐blind placebo controlled comparative study of paroxetine and clomipramine in the treatment of panic disorder. GSK‐ClinicalStudy Register (www.gsk‐clinicalstudyregister.com) 1993/11/12. LecrubierY , BakkerA , DunbarG , Judge R and the Collaborative Panic Study Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatrica Scandinavica1997;95:145‐52. LecrubierY , Judge R and the Collaborative Paroxetine Panic Study Investigators. Long‐term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatrica Scandinavica1997;95:153‐60. ">Lecrubier 1997</a>; <a href="./references#CD011567-bbs2-0018" title="BakishD , HooperCL , FilteauMJ , CharbonneauY , FraserG , WestDL , et al. A double‐blind placebo‐controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacology Bulletin1996;32(1):135‐41. NairNP , BakishD , SaxenaB , AminM , SchwartzG , WestTE . Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety1996;2(4):192‐8. ">Nair 1996</a>) did not change the results (RR 1.22, 95% CI 0.47 to 3.15; participants = 95; studies = 2; I² = 0%) (<a href="./references#CD011567-fig-0134" title="">Analysis 31.1</a>). </p> </section> <section id="CD011567-sec-0412"> <p><b>Total number of dropouts</b></p> <p>Excluding two studies in which irregular use of benzodiazepines was allowed (<a href="./references#CD011567-bbs2-0015" title="GlaxoSmithKline . A double‐blind placebo controlled comparative study of paroxetine and clomipramine in the treatment of panic disorder. GSK‐ClinicalStudy Register (www.gsk‐clinicalstudyregister.com) 1993/11/12. LecrubierY , BakkerA , DunbarG , Judge R and the Collaborative Panic Study Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatrica Scandinavica1997;95:145‐52. LecrubierY , Judge R and the Collaborative Paroxetine Panic Study Investigators. Long‐term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatrica Scandinavica1997;95:153‐60. ">Lecrubier 1997</a>; <a href="./references#CD011567-bbs2-0018" title="BakishD , HooperCL , FilteauMJ , CharbonneauY , FraserG , WestDL , et al. A double‐blind placebo‐controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacology Bulletin1996;32(1):135‐41. NairNP , BakishD , SaxenaB , AminM , SchwartzG , WestTE . Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety1996;2(4):192‐8. ">Nair 1996</a>) did not change the results (RR 1.24, 95% CI 0.85 to 1.81; participants = 585; studies = 5; I² = 0%) (<a href="./references#CD011567-fig-0135" title="">Analysis 31.2</a>). </p> </section> </section> <section id="CD011567-sec-0413"> <h6 class="title">TCAs versus MAOIs</h6> <p>Excluding studies in which irregular use of benzodiazepines was allowed, no trials provided data for this analysis. </p> </section> <section id="CD011567-sec-0414"> <h6 class="title">SSRIs versus MAOIs</h6> <section id="CD011567-sec-0415"> <p><b>Failure to respond</b></p> <p>Excluding one study in which irregular use of benzodiazepines was allowed (<a href="./references#CD011567-bbs2-0032" title="SlaapBR , vanVlietIM , WestenbergHGM , denBoerJA . Phobic symptoms as predictors of nonresponse to drug therapy in panic disorder patients (a preliminary report). Journal of Affective Disorders1995;33(1):31‐8. vanVlietIM , denBoerJA , WestenbergHGM , SlaapBR . A double‐blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. Journal of Clinical Psychopharmacology1996;16(4):299‐306. ">Van Vliet 1996</a>) did not change the results (RR 1.08, 95% CI 0.76 to 1.54; participants = 366; studies = 1; I² = 0%) (<a href="./references#CD011567-fig-0136" title="">Analysis 32.1</a>). </p> </section> <section id="CD011567-sec-0416"> <p><b>Total number of dropouts</b></p> <p>Excluding studies in which irregular use of benzodiazepines was allowed, no trials provided data for this analysis. </p> </section> </section> <section id="CD011567-sec-0417"> <h6 class="title">SSRIs versus SNRIs</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0067" title="">Analysis 7.1</a>; <a href="./references#CD011567-fig-0068" title="">Analysis 7.2</a>). </p> </section> <section id="CD011567-sec-0418"> <h6 class="title">SSRIs versus NaSSAs</h6> <section id="CD011567-sec-0419"> <p><b>Failure to respond</b></p> <p>No data were available for this analysis.</p> </section> <section id="CD011567-sec-0420"> <p><b>Total number of dropouts</b></p> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0077" title="">Analysis 8.2</a>). </p> </section> </section> <section id="CD011567-sec-0421"> <h6 class="title">Individual antidepressants versus individual antidepressants</h6> <section id="CD011567-sec-0422"> <p><b>Failure to respond</b></p> <p>Excluding two studies in which irregular use of benzodiazepines was allowed (<a href="./references#CD011567-bbs2-0004" title="BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , DombrowskiA , et al. Sertraline versus paroxetine in the treatment of panic disorder: a multinational randomized double‐blind 15 week study. European Neuropsychopharmacology2002;12(Suppl 3):S363. BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , GoebelC , et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double‐blind noninferiority comparison. Journal of Clinical Psychiatry2004;65(3):405‐13. ">Bandelow 2004</a>; <a href="./references#CD011567-bbs2-0027" title="BandelowB , SteinDJ , DolbergOT , AndersenHF , BaldwinDS . Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry2007;40:152‐6. ForestLaboratories . Flexible‐dose comparison of the safety and efficacy of Lu 26‐054 (escitalopram), citalopram and placebo in the treatment of panic disorder. Forest Laboratories Clinical Study Register [www.forestclinicaltrials.com]. StahlS , GergelI , LiD . Escitalopram in the treatment of panic disorder: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2003;64:1322‐7. ">Stahl 2003</a>) did not change the results for sertraline versus paroxetine (RR 0.95, 95% CI 0.70 to 1.30; participants = 321; studies = 1; I² = 0%) (<a href="./references#CD011567-fig-0137" title="">Analysis 33.1</a>). </p> </section> <section id="CD011567-sec-0423"> <p><b>Total number of dropouts</b></p> <p>Excluding two studies in which irregular use of benzodiazepines was allowed (<a href="./references#CD011567-bbs2-0004" title="BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , DombrowskiA , et al. Sertraline versus paroxetine in the treatment of panic disorder: a multinational randomized double‐blind 15 week study. European Neuropsychopharmacology2002;12(Suppl 3):S363. BandelowB , BehnkeK , LenoirS , HendriksGJ , AlkinT , GoebelC , et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double‐blind noninferiority comparison. Journal of Clinical Psychiatry2004;65(3):405‐13. ">Bandelow 2004</a>; <a href="./references#CD011567-bbs2-0027" title="BandelowB , SteinDJ , DolbergOT , AndersenHF , BaldwinDS . Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry2007;40:152‐6. ForestLaboratories . Flexible‐dose comparison of the safety and efficacy of Lu 26‐054 (escitalopram), citalopram and placebo in the treatment of panic disorder. Forest Laboratories Clinical Study Register [www.forestclinicaltrials.com]. StahlS , GergelI , LiD . Escitalopram in the treatment of panic disorder: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2003;64:1322‐7. ">Stahl 2003</a>) did not change the results for sertraline versus paroxetine (RR 0.62, 95% CI 0.40 to 0.97; participants = 321; studies = 1; I² = 0%) (<a href="./references#CD011567-fig-0138" title="">Analysis 33.2</a>). </p> </section> </section> <section id="CD011567-sec-0424"> <h6 class="title">Individual benzodiazepines versus individual benzodiazepines</h6> <p>No studies were excluded, so the results did not change (<a href="./references#CD011567-fig-0098" title="">Analysis 11.1</a>; <a href="./references#CD011567-fig-0099" title="">Analysis 11.2</a>). </p> </section> </section> </section> <section id="CD011567-sec-0425"> <h4 class="title">Reporting Bias</h4> <p>We did not visually inspect funnel plots to assess publication bias as no comparison included at least 10 studies. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011567-sec-0426" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011567-sec-0426"></div> <section id="CD011567-sec-0427"> <h3 class="title" id="CD011567-sec-0427">Summary of main results</h3> <p>By systematically reviewing the comparative efficacy and tolerability of antidepressants and benzodiazepines for panic disorder in adults (see also <a href="./full#CD011567-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011567-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011567-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD011567-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD011567-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD011567-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD011567-tbl-0007">summary of findings Table 7</a>; <a href="./full#CD011567-tbl-0008">summary of findings Table 8</a>) we were able to include 35 studies with 6785 participants, 5365 of which in the arms of interest. However, considering the high number of individual medicines included, very few studies and participants contributed to individual comparisons. Even when antidepressants and benzodiazepines were considered as homogeneous groups, limited data were identified. </p> <p>We found low‐quality evidence that failed to find a difference between antidepressants and benzodiazepines in terms of efficacy measured as response rate. The same finding was observed when serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) were compared with benzodiazepines. However, only two studies with 215 participants contributed to this analysis, so it is not possible to determine whether there is a clinically important difference between antidepressants and benzodiazepines. </p> <p>Analysis of remission rates showed a benefit for benzodiazepines compared to antidepressants, even if the effect was very small and close to no difference. </p> <p>There was no difference between antidepressants and benzodiazepines in terms of efficacy on panic symptoms, frequency of panic attacks, agoraphobia and general anxiety. </p> <p>We observed a difference in favour of antidepressants over benzodiazepines in terms of depressive symptoms (standardised mean difference (SMD) ‐0.14, 95% confidence interval (CI) ‐0.29 to 0.02; participants = 892; studies = 6; I<sup>2</sup> = 7%), although the confidence interval was of borderline statistical significance and the magnitude of effect of uncertain clinical meaning. This difference was still present when the SSRIs were compared with benzodiazepines, but not when TCAs were compared with benzodiazepines. </p> <p>In terms of tolerability, we found evidence suggesting a benefit for benzodiazepines compared to antidepressants when looking at number of dropouts due to any cause (risk ratio (RR) 1.64, 95% CI 1.03 to 2.63; participants = 1449; studies = 7), even if the degree of heterogeneity between studies was substantial (I<sup>2</sup> = 75%) and the wide confidence interval close to no difference. In terms of dropout due to adverse effects, a meta‐analysis of three studies showed that benzodiazepines were better tolerated in comparison with antidepressants as a whole (RR 1.72, 95% CI 1.03 to 2.87; participants = 1002) and with TCAs (RR 2.10, 95% CI 1.13 to 3.93; participants = 848; two studies), but not in comparison with the SSRIs. For the SSRIs, in terms of participants who dropped out due to any cause, we found a difference in favour of benzodiazepines, although only one study contributed to this analysis (RR 1.71, 95% CI 1.03 to 2.84; participants = 154). Only one study provided information on the number of patients experiencing adverse effect, showing no difference between antidepressants and benzodiazepines. </p> <p>When looking at the comparisons between antidepressants, a meta‐analysis of four studies confirmed a benefit for SSRIs compared to TCAs in terms of number of patients experiencing adverse effects (RR 1.29, 95% CI 1.02 to 1.65; participants = 489; studies = 4; I<sup>2</sup> = 78%), although the magnitude of effect is small. Low‐quality evidence suggests that there is no significant difference between the class of TCAs and the class of SSRIs in terms of response rate (four studies, 438 participants) and dropout due to any reason (seven studies, 928 participants). </p> <p>When looking at the comparison between individual benzodiazepines, the available evidence, focused on a small number of medicines (alprazolam, clonazepam and diazepam), suggests that there is no significant difference between individual benzodiazepines in terms of response rate and dropout due to any reason. </p> </section> <section id="CD011567-sec-0428"> <h3 class="title" id="CD011567-sec-0428">Overall completeness and applicability of evidence</h3> <p>The identified studies are not sufficient to comprehensively address the objectives of the present review. The majority of studies enrolled a very small number of participants and did not provide data for all the outcomes specified in the protocol. For these reasons, most of the analyses were underpowered and this relevantly limits the overall completeness of evidence. For the primary efficacy outcome, pooling of results was possible in two studies, and for many secondary outcomes data were too sparse to allow reasonable conclusions to be drawn. For most comparisons, confidence intervals were very wide and could not rule out the possibility of clinically relevant differences. Therefore, the main question of whether there are differences between antidepressants and benzodiazepines, and between individual antidepressants and individual benzodiazepines, remains unanswered. This situation will unlikely change in the future as recent studies no longer focus on the efficacy of benzodiazepines. </p> <p>Only short‐term data on acceptability and adverse effects of antidepressants and benzodiazepines were available. Clinically, this is a major limitation as long‐term use of benzodiazepines is controversial due to concerns about adverse psychological and physical effects, physical dependence and withdrawal. Similar concerns have been raised for long‐term exposure to antidepressants, in particular the SSRIs. </p> <p>In terms of applicability, considering the very low number of participants, it is difficult to assume that this population could reflect the complexity of people with panic disorder from a 'real world' setting. </p> </section> <section id="CD011567-sec-0429"> <h3 class="title" id="CD011567-sec-0429">Quality of the evidence</h3> <p>The overall methodological quality of the included studies was poor. No study showed an overall low risk of bias. The majority of studies showed mixed features, with a large prevalence of an unclear risk of bias in different domains, which seems to reflect the lack of exhaustive reporting rather than a clear evidence of bias. This is consistent with the finding of a general sub‐optimal reporting of randomised controlled trials (RCTs) in medical journals, despite the large diffusion of instruments designed to help transparent reporting, such as the CONSORT (Consolidated Standards of Reporting Trials) statement. </p> <p>The GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology allows the provision of outcome‐specific information concerning the overall quality of evidence. In general, the confidence in the estimate of effect appeared to be from 'very low' to 'moderate' for most of the outcomes assessed. This judgement is primarily due to limitations in the included studies (high dropout rates), imprecision (wide confidence intervals) and inconsistency (heterogeneity between studies results). In accordance with that, any estimate of effect should be considered very uncertain, and further research is very likely to change the estimate of effect and thus the degree of confidence for its applicability in routine clinical practice. </p> </section> <section id="CD011567-sec-0430"> <h3 class="title" id="CD011567-sec-0430">Potential biases in the review process</h3> <p>Several possible limitations of this review should be highlighted. Some limitations are intrinsically related to the actual process of retrieving, collecting, selecting and extracting data. In order to reduce the potential bias of this complex process two authors independently worked on each of these steps. It has been highlighted that two independent extractors are overall more reliable than the extraction performed by a single author followed by verification by a second author (<a href="./references#CD011567-bbs2-0098" title="BuscemiN , HartlingL , VandermeerB , TjosvoldL , KlassenTP . Single data extraction generated more errors than double data extraction in systematic reviews. Journal of Clinical Epidemiology2006;59(7):697‐703. ">Buscemi 2006</a>). We applied the same process for the 'Risk of bias' assessment. Furthermore, disagreements were discussed with a third author, who also checked the data extracted from RCTs when the analysis was performed. Another relevant problem concerns the 'systematic' nature of the search. We chose to include only randomised trials as they provide the strongest level of evidence available. In this type of review there is some risk of publication bias, which means that negative studies may not have been published. Although the search was thorough, it is possible that unpublished studies have not been identified, considering that there are no shared procedures to perform this kind of search. The impact of unpublished literature on the results of this review is uncertain, however it is expected that the analysis of only published literature would lead to overestimation of the efficacy of a given intervention. We did not check this formally with a funnel plot analysis, as less than 10 studies contributed to any analyses, thus making the funnel plot methodology less informative. </p> <p>It is important to bear in mind that some of the included studies were funded by the pharmaceutical industry, and this may again introduce an overestimation of the efficacy of interventions. </p> </section> <section id="CD011567-sec-0431"> <h3 class="title" id="CD011567-sec-0431">Agreements and disagreements with other studies or reviews</h3> <p>The results of this systematic review are not completely in line with respect to previous reviews and meta‐analyses. Offidani and colleagues, who compared benzodiazepines and antidepressants in panic disorder, found that benzodiazepines were more effective than TCAs in terms of response to treatment (<a href="./references#CD011567-bbs2-0122" title="OffidaniE , GuidiJ , TombaE , FavaGA . Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta‐analysis. Psychotherapy and Psychosomatics2013;82:355‐62. ">Offidani 2013</a>). However, the Offidani review included a single‐blind study, three reports that are part of the same multicentre trial (<a href="./references#CD011567-bbs2-0006" title="AlbusM , LecrubierY , MaierW , BullerR , RosenbergR , HippiusH . Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatrica Scandinavica1990;82(5):359‐65. AlbusM , MaierW , SheraD , BechP . Consistencies and discrepancies in self‐ and observer‐rated anxiety scales. A comparison between the self‐ and observer‐rated Marks‐Sheehan scales. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):96‐102. AnderschS , HansonL , HallstromT . Panic disorder: a five‐year follow‐up study in 52 patients. European Journal of Psychiatry1997;11(3):145‐55. AnderschS , HettaJ . A 15‐year follow‐up study of patients with panic disorder. European Psychiatry2003;18(8):401‐08. AnderschS , RosenbergNK , KullingsjöH , OttossonJO , BechP , Bruun‐HansenJ , et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatrica Scandinavica. Supplementum1991;365:18‐27. BerlangaC , CanettiA , ChavezE , De LaFuenteR , delCarmen LaraM , LeonC , et al. Pharmacologic treatment of panic disorders: Comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study [Tratamiento farmacologico de las crisis de angustia Reporte comparativo de la eficacia y seguridad del alprazolam y la imipramina en un estudio controlado]. Salud Mental1991;14(1):1‐5. BullerR , MaierW , GoldenbergIM , LavoriPW , BenkertO . Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross‐National Collaborative Panic Study. European Archives of Psychiatry and Clinical Neuroscience1991;240(3):163‐8. CassanoGB , ToniC , PetraccaA , DeltitoJ , BenkertO , CurtisG , et al. Adverse effects associated with the short‐term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology1994;4(1):47‐53. Cross National Collaborative Panic Study Second Phase Investigators. Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. British Journal of Psychiatry1992;160:191‐202. CurtisGC , MassanaJ , UdinaC , AyusoJL , CassanoGB , PerugiG . Maintenance drug therapy of panic disorder. Journal of Psychiatry Research1993;27(Suppl 1):127‐42. DeltitoJA , ArgyleN , BullerR , NutzingerD , OttossonJO , BrandonS , et al. The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(2):120‐9. DeltitoJA , ArgyleN , KlermanGL . Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Journal of Clinical Psychiatry1991;52(3):121‐7. GreenMA , CurtisGC . Personality disorders in panic patients: Response to termination of antipanic medication. Journal of Personality Disorders1988;2(4):303‐14. KatschnigH , AmeringM , StolkJM , KlermanGL , BallengerJC , BriggsA , et al. Long‐term follow‐up after a drug trial for panic disorder. British Journal of Psychiatry1995;167(4):487‐94. KlermanGL . Depression and panic anxiety: the effect of depressive co‐morbidity on response to drug treatment of patients with panic disorder and agoraphobia. Journal of Psychiatric Research1990;24(Suppl 2):27‐41. KlermanGL , ColemanJH , PurpuraRP . The design and conduct of the Upjohn Cross‐National Collaborative Panic Study. Psychopharmacology Bulletin1986;22(1):59‐64. LavoriPW , DawsonR , SheraD . A multiple imputation strategy for clinical trials with truncation of patient data. Statistics in Medicine1995;14(17):1913‐25. LeónCA , DeArangoMV , ArevaloW , CalvoA , MontoyaA , LeónA . Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia [Comparacion del efecto del alprazolam, la imipramina y placebo en el tratamiento del trastorno de panico en Cali, Colombia]. Acta Psiquiatrica y Psicologica de America Latina1990;36(1‐2):59‐72. MaierW , AlbusM , BullerR , NutzingerD , SheraD , BechP . Self‐ and observer assessment in anxiolytic drug trials: a comparison of their validity. European Archives of Psychiatry and Clinical Neuroscience1990;240(2):103‐8. MaierW , RothSM , ArgyleN , BullerR , LavoriP , BrandonS , et al. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?. European Archives of Psychiatry and Clinical Neuroscience1991;241(3):151‐8. MaierWA , RothM , BullerR , ArgyleN , RosenbergR , SydneyB , et al. Agoraphobia in panic disorder: An indicator of the severity of panic disorder or a distinct diagnostic entity?. Psychiatric Annals1991;21(6):374‐81. RifkinA . The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry1991;32(6):559‐60. RosenbergNK , MellergårdM , RosenbergR , BeckP , OttossonJO . Characteristics of panic disorder patients responding to placebo. Acta Psychiatrica Scandinavica Supplementum1991;365:33‐8. RosenbergR , BechP , MellergårdM , OttossonJO . Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response. Acta Psychiatrica Scandinavica. Supplementum1991;365:46‐52. SwobodaH , AmeringM , WindhaberJ , KatschnigH . The long‐term course of panic disorder‐‐an 11 year follow‐up. Journal of Anxiety Disorders2003;17(2):223‐32. ">CNCPS 1992</a>), and studies with participants with a primary diagnosis other than panic disorder. Further, different definitions of response rate were applied. </p> <p>Based on data from our review, the only evidence in terms of efficacy that favours benzodiazepines is about remission rates. We may argue that this outcome is usually measured in a more standard way than response rates, looking at patients who are free from panic attacks. In these terms, benzodiazepines may have the edge over antidepressants. </p> <p>Further, we found that benzodiazepines are better tolerated than antidepressants; for example, in terms of participants who dropped out due to any cause, we found a difference in favour of benzodiazepines over antidepressants, and this difference is more significant in the comparison with SSRIs (that were not included in the previous review by Offidani). However, it should be recognised that short‐term randomised studies can not provide a comprehensive assessment of the harmful consequences associated with drug treatment, including long‐term exposure. This holds particularly true for benzodiazepines, as most concerns refer to long‐term exposure to these agents. The role of benzodiazepines is still controversial; according to NICE guidelines benzodiazepines are not recommended for panic disorder, precisely because of less favourable long‐term outcomes (<a href="./references#CD011567-bbs2-0121" title="National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: Management in primary, secondary and community care. NICE guidelines [CG113]. Published date: January 2011. Available from http://www.nice.org.uk/guidance/cg113/chapter/guidance. ">NICE 2011</a>). However, some authors claim for a reconsideration of the role of benzodiazepines, suggesting that they can be effective and safe in the long‐term use for anxiety disorders, including panic disorder (<a href="./references#CD011567-bbs2-0127" title="StarcevicV . The reappraisal of benzodiazepines in the treatment of anxiety and related disorders. Expert Review of Neurotherapeutics2014;14(11):1275‐1286. ">Starcevic 2014</a>). </p> <p>Bakker and colleagues, who carried out a systematic review comparing TCAs and SSRIs in people with panic disorder, concluded that TCAs and SSRI were equally effective (<a href="./references#CD011567-bbs2-0087" title="BakkerA , vanBalkomAJ , SpinhovenP . SSRIs vs. TCAs in the treatment of panic disorder: a meta‐analysis. Acta Psychiatrica Scandinavica2002;106:163‐7. ">Bakker 2002</a>). Similarly to Bakker and colleagues, we did not find any difference between TCAs and SSRI in terms of efficacy, but we note that a power problem might limit the interpretation of this finding. For all efficacy outcomes, the confidence intervals were wide and could not exclude the possibility of a type‐II error, namely not detecting a difference which might be real because too few participants contributed to the analysis. However, we agree with Bakker and colleagues in noting that there are no strong pre‐defined reasons to hypothesise that these two classes of antidepressants should differ in terms of efficacy in panic disorder. We argue that only adding the result of this systematic review to the other ongoing Cochrane reviews in patients with panic disorder will help rank treatments in terms of efficacy, possibly increasing statistical power by means of indirect comparisons. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011567-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011567-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011567-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011567-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antidepressants versus benzodiazepines, outcome: 1.1 Failure to respond." data-id="CD011567-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antidepressants versus benzodiazepines, outcome: 1.1 Failure to respond. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antidepressants versus benzodiazepines, outcome: 1.2 Total number of dropouts." data-id="CD011567-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antidepressants versus benzodiazepines, outcome: 1.2 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressants versus benzodiazepines, Outcome 1 Failure to respond." data-id="CD011567-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Antidepressants versus benzodiazepines, Outcome 1 Failure to respond.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressants versus benzodiazepines, Outcome 2 Total number of dropouts." data-id="CD011567-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Antidepressants versus benzodiazepines, Outcome 2 Total number of dropouts.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressants versus benzodiazepines, Outcome 3 Failure to remit." data-id="CD011567-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Antidepressants versus benzodiazepines, Outcome 3 Failure to remit.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressants versus benzodiazepines, Outcome 4 Panic symptoms ‐ endpoint score." data-id="CD011567-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Antidepressants versus benzodiazepines, Outcome 4 Panic symptoms ‐ endpoint score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressants versus benzodiazepines, Outcome 5 Panic symptoms ‐ mean change." data-id="CD011567-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Antidepressants versus benzodiazepines, Outcome 5 Panic symptoms ‐ mean change. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressants versus benzodiazepines, Outcome 6 Frequency of panic attacks." data-id="CD011567-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Antidepressants versus benzodiazepines, Outcome 6 Frequency of panic attacks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressants versus benzodiazepines, Outcome 7 Agoraphobia." data-id="CD011567-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Antidepressants versus benzodiazepines, Outcome 7 Agoraphobia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressants versus benzodiazepines, Outcome 8 General anxiety." data-id="CD011567-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Antidepressants versus benzodiazepines, Outcome 8 General anxiety.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressants versus benzodiazepines, Outcome 9 Depression." data-id="CD011567-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Antidepressants versus benzodiazepines, Outcome 9 Depression.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressants versus benzodiazepines, Outcome 10 Social functioning." data-id="CD011567-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Antidepressants versus benzodiazepines, Outcome 10 Social functioning.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressants versus benzodiazepines, Outcome 14 Number of dropouts due to adverse effects." data-id="CD011567-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Antidepressants versus benzodiazepines, Outcome 14 Number of dropouts due to adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressants versus benzodiazepines, Outcome 15 Number of patients experiencing at least one adverse effect." data-id="CD011567-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Antidepressants versus benzodiazepines, Outcome 15 Number of patients experiencing at least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TCAs versus benzodiazepines, Outcome 1 Failure to respond." data-id="CD011567-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 TCAs versus benzodiazepines, Outcome 1 Failure to respond.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TCAs versus benzodiazepines, Outcome 2 Total number of dropouts." data-id="CD011567-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 TCAs versus benzodiazepines, Outcome 2 Total number of dropouts.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TCAs versus benzodiazepines, Outcome 3 Failure to remit." data-id="CD011567-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 TCAs versus benzodiazepines, Outcome 3 Failure to remit.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TCAs versus benzodiazepines, Outcome 4 Panic symptoms ‐ endpoint score." data-id="CD011567-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 TCAs versus benzodiazepines, Outcome 4 Panic symptoms ‐ endpoint score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TCAs versus benzodiazepines, Outcome 5 Panic symptoms ‐ mean change." data-id="CD011567-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 TCAs versus benzodiazepines, Outcome 5 Panic symptoms ‐ mean change.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TCAs versus benzodiazepines, Outcome 6 Frequency of panic attacks." data-id="CD011567-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 TCAs versus benzodiazepines, Outcome 6 Frequency of panic attacks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TCAs versus benzodiazepines, Outcome 7 Agoraphobia." data-id="CD011567-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 TCAs versus benzodiazepines, Outcome 7 Agoraphobia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TCAs versus benzodiazepines, Outcome 8 General anxiety." data-id="CD011567-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 TCAs versus benzodiazepines, Outcome 8 General anxiety.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TCAs versus benzodiazepines, Outcome 9 Depression." data-id="CD011567-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 TCAs versus benzodiazepines, Outcome 9 Depression.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TCAs versus benzodiazepines, Outcome 10 Social functioning." data-id="CD011567-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 TCAs versus benzodiazepines, Outcome 10 Social functioning.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TCAs versus benzodiazepines, Outcome 14 Number of dropouts due to adverse effects." data-id="CD011567-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 TCAs versus benzodiazepines, Outcome 14 Number of dropouts due to adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 SSRIs versus benzodiazepines, Outcome 1 Failure to respond." data-id="CD011567-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 SSRIs versus benzodiazepines, Outcome 1 Failure to respond.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 SSRIs versus benzodiazepines, Outcome 2 Total number of dropouts." data-id="CD011567-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 SSRIs versus benzodiazepines, Outcome 2 Total number of dropouts.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 SSRIs versus benzodiazepines, Outcome 3 Failure to remit." data-id="CD011567-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 SSRIs versus benzodiazepines, Outcome 3 Failure to remit.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 SSRIs versus benzodiazepines, Outcome 4 Panic symptoms." data-id="CD011567-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 SSRIs versus benzodiazepines, Outcome 4 Panic symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 SSRIs versus benzodiazepines, Outcome 5 Frequency of panic attacks." data-id="CD011567-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 SSRIs versus benzodiazepines, Outcome 5 Frequency of panic attacks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 SSRIs versus benzodiazepines, Outcome 6 Agoraphobia." data-id="CD011567-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 SSRIs versus benzodiazepines, Outcome 6 Agoraphobia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 SSRIs versus benzodiazepines, Outcome 7 General anxiety." data-id="CD011567-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 SSRIs versus benzodiazepines, Outcome 7 General anxiety.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 SSRIs versus benzodiazepines, Outcome 8 Depression." data-id="CD011567-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 SSRIs versus benzodiazepines, Outcome 8 Depression.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 SSRIs versus benzodiazepines, Outcome 9 Social functioning." data-id="CD011567-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 SSRIs versus benzodiazepines, Outcome 9 Social functioning.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 SSRIs versus benzodiazepines, Outcome 13 Number of dropouts due to adverse effects." data-id="CD011567-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 SSRIs versus benzodiazepines, Outcome 13 Number of dropouts due to adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 SSRIs versus benzodiazepines, Outcome 14 Number of patients experiencing at least one adverse effect." data-id="CD011567-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 SSRIs versus benzodiazepines, Outcome 14 Number of patients experiencing at least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCAs versus SSRIs, Outcome 1 Failure to respond." data-id="CD011567-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 TCAs versus SSRIs, Outcome 1 Failure to respond.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCAs versus SSRIs, Outcome 2 Total number of dropouts." data-id="CD011567-fig-0041" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 TCAs versus SSRIs, Outcome 2 Total number of dropouts.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCAs versus SSRIs, Outcome 3 Failure to remit." data-id="CD011567-fig-0042" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 TCAs versus SSRIs, Outcome 3 Failure to remit.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCAs versus SSRIs, Outcome 4 Panic symptoms." data-id="CD011567-fig-0043" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 TCAs versus SSRIs, Outcome 4 Panic symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCAs versus SSRIs, Outcome 5 Frequency of panic attacks." data-id="CD011567-fig-0044" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 TCAs versus SSRIs, Outcome 5 Frequency of panic attacks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCAs versus SSRIs, Outcome 6 Agoraphobia." data-id="CD011567-fig-0045" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 TCAs versus SSRIs, Outcome 6 Agoraphobia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCAs versus SSRIs, Outcome 7 General anxiety ‐ endpoint score." data-id="CD011567-fig-0046" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 TCAs versus SSRIs, Outcome 7 General anxiety ‐ endpoint score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCAs versus SSRIs, Outcome 8 General anxiety ‐ mean change." data-id="CD011567-fig-0047" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 TCAs versus SSRIs, Outcome 8 General anxiety ‐ mean change.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCAs versus SSRIs, Outcome 9 Depression ‐ endpoint score." data-id="CD011567-fig-0048" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 TCAs versus SSRIs, Outcome 9 Depression ‐ endpoint score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCAs versus SSRIs, Outcome 10 Depression ‐ mean change." data-id="CD011567-fig-0049" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 TCAs versus SSRIs, Outcome 10 Depression ‐ mean change.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-004-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-004-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCAs versus SSRIs, Outcome 15 Number of dropouts due to adverse effects." data-id="CD011567-fig-0050" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 TCAs versus SSRIs, Outcome 15 Number of dropouts due to adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-004-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-004-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCAs versus SSRIs, Outcome 16 Number of patients experiencing at least one adverse effect." data-id="CD011567-fig-0051" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 TCAs versus SSRIs, Outcome 16 Number of patients experiencing at least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-004-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 TCAs versus MAOIs, Outcome 1 Failure to respond." data-id="CD011567-fig-0052" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 TCAs versus MAOIs, Outcome 1 Failure to respond.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 TCAs versus MAOIs, Outcome 2 Total number of dropouts." data-id="CD011567-fig-0053" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 TCAs versus MAOIs, Outcome 2 Total number of dropouts.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 TCAs versus MAOIs, Outcome 4 Panic symptoms." data-id="CD011567-fig-0054" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 TCAs versus MAOIs, Outcome 4 Panic symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 TCAs versus MAOIs, Outcome 5 Frequency of panic attacks." data-id="CD011567-fig-0055" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 TCAs versus MAOIs, Outcome 5 Frequency of panic attacks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 TCAs versus MAOIs, Outcome 7 General anxiety." data-id="CD011567-fig-0056" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 TCAs versus MAOIs, Outcome 7 General anxiety.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 TCAs versus MAOIs, Outcome 8 Depression." data-id="CD011567-fig-0057" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 TCAs versus MAOIs, Outcome 8 Depression.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-005-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-005-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 TCAs versus MAOIs, Outcome 13 Number of dropouts due to adverse effects." data-id="CD011567-fig-0058" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-005-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5 TCAs versus MAOIs, Outcome 13 Number of dropouts due to adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-005-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-005-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-005-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 TCAs versus MAOIs, Outcome 14 Number of patients experiencing at least one adverse effect." data-id="CD011567-fig-0059" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-005-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5 TCAs versus MAOIs, Outcome 14 Number of patients experiencing at least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-005-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 SSRIs versus MAOIs, Outcome 1 Failure to respond." data-id="CD011567-fig-0060" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 SSRIs versus MAOIs, Outcome 1 Failure to respond.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 SSRIs versus MAOIs, Outcome 2 Total number of dropouts." data-id="CD011567-fig-0061" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 SSRIs versus MAOIs, Outcome 2 Total number of dropouts.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 SSRIs versus MAOIs, Outcome 3 Failure to remit." data-id="CD011567-fig-0062" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 SSRIs versus MAOIs, Outcome 3 Failure to remit.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 SSRIs versus MAOIs, Outcome 6 Agoraphobia." data-id="CD011567-fig-0063" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 SSRIs versus MAOIs, Outcome 6 Agoraphobia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 SSRIs versus MAOIs, Outcome 7 General anxiety." data-id="CD011567-fig-0064" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 SSRIs versus MAOIs, Outcome 7 General anxiety.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-006-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-006-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 SSRIs versus MAOIs, Outcome 13 Number of dropouts due to adverse effects." data-id="CD011567-fig-0065" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-006-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6 SSRIs versus MAOIs, Outcome 13 Number of dropouts due to adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-006-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-006-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-006-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 SSRIs versus MAOIs, Outcome 14 Number of patients experiencing at least one adverse effect." data-id="CD011567-fig-0066" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-006-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6 SSRIs versus MAOIs, Outcome 14 Number of patients experiencing at least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-006-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 SSRIs versus SNRIs, Outcome 1 Failure to respond." data-id="CD011567-fig-0067" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 SSRIs versus SNRIs, Outcome 1 Failure to respond.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 SSRIs versus SNRIs, Outcome 2 Total number of dropouts." data-id="CD011567-fig-0068" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 SSRIs versus SNRIs, Outcome 2 Total number of dropouts.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 SSRIs versus SNRIs, Outcome 3 Failure to remit." data-id="CD011567-fig-0069" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 SSRIs versus SNRIs, Outcome 3 Failure to remit.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 SSRIs versus SNRIs, Outcome 4 Panic symptoms." data-id="CD011567-fig-0070" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 SSRIs versus SNRIs, Outcome 4 Panic symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 SSRIs versus SNRIs, Outcome 6 Agoraphobia." data-id="CD011567-fig-0071" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 SSRIs versus SNRIs, Outcome 6 Agoraphobia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-007-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-007-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 SSRIs versus SNRIs, Outcome 7 General anxiety." data-id="CD011567-fig-0072" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 SSRIs versus SNRIs, Outcome 7 General anxiety.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-007-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-007-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 SSRIs versus SNRIs, Outcome 9 Social functioning." data-id="CD011567-fig-0073" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7 SSRIs versus SNRIs, Outcome 9 Social functioning.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-007-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-007-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 SSRIs versus SNRIs, Outcome 10 Quality of life." data-id="CD011567-fig-0074" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.10</div> <div class="figure-caption"> <p>Comparison 7 SSRIs versus SNRIs, Outcome 10 Quality of life.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-007-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-007-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 SSRIs versus SNRIs, Outcome 13 Number of dropouts due to adverse effects." data-id="CD011567-fig-0075" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.13</div> <div class="figure-caption"> <p>Comparison 7 SSRIs versus SNRIs, Outcome 13 Number of dropouts due to adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-007-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-007-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 SSRIs versus SNRIs, Outcome 14 Number of patients experiencing at least one adverse effect." data-id="CD011567-fig-0076" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.14</div> <div class="figure-caption"> <p>Comparison 7 SSRIs versus SNRIs, Outcome 14 Number of patients experiencing at least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-007-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 SSRIs versus NaSSAs, Outcome 2 Total number of dropouts." data-id="CD011567-fig-0077" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 SSRIs versus NaSSAs, Outcome 2 Total number of dropouts.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 SSRIs versus NaSSAs, Outcome 4 Panic symptoms." data-id="CD011567-fig-0078" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 SSRIs versus NaSSAs, Outcome 4 Panic symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 SSRIs versus NaSSAs, Outcome 7 General anxiety." data-id="CD011567-fig-0079" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 SSRIs versus NaSSAs, Outcome 7 General anxiety.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-008-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-008-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 SSRIs versus NaSSAs, Outcome 13 Number of dropouts due to adverse effects." data-id="CD011567-fig-0080" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-008-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.13</div> <div class="figure-caption"> <p>Comparison 8 SSRIs versus NaSSAs, Outcome 13 Number of dropouts due to adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-008-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 SSRIs versus Other Antidepressants, Outcome 1 Failure to respond." data-id="CD011567-fig-0081" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 SSRIs versus Other Antidepressants, Outcome 1 Failure to respond.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 SSRIs versus Other Antidepressants, Outcome 2 Total number of dropouts." data-id="CD011567-fig-0082" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 SSRIs versus Other Antidepressants, Outcome 2 Total number of dropouts.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-009-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-009-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 SSRIs versus Other Antidepressants, Outcome 6 Agoraphobia." data-id="CD011567-fig-0083" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-009-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9 SSRIs versus Other Antidepressants, Outcome 6 Agoraphobia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-009-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-009-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-009-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 SSRIs versus Other Antidepressants, Outcome 7 General anxiety." data-id="CD011567-fig-0084" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-009-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9 SSRIs versus Other Antidepressants, Outcome 7 General anxiety.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-009-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-009-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-009-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 SSRIs versus Other Antidepressants, Outcome 8 Depression." data-id="CD011567-fig-0085" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-009-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9 SSRIs versus Other Antidepressants, Outcome 8 Depression.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-009-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-009-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-009-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 SSRIs versus Other Antidepressants, Outcome 13 Number of dropouts due to adverse effects." data-id="CD011567-fig-0086" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-009-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.13</div> <div class="figure-caption"> <p>Comparison 9 SSRIs versus Other Antidepressants, Outcome 13 Number of dropouts due to adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-009-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 1 Failure to respond." data-id="CD011567-fig-0087" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 1 Failure to respond. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 2 Total number of dropouts." data-id="CD011567-fig-0088" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 2 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 3 Failure to remit." data-id="CD011567-fig-0089" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 3 Failure to remit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 4 Panic symptoms." data-id="CD011567-fig-0090" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 4 Panic symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-010-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-010-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 5 Frequency of panic attacks." data-id="CD011567-fig-0091" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 5 Frequency of panic attacks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-010-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-010-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 6 Agoraphobia." data-id="CD011567-fig-0092" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 6 Agoraphobia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-010-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-010-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 7 General anxiety." data-id="CD011567-fig-0093" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.7</div> <div class="figure-caption"> <p>Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 7 General anxiety. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-010-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-010-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 8 Depression." data-id="CD011567-fig-0094" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.8</div> <div class="figure-caption"> <p>Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 8 Depression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-010-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-010-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 10 Quality of life." data-id="CD011567-fig-0095" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.10</div> <div class="figure-caption"> <p>Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 10 Quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-010-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-010-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 13 Number of dropouts due to adverse effects." data-id="CD011567-fig-0096" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.13</div> <div class="figure-caption"> <p>Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 13 Number of dropouts due to adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-010-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-010-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 14 Number of patients experiencing at least one adverse effect." data-id="CD011567-fig-0097" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.14</div> <div class="figure-caption"> <p>Comparison 10 Individual Antidepressants versus another antidepressant within the same class, Outcome 14 Number of patients experiencing at least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-010-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 1 Failure to respond." data-id="CD011567-fig-0098" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 1 Failure to respond. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 2 Total number of dropouts." data-id="CD011567-fig-0099" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 2 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 3 Failure to remit." data-id="CD011567-fig-0100" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 3 Failure to remit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-011-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-011-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 4 Panic symptoms." data-id="CD011567-fig-0101" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 4 Panic symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-011-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-011-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 5 Frequency of panic attacks." data-id="CD011567-fig-0102" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 5 Frequency of panic attacks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-011-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-011-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 7 General anxiety." data-id="CD011567-fig-0103" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.7</div> <div class="figure-caption"> <p>Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 7 General anxiety. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-011-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-011-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 8 Depression." data-id="CD011567-fig-0104" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.8</div> <div class="figure-caption"> <p>Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 8 Depression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-011-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-011-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 9 Social functioning." data-id="CD011567-fig-0105" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.9</div> <div class="figure-caption"> <p>Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 9 Social functioning. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-011-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-011-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 10 Quality of life." data-id="CD011567-fig-0106" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.10</div> <div class="figure-caption"> <p>Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 10 Quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-011-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-011-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 13 Number of dropouts due to adverse effects." data-id="CD011567-fig-0107" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.13</div> <div class="figure-caption"> <p>Comparison 11 Individual benzodiazepines versus another benzodiazepine, Outcome 13 Number of dropouts due to adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-011-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 High risk of bias excluded ‐ Antidepressants versus benzodiazepines, Outcome 1 Total number of dropouts." data-id="CD011567-fig-0108" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 High risk of bias excluded ‐ Antidepressants versus benzodiazepines, Outcome 1 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 High risk of bias excluded ‐ TCAs versus benzodiazepines, Outcome 1 Total number of dropouts." data-id="CD011567-fig-0109" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 High risk of bias excluded ‐ TCAs versus benzodiazepines, Outcome 1 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 High risk of bias excluded ‐ TCAs versus SSRIs, Outcome 1 Total number of dropouts." data-id="CD011567-fig-0110" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 High risk of bias excluded ‐ TCAs versus SSRIs, Outcome 1 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 High risk of bias excluded ‐ TCAs versus MAOIs, Outcome 1 Total number of dropouts." data-id="CD011567-fig-0111" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 High risk of bias excluded ‐ TCAs versus MAOIs, Outcome 1 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-016-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-016-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 High risk of bias excluded ‐ SSRIs versus MAOIs, Outcome 1 Failure to respond." data-id="CD011567-fig-0112" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-016-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 High risk of bias excluded ‐ SSRIs versus MAOIs, Outcome 1 Failure to respond. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-016-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-017-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-017-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 High dropout rates excluded ‐ Antidepressants versus benzodiazepines, Outcome 1 Total number of dropouts." data-id="CD011567-fig-0113" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-017-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 High dropout rates excluded ‐ Antidepressants versus benzodiazepines, Outcome 1 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-017-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-018-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-018-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 High dropout rates excluded ‐ TCAs versus benzodiazepines, Outcome 1 Total number of dropouts." data-id="CD011567-fig-0114" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-018-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18 High dropout rates excluded ‐ TCAs versus benzodiazepines, Outcome 1 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-018-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-019-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-019-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 High dropout rates excluded ‐ TCAs versus SSRIs, Outcome 1 Failure to respond." data-id="CD011567-fig-0115" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-019-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19 High dropout rates excluded ‐ TCAs versus SSRIs, Outcome 1 Failure to respond. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-019-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-019-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-019-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 High dropout rates excluded ‐ TCAs versus SSRIs, Outcome 2 Total number of dropouts." data-id="CD011567-fig-0116" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-019-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19 High dropout rates excluded ‐ TCAs versus SSRIs, Outcome 2 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-019-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-020-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-020-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Funded excluded ‐ Antidepressants versus benzodiazepines, Outcome 1 Total number of dropouts." data-id="CD011567-fig-0117" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-020-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20 Funded excluded ‐ Antidepressants versus benzodiazepines, Outcome 1 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-020-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-021-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-021-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Funded excluded ‐ TCAs versus benzodiazepines, Outcome 1 Total number of dropouts." data-id="CD011567-fig-0118" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-021-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21 Funded excluded ‐ TCAs versus benzodiazepines, Outcome 1 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-021-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-022-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-022-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Funded excluded ‐ TCAs versus SSRIs, Outcome 1 Failure to respond." data-id="CD011567-fig-0119" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-022-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22 Funded excluded ‐ TCAs versus SSRIs, Outcome 1 Failure to respond.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-022-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-022-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-022-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Funded excluded ‐ TCAs versus SSRIs, Outcome 2 Total number of dropouts." data-id="CD011567-fig-0120" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-022-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.2</div> <div class="figure-caption"> <p>Comparison 22 Funded excluded ‐ TCAs versus SSRIs, Outcome 2 Total number of dropouts.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-022-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-023-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-023-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Funded excluded ‐ SSRIs versus MAOIs, Outcome 1 Failure to respond." data-id="CD011567-fig-0121" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-023-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23 Funded excluded ‐ SSRIs versus MAOIs, Outcome 1 Failure to respond.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-023-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-024-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-024-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Psychiatric comorbidities excluded ‐ Antidepressants versus benzodiazepines, Outcome 1 Failure to respond." data-id="CD011567-fig-0122" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-024-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.1</div> <div class="figure-caption"> <p>Comparison 24 Psychiatric comorbidities excluded ‐ Antidepressants versus benzodiazepines, Outcome 1 Failure to respond. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-024-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-024-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-024-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Psychiatric comorbidities excluded ‐ Antidepressants versus benzodiazepines, Outcome 2 Total number of dropouts." data-id="CD011567-fig-0123" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-024-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.2</div> <div class="figure-caption"> <p>Comparison 24 Psychiatric comorbidities excluded ‐ Antidepressants versus benzodiazepines, Outcome 2 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-024-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-025-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-025-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 25 Psychiatric comorbidities excluded ‐ TCAs versus benzodiazepines, Outcome 1 Total number of dropouts." data-id="CD011567-fig-0124" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-025-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.1</div> <div class="figure-caption"> <p>Comparison 25 Psychiatric comorbidities excluded ‐ TCAs versus benzodiazepines, Outcome 1 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-025-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-026-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-026-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 Psychiatric comorbidities excluded ‐ TCAs versus SSRIs, Outcome 1 Failure to respond." data-id="CD011567-fig-0125" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-026-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.1</div> <div class="figure-caption"> <p>Comparison 26 Psychiatric comorbidities excluded ‐ TCAs versus SSRIs, Outcome 1 Failure to respond. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-026-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-026-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-026-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 Psychiatric comorbidities excluded ‐ TCAs versus SSRIs, Outcome 2 Total number of dropouts." data-id="CD011567-fig-0126" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-026-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.2</div> <div class="figure-caption"> <p>Comparison 26 Psychiatric comorbidities excluded ‐ TCAs versus SSRIs, Outcome 2 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-026-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-027-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-027-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 27 Psychiatric comorbidities excluded ‐ Individual antidepressants versus individual antidepressants (within the same class), Outcome 1 Failure to respond." data-id="CD011567-fig-0127" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-027-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.1</div> <div class="figure-caption"> <p>Comparison 27 Psychiatric comorbidities excluded ‐ Individual antidepressants versus individual antidepressants (within the same class), Outcome 1 Failure to respond. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-027-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-027-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-027-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 27 Psychiatric comorbidities excluded ‐ Individual antidepressants versus individual antidepressants (within the same class), Outcome 2 Total number of dropouts." data-id="CD011567-fig-0128" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-027-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.2</div> <div class="figure-caption"> <p>Comparison 27 Psychiatric comorbidities excluded ‐ Individual antidepressants versus individual antidepressants (within the same class), Outcome 2 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-027-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-028-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-028-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 28 Psychiatric comorbidities excluded ‐ Individual benzodiazepines versus individual benzodiazepines, Outcome 1 Total number of dropouts." data-id="CD011567-fig-0129" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-028-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.1</div> <div class="figure-caption"> <p>Comparison 28 Psychiatric comorbidities excluded ‐ Individual benzodiazepines versus individual benzodiazepines, Outcome 1 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-028-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-029-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-029-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 29 Imputation excluded ‐ TCAs versus SSRIs, Outcome 1 Failure to respond." data-id="CD011567-fig-0130" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-029-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.1</div> <div class="figure-caption"> <p>Comparison 29 Imputation excluded ‐ TCAs versus SSRIs, Outcome 1 Failure to respond.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-029-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-029-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-029-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 29 Imputation excluded ‐ TCAs versus SSRIs, Outcome 2 Total number of dropouts." data-id="CD011567-fig-0131" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-029-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.2</div> <div class="figure-caption"> <p>Comparison 29 Imputation excluded ‐ TCAs versus SSRIs, Outcome 2 Total number of dropouts.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-029-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-030-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-030-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 Imputation excluded ‐ Individual antidepressants versus individual antidepressants (within the same class), Outcome 1 Failure to respond." data-id="CD011567-fig-0132" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-030-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.1</div> <div class="figure-caption"> <p>Comparison 30 Imputation excluded ‐ Individual antidepressants versus individual antidepressants (within the same class), Outcome 1 Failure to respond. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-030-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-030-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-030-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 Imputation excluded ‐ Individual antidepressants versus individual antidepressants (within the same class), Outcome 2 Total number of dropouts." data-id="CD011567-fig-0133" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-030-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.2</div> <div class="figure-caption"> <p>Comparison 30 Imputation excluded ‐ Individual antidepressants versus individual antidepressants (within the same class), Outcome 2 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-030-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-031-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-031-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 31 Irregular benzodiazepines use excluded ‐ TCAs versus SSRIs, Outcome 1 Failure to respond." data-id="CD011567-fig-0134" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-031-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.1</div> <div class="figure-caption"> <p>Comparison 31 Irregular benzodiazepines use excluded ‐ TCAs versus SSRIs, Outcome 1 Failure to respond. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-031-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-031-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-031-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 31 Irregular benzodiazepines use excluded ‐ TCAs versus SSRIs, Outcome 2 Total number of dropouts." data-id="CD011567-fig-0135" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-031-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.2</div> <div class="figure-caption"> <p>Comparison 31 Irregular benzodiazepines use excluded ‐ TCAs versus SSRIs, Outcome 2 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-031-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-032-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-032-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 32 Irregular benzodiazepines use excluded ‐ SSRIs versus MAOIs, Outcome 1 Failure to respond." data-id="CD011567-fig-0136" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-032-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.1</div> <div class="figure-caption"> <p>Comparison 32 Irregular benzodiazepines use excluded ‐ SSRIs versus MAOIs, Outcome 1 Failure to respond. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-032-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-033-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-033-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 33 Irregular benzodiazepines use excluded ‐ Individual antidepressants versus individual antidepressants (within the same class), Outcome 1 Failure to respond." data-id="CD011567-fig-0137" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-033-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.1</div> <div class="figure-caption"> <p>Comparison 33 Irregular benzodiazepines use excluded ‐ Individual antidepressants versus individual antidepressants (within the same class), Outcome 1 Failure to respond. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-033-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011567-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/urn:x-wiley:14651858:media:CD011567:CD011567-CMP-033-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_t/tCD011567-CMP-033-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 33 Irregular benzodiazepines use excluded ‐ Individual antidepressants versus individual antidepressants (within the same class), Outcome 2 Total number of dropouts." data-id="CD011567-fig-0138" src="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-033-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.2</div> <div class="figure-caption"> <p>Comparison 33 Irregular benzodiazepines use excluded ‐ Individual antidepressants versus individual antidepressants (within the same class), Outcome 2 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/media/CDSR/CD011567/image_n/nCD011567-CMP-033-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011567-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antidepressants compared to benzodiazepines for adults with panic disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antidepressants compared to benzodiazepines for adults with panic disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with panic disorder<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> Antidepressants<br/> <b>Comparison:</b> benzodiazepines </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Benzodiazepines</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Antidepressants</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to respond</b> <br/> Follow‐up: 8‐10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>314 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>310 per 1000</b> <br/> (210 to 461) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> <br/> (0.67 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>total number of dropouts</b> <br/> Follow‐up: 8‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>213 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>350 per 1000</b> <br/> (220 to 561) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.64</b> <br/> (1.03 to 2.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1449<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to remit</b> <br/> Follow‐up: 8‐10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>360 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>425 per 1000</b> <br/> (364 to 493) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> <br/> (1.01 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1002<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms ‐ endpoint score</b> <br/> Follow‐up: 8‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms ‐ endpoint score in the intervention groups was<br/> <b>0.13 lower</b> <br/> (0.72 to 0.47 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1144<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms ‐mean change</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms ‐ mean change in the intervention groups was<br/> <b>0.40 higher</b> <br/> (0.83 lower to 1.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>number of dropouts due to adverse effects</b> <br/> Follow‐up: 8‐10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> <br/> (54 to 149) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.72</b> <br/> (1.03 to 2.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1002<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one point due to high dropout rates (30%) </p> <p><sup>2</sup> Downgraded one point due to imprecision: 95% CI interval ranges from possible benefit with antidepressants to possible benefit with benzodiazepines </p> <p><sup>3</sup> Downgraded one point due to substantial heterogeneity (I<sup>2</sup> = 75%) </p> <p><sup>4</sup> Downgraded one point due to imprecision: 95% CI interval ranges from no difference to possible benefit associated with benzodiazepines </p> <p><sup>5</sup> Downgraded two points due to substantial heterogeneity (I<sup>2</sup> = 95%)<br/> <sup>6</sup> Downgraded two points due to imprecision: number of individuals included in the trial is low (44) and 95% CI ranges from appreciable benefit with TCAs to appreciable benefit with benzodiazepines </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antidepressants compared to benzodiazepines for adults with panic disorder</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011567-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">TCAs compared to benzodiazepines for adults with panic disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TCAs compared to benzodiazepines for adults with panic disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with panic disorder<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> TCAs<br/> <b>Comparison:</b> benzodiazepines </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Benzodiazepines</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TCAs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to respond</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>537 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>547 per 1000</b> <br/> (338 to 896) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> <br/> (0.63 to 1.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>total number of dropouts</b> <br/> Follow‐up: 8‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>212 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>355 per 1000</b> <br/> (197 to 635) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.67</b> <br/> (0.93 to 2.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1295<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to remit</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>414 per 1000</b> <br/> (348 to 490) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> <br/> (1 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>848<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms ‐ endpoint score</b> <br/> Follow‐up: 8‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms ‐ endpoint score in the intervention groups was<br/> <b>0.25 lower</b> <br/> (1.72 lower to 1.22 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>998<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms ‐ mean change</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms ‐ mean change in the intervention groups was<br/> <b>0.40 higher</b> <br/> (0.83 lower to 1.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>number of dropouts due to adverse effects</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>79 per 1000</b> <br/> (43 to 149) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.10</b> <br/> (1.13 to 3.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>848<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one point due to high dropout rates (around 30%)<br/> <sup>2</sup> Downgraded two points due to imprecision: number of individuals included in the trial is low (61) and 95% CI ranges from appreciable benefit with TCAs to appreciable benefit with benzodiazepines </p> <p><sup>3</sup> Downgraded two points due to substantial heterogeneity (I<sup>2</sup> = 79%) </p> <p><sup>4</sup> Downgraded one point due to imprecision: 95% CI ranges from no difference to appreciable superiority of benzodiazepines in lowering the number of dropouts </p> <p><sup>5</sup> Downgraded two points due to substantial heterogeneity (I<sup>2</sup> = 97%)<br/> <sup>6</sup> Downgraded one point due to imprecision: 95% CI is very wide and ranges from benefit with TCAs and benefit with benzodiazepines<br/> <sup>7</sup> Downgraded two points due to imprecision: number of individuals included in the trial is low (44) and 95% CI ranges from appreciable benefit with TCAs to appreciable benefit with benzodiazepines </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">TCAs compared to benzodiazepines for adults with panic disorder</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011567-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">SSRIs compared to benzodiazepines for adults with panic disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>SSRIs compared to benzodiazepines for adults with panic disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with panic disorder<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> SSRI<br/> <b>Comparison:</b> benzodiazepines </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Benzodiazepines</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SSRI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to respond</b> <br/> Follow‐up: 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>195 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>181 per 1000</b> <br/> (94 to 351) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b> <br/> (0.48 to 1.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>total number of dropouts</b> <br/> Follow‐up: 10 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>221 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>378 per 1000</b> <br/> (227 to 627) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.71</b> <br/> (1.03 to 2.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to remit</b> <br/> Follow‐up: 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>429 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>480 per 1000</b> <br/> (339 to 681) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/> (0.79 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms in the intervention groups was<br/> <b>0.10 higher</b> <br/> (0.34 lower to 0.54 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>number of dropouts due to adverse effects</b> <br/> Follow‐up: 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>156 per 1000</b> <br/> (71 to 339) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> <br/> (0.55 to 2.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one point due to high dropout rates (30%)<br/> <sup>2</sup> Downgraded two points due to imprecision: number of individuals included in the trial is low (= 154) and 95% CI is wide, including benefit with SSRIs and benefit with benzodiazepines; only one study provides data<br/> <sup>3</sup> Downgraded two points due to imprecision: number of individuals included in the trial is low (= 154) and 95% CI ranges from no difference to appreciable superiority of with benzodiazepines in lowering the number of dropouts; only one study provides data<br/> <sup>4</sup> Downgraded one point due to imprecision: number of individuals included in the trial is low </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">SSRIs compared to benzodiazepines for adults with panic disorder</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011567-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">TCAs compared to SSRI for adults with panic disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TCAs compared to SSRI for adults with panic disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with panic disorder<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> TCA<br/> <b>Comparison:</b> SSRI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SSRI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TCA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to respond</b> <br/> Follow‐up: 8‐12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>378 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>409 per 1000</b> <br/> (269 to 628) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/> (0.71 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>438<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>total number of dropouts</b> <br/> Follow‐up: 8‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>243 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>238 per 1000</b> <br/> (158 to 359) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> <br/> (0.65 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>928<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to remit</b> <br/> Follow‐up: 8‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>502 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>447 per 1000</b> <br/> (316 to 633) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> <br/> (0.63 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>475<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms</b> <br/> Follow‐up: 8‐10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms in the intervention groups was<br/> <b>0.20 lower</b> <br/> (0.88 lower to 0.48 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>number of dropouts due to adverse effects</b> <br/> Follow‐up: 8‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>104 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> <br/> (85 to 257) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.43</b> <br/> (0.82 to 2.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>476<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one point due to moderate heterogeneity (I squared = 61%)<br/> <sup>2</sup> Downgraded one point due to imprecision: 95% CI ranges from appreciable benefit with TCAs to appreciable benefit with SSRIs<br/> <sup>3</sup> Downgraded one point due to moderate heterogeneity (I squared = 47%)<br/> <sup>4</sup> Downgraded one point due to moderate heterogeneity (I squared = 58%)<br/> <sup>5</sup> Downgraded one point due to imprecision: dropout rate in one of the included studies (Nair 1996) is 48% <br/> <sup>6</sup> Downgraded one point due to moderate heterogeneity (I squared = 46%)<br/> <sup>7</sup> Downgraded one point due to imprecision: 95% CI ranges from appreciable benefit with TCAs to no difference<br/> <sup>8</sup> Downgraded one point due to imprecision: 95% CI ranges from no difference to appreciable superiority of SSRIs in lowering the number of dropouts </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">TCAs compared to SSRI for adults with panic disorder</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011567-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">TCA compared to MAOI for adults with panic disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TCA compared to MAOI for adults with panic disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with panic disorder<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> TCA<br/> <b>Comparison:</b> MAOI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> MAOI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TCA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to respond</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>224 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b> <br/> (63 to 282) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b> <br/> (0.28 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>total number of dropouts</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>386 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>324 per 1000</b> <br/> (235 to 452) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b> <br/> (0.61 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to remit</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies provided data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms in the intervention groups was<br/> <b>0.20 lower</b> <br/> (0.75 lower to 0.35 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>number of dropouts due to adverse events</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>104 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> <br/> (52 to 335) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.27</b> <br/> (0.5 to 3.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two points due to imprecision: number of individuals included in the study is low (= 135) and 95% CI ranges from appreciable benefit with TCAs to no difference; only one study provides data<br/> <sup>2</sup> Downgraded one point due high dropout rates<br/> <sup>3</sup> Downgraded two points due to imprecision: number of individuals included in the study is low (= 135) and 95% CI ranges from appreciable benefit with TCAs to no difference; only one study provides data.<br/> <sup>4</sup> Downgrded two points due to imprecision: number of individuals included in the study is low (= 135) and 95% CI ranges from appreciable benefit with TCAs to appreciable benefit with MAOIs; only one study provides data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">TCA compared to MAOI for adults with panic disorder</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011567-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">SSRIs compared to MAOIs for adults with panic disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>SSRIs compared to MAOIs for adults with panic disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with panic disorder<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> SSRI<br/> <b>Comparison:</b> MAOI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> MAOI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SSRI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to respond</b> <br/> Follow‐up: 8‐12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>264 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b> <br/> (219 to 401) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/> (0.83 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>396<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>total number of dropouts</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> <br/> (5 to 970) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> <br/> (0.07 to 14.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to remit</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>467 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>434 per 1000</b> <br/> (346 to 546) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b> <br/> (0.74 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>366<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies provided data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>number of dropouts due to adverse events</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>76 per 1000</b> <br/> (36 to 163) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> <br/> (0.59 to 2.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>366<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one point due to imprecision: 95% CI ranges from no difference to appreciable benefit with MAOIs<br/> <sup>2</sup> Downgraded two points due to imprecision: number of individuals included in the trial is very low (= 30) and 95% CI is very wide, ranging from appreciable benefit with SSRIs to appreciable benefit with MAOIs; only one study provides data<br/> <sup>3</sup> Downgraded one point due to imprecision: even though the number of individuals included in the analysis is not low, only one study provides data<br/> <sup>4</sup> Downgrded two points due to imprecision: 95% CI ranges from appreciable benefit with SSRIs to appreciable benefit with MAOIs; only one study provides data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">SSRIs compared to MAOIs for adults with panic disorder</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011567-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">SSRIs compared to SNRIs for adults with panic disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>SSRIs compared to SNRIs for adults with panic disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with panic disorder<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> SSRI<br/> <b>Comparison:</b> SNRI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SNRI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SSRI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to respond</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>232 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>223 per 1000</b> <br/> (174 to 285) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> <br/> (0.75 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>991<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>total number of dropouts</b> <br/> Follow‐up: 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>181 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b> <br/> (134 to 298) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.11</b> <br/> (0.74 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>991<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to remit</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>577 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>606 per 1000</b> <br/> (525 to 698) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> <br/> (0.91 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>991<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms in the intervention groups was<br/> <b>0.12 lower</b> <br/> (0.33 lower to 0.10 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>945<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>number of dropouts due to adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>104 per 1000</b> <br/> (27 to 393) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.86</b> <br/> (0.49 to 7.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>991<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one point due to moderate heterogeneity (I<sup>2</sup> = 53%)<br/> <sup>2</sup> Downgraded one point due to imprecision: 95% CI ranges from appreciable benefit with SSRIs to appreciable benefit with SNRIs<br/> <sup>3</sup> Downgraded one point due to substantial heterogeneity (I<sup>2</sup> = 76%)<br/> <sup>4</sup> Downgraded one point due to serious imprecision: 95% CI ranges from no difference to benefit with SNRIs </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">SSRIs compared to SNRIs for adults with panic disorder</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011567-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">SSRIs compared to NaSSAs for adults with panic disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>SSRIs compared to NaSSAs for adults with panic disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with panic disorder<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> SSRI<br/> <b>Comparison:</b> NaSSA </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> NaSSA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SSRI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to respond</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>total number of dropouts</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> <br/> (39 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.50</b> <br/> (0.29 to 7.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>failure to remit</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies provided data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>panic symptoms</b> <br/> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean panic symptoms in the intervention groups was<br/> <b>0.30 higher</b> <br/> (0.49 lower to 1.09 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>number of dropouts due to adverse events</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> <br/> (39 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.50</b> <br/> (0.29 to 7.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two points due to imprecision: number of individuals included in the trial is very low (= 30) and 95% CI is very wide, ranging from appreciable benefit with SSRIs to appreciable benefit with NaSSAs; only one study provides data<br/> <sup>2</sup> Downgraded two points due to imprecision: number of individuals included in the trial is very low (= 22) and 95% CI is very wide, ranging from appreciable benefit with SSRIs to appreciable benefit with NaSSAs; only one study provides data </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">SSRIs compared to NaSSAs for adults with panic disorder</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/full#CD011567-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antidepressants versus benzodiazepines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.67, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.63, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.48, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.03, 2.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.93, 2.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.03, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Failure to remit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [1.01, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.00, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.79, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Panic symptoms ‐ endpoint score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐1.06, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐1.72, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.34, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Panic symptoms ‐ mean change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.83, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.83, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Frequency of panic attacks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>595</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [‐0.72, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.81, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐3.31, 5.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Agoraphobia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.08, 0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>949</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.08, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.37, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 General anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.25, 0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.28, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.42, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.29, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.22, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.81, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Social functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐0.12, 0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.03, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.57, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11 Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12 Patient satisfaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13 Economic costs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Number of dropouts due to adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [1.03, 2.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [1.13, 3.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.2 [0.55, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Number of patients experiencing at least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.92, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.92, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antidepressants versus benzodiazepines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">TCAs versus benzodiazepines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.63, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Imipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.63, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.93, 2.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Imipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [1.47, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Clomipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.49, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Failure to remit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.00, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Imipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.00, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Panic symptoms ‐ endpoint score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐1.72, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Imipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.21, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Clomipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐1.37, ‐0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Panic symptoms ‐ mean change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.83, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Imipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.83, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Frequency of panic attacks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.81, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Imipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [‐0.44, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Clomipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.6 [‐3.17, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Agoraphobia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>949</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.08, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Imipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>949</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.08, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 General anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.28, 0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Imipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.10, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Clomipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐0.94, ‐0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.22, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Imipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.22, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Social functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.09, 0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Imipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.09, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11 Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12 Patient satisfaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13 Economic costs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Number of dropouts due to adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [1.13, 3.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Imipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [1.13, 3.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15 Number of patients experiencing at least one adverse effect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">TCAs versus benzodiazepines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">SSRIs versus benzodiazepines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.48, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Paroxetine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.48, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.03, 2.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Paroxetine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.03, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Failure to remit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.79, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Paroxetine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.79, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Panic symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.34, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Paroxetine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.34, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Frequency of panic attacks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐3.31, 5.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Paroxetine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐3.31, 5.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Agoraphobia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.37, 0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Paroxetine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.37, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 General anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐3.35, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Paroxetine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐3.35, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.60 [‐6.36, ‐0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Paroxetine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.60 [‐6.36, ‐0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Social functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.40 [‐8.81, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Paroxetine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.40 [‐8.81, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10 Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11 Patient satisfaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12 Economic costs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Number of dropouts due to adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.2 [0.55, 2.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Paroxetine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.2 [0.55, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Number of patients experiencing at least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.92, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Paroxetine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.92, 1.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">SSRIs versus benzodiazepines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">TCAs versus SSRIs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.71, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>928</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.65, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Failure to remit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.63, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Panic symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.88, 0.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Frequency of panic attacks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [‐0.11, 4.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Agoraphobia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.68, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 General anxiety ‐ endpoint score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.27, 0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 General anxiety ‐ mean change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [‐1.39, 3.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Depression ‐ endpoint score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.26, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Depression ‐ mean change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.31, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11 Social functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12 Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13 Patient satisfaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14 Economic costs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Number of dropouts due to adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.82, 2.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Number of patients experiencing at least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.02, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">TCAs versus SSRIs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">TCAs versus MAOIs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.28, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.61, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3 Failure to remit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Panic symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.75, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Frequency of panic attacks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐3.35, 2.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6 Agoraphobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 General anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐3.03, 3.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.1 [‐8.14, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9 Social functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10 Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11 Patient satisfaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12 Economic costs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Number of dropouts due to adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.50, 3.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Number of patients experiencing at least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.06, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">TCAs versus MAOIs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">SSRIs versus MAOIs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.83, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Failure to remit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.74, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4 Panic symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5 Frequency of panic attacks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Agoraphobia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [‐4.47, 7.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 General anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.10, ‐0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9 Social functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10 Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11 Patient satisfaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12 Economic costs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Number of dropouts due to adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.59, 2.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Number of patients experiencing at least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.94, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">SSRIs versus MAOIs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">SSRIs versus SNRIs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.75, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.74, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Failure to remit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.91, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Panic symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>945</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.33, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5 Frequency of panic attacks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Agoraphobia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.19, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 General anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐1.83, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Social functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.71, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐2.11, 2.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11 Patient satisfaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12 Economic costs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Number of dropouts due to adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.49, 7.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Number of patients experiencing at least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.88, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">SSRIs versus SNRIs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">SSRIs versus NaSSAs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1 Failure to respond</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.29, 7.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3 Failure to remit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Panic symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.49, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5 Frequency of panic attacks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6 Agoraphobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 General anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [‐6.04, 8.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9 Social functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10 Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11 Patient satisfaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12 Economic costs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Number of dropouts due to adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.29, 7.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14 Number of patients experiencing at least one adverse effect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">SSRIs versus NaSSAs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">SSRIs versus Other Antidepressants</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.13, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3 Failure to remit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4 Panic symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5 Frequency of panic attacks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Agoraphobia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.35 [‐13.73, ‐0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 General anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.55 [‐5.07, ‐2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.38 [‐7.90, ‐2.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9 Social functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10 Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11 Patient satisfaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12 Economic costs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Number of dropouts due to adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14 Number of patients experiencing at least one adverse effect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">SSRIs versus Other Antidepressants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Individual Antidepressants versus another antidepressant within the same class</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Escitalopram versus citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.79, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Fluoxetine versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.20, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Sertraline versus paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.80, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Escitalopram versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.53, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Fluoxetine versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Sertraline versus Paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.55, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Imipramine versus Clomipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.35, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Failure to remit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.71, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Escitalopram versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.71, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Panic symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Escitalopram versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.35, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Sertraline versus Paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.23, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Frequency of panic attacks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Sertraline versus Paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [‐1.02, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Agoraphobia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Escitalopram versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐3.46, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 General anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Escitalopram versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐3.14, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Sertraline versus Paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.72 [‐2.42, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Escitalopram versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.36, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Sertraline versus Paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.28, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9 Social functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Escitalopram versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [‐1.51, 4.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11 Patient satisfaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12 Economic costs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Number of dropouts due to adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Escitalopram versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.32, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Fluoxetine versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Sertraline versus Paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.42, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Imipramine versus Clomipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.08, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Number of patients experiencing at least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Escitalopram versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.85, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Sertraline versus Paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.89, 1.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Individual Antidepressants versus another antidepressant within the same class</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Individual benzodiazepines versus another benzodiazepine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Alprazolam versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.63, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.49, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Alprazolam versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.44, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Alprazolam versus clonazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [0.44, 10.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Failure to remit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.58, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Alprazolam versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.48, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Alprazolam versus clonazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.73, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Panic symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐0.62, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Alprazolam versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.70, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Alprazolam versus clonazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐0.12, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Frequency of panic attacks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [‐1.29, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Alprazolam versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐1.34, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Alprazolam versus clonazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐6.75, 7.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6 Agoraphobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 General anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Alprazolam versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐2.28, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Alprazolam versus clonazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.3 [‐2.83, 7.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Social functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Alprazolam versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.47, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Alprazolam versus clonazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.07, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11 Patient satisfaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12 Economic costs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Number of dropouts due to adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.33, 8.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Alprazolam versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.15, 7.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Alprazolam versus clonazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.4 [0.27, 107.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14 Number of patients experiencing at least one adverse effect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Individual benzodiazepines versus another benzodiazepine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">High risk of bias excluded ‐ Antidepressants versus benzodiazepines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.82, 3.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.64, 4.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.03, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">High risk of bias excluded ‐ Antidepressants versus benzodiazepines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">High risk of bias excluded ‐ TCAs versus benzodiazepines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.64, 4.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Imipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [1.42, 4.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Clomipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.49, 0.98]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">High risk of bias excluded ‐ TCAs versus benzodiazepines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">High risk of bias excluded ‐ TCAs versus SSRIs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.62, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">High risk of bias excluded ‐ TCAs versus SSRIs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">High risk of bias excluded ‐ TCAs versus MAOIs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.47, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">High risk of bias excluded ‐ TCAs versus MAOIs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">High risk of bias excluded ‐ SSRIs versus MAOIs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.76, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">High risk of bias excluded ‐ SSRIs versus MAOIs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">High dropout rates excluded ‐ Antidepressants versus benzodiazepines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [0.61, 9.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [0.61, 9.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">High dropout rates excluded ‐ Antidepressants versus benzodiazepines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">High dropout rates excluded ‐ TCAs versus benzodiazepines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [0.61, 9.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Imipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [0.61, 9.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Clomipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">High dropout rates excluded ‐ TCAs versus benzodiazepines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">High dropout rates excluded ‐ TCAs versus SSRIs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.47, 3.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.02 [1.00, 9.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">High dropout rates excluded ‐ TCAs versus SSRIs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Funded excluded ‐ Antidepressants versus benzodiazepines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>469</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.44, 2.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.49, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.03, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Funded excluded ‐ Antidepressants versus benzodiazepines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Funded excluded ‐ TCAs versus benzodiazepines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.49, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Imipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Clomipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.49, 0.98]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Funded excluded ‐ TCAs versus benzodiazepines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Funded excluded ‐ TCAs versus SSRIs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.46, 8.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.77, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Funded excluded ‐ TCAs versus SSRIs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Funded excluded ‐ SSRIs versus MAOIs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.69, 2.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Funded excluded ‐ SSRIs versus MAOIs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Psychiatric comorbidities excluded ‐ Antidepressants versus benzodiazepines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.63, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.63, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.64, 4.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 TCAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.64, 4.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 SSRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 MAOIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 SNRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 NaSSAs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 NDRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 NRIs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Other ADs versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Psychiatric comorbidities excluded ‐ Antidepressants versus benzodiazepines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Psychiatric comorbidities excluded ‐ TCAs versus benzodiazepines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.64, 4.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Imipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [1.42, 4.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Clomipramine versus BDZs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.49, 0.98]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Psychiatric comorbidities excluded ‐ TCAs versus benzodiazepines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Psychiatric comorbidities excluded ‐ TCAs versus SSRIs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.66, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.62, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Psychiatric comorbidities excluded ‐ TCAs versus SSRIs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Psychiatric comorbidities excluded ‐ Individual antidepressants versus individual antidepressants (within the same class)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Escitalopram versus citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.79, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Fluoxetine versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.20, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Sertraline versus paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.78, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Escitalopram versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.53, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Fluoxetine versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Sertraline versus Paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.57, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Imipramine versus Clomipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Psychiatric comorbidities excluded ‐ Individual antidepressants versus individual antidepressants (within the same class)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0036"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">Psychiatric comorbidities excluded ‐ Individual benzodiazepines versus individual benzodiazepines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.44, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Alprazolam versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.44, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Alprazolam versus clonazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">Psychiatric comorbidities excluded ‐ Individual benzodiazepines versus individual benzodiazepines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0036">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0037"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">Imputation excluded ‐ TCAs versus SSRIs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.95, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.80, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">Imputation excluded ‐ TCAs versus SSRIs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0037">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0038"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">Imputation excluded ‐ Individual antidepressants versus individual antidepressants (within the same class)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Escitalopram versus citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Fluoxetine versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.20, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Sertraline versus paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.70, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Escitalopram versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Fluoxetine versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Sertraline versus Paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.40, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Imipramine versus Clomipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.35, 2.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">Imputation excluded ‐ Individual antidepressants versus individual antidepressants (within the same class)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0038">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0039"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">Irregular benzodiazepines use excluded ‐ TCAs versus SSRIs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.47, 3.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.85, 1.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">Irregular benzodiazepines use excluded ‐ TCAs versus SSRIs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0039">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0040"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">Irregular benzodiazepines use excluded ‐ SSRIs versus MAOIs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.76, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">Irregular benzodiazepines use excluded ‐ SSRIs versus MAOIs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0040">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011567-tbl-0041"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">Irregular benzodiazepines use excluded ‐ Individual antidepressants versus individual antidepressants (within the same class)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to respond <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Escitalopram versus citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Fluoxetine versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.20, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Sertraline versus paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.70, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Escitalopram versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Fluoxetine versus Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Sertraline versus Paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.40, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Imipramine versus Clomipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.35, 2.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">Irregular benzodiazepines use excluded ‐ Individual antidepressants versus individual antidepressants (within the same class)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011567.pub2/references#CD011567-tbl-0041">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011567.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011567-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011567-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011567-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="ru#CD011567-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011567-note-0015">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011567\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011567\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011567\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011567\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011567\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011567\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011567\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011567\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011567\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011567\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011567\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011567\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011567\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011567\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011567\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011567\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011567\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011567\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011567.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011567.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011567.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011567.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011567.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716553002"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011567.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716553006"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011567.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da2493aa49379',t:'MTc0MDcxNjU1My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 